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Summary 
 
Plasmodium falciparum is the most pathogenic malarial parasite and a major cause 
of morbidity and mortality among young children in sub-Saharan Africa. The 
virulence of P. falciparum has been linked to its expression of variant surface 
antigens (VSAs) on the surface of infected red blood cells. These VSAs subvert 
acquisition of protective immunity and mediate cytoadherence of infected 
erythrocytes to the microvasculature lining of various endothelial cell receptors. It 
causes sequestration of infected erythrocytes in post capillary venules of the vital 
organs such as the brain or placenta. Cytoadherence causes retention and 
accumulation of the infected erythrocytes to endothelial membranes of deep post-
venous capillaries leading to occlusion of micro-vessels. This result in obstruction 
of free blood flow with serious pathological consequences associated with severe 
malaria. Sequestration facilitates parasite multiplication and enables the parasites 
to avoid the passage of infected erythrocytes through the spleen, where deformed 
erythrocytes are removed from blood circulations. This cytoadherence is mediated 
by P. falciparum erythrocyte membrane protein 1 (PfEMP1). PfEMP1 is a VSA 
family encoded by ~ 60 highly polymorphic var genes per haploid genome, 
expressed on the surface of infected red blood cells. PfEMP1 is expressed in a 
mutually exclusive manner, and switching the expression creates extensive 
antigenic variation and the potential for multiple adhesion profile.  Antigenic 
variation is a strategy employed by P. falciparum to avoid antibody-mediated 
destruction by alternating expression of individual var genes each of which 
encodes an antigenically distinct form of PfEMP1. Sequence analysis of the var 
gene repertoire of the 3D7 clone revealed genetic structuring in which var genes 
fall into 3 distinct groups (A, B, and C) and two intermediate groups (B/A and 
B/C) based on chromosomal location, gene orientation and the 5' flanking 
sequences. It has been postulated that this genetic organization helps to restrict 
recombination within a specific group of genes and leads to their structural and 
functional specialization for binding to different endothelial receptors. 
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The sequences of var genes vary substantially within and between the parasites 
genome. This has been clearly indicated by the fact that there is minimal overlap 
in the var gene repertoire between isolates due to high inter-genic and intra-genic 
recombination within the var gene family. Despite the complex nature of this 
molecule, the var gene still remains the best defined factor contributing to malaria 
pathogenesis. Different research groups have attempted to define the repertoire of 
var gene from different isolates, and reported vast global var gene diversity. Only a 
tip of iceberg of the var genes diversity is currently in view. The big challenge to 
date is to understand how the var gene diversity and selection pressure influence 
malaria pathogenesis in order to device a control strategy based on interference 
with PfEMP1 expression.  
 
Clinical and sero-epidemiological studies have suggested that severe disease is 
attributed by the parasite expressing a restricted and antigenically conserved 
subset of VSAs which are frequently recognized by sera from semi-immune 
individuals, proposing that expression of a particular VSA may be associated with 
disease manifestation. Pregnancy associated malaria (PAM) is well understood 
and has often been linked with the expression of a var gene called var2csa which is 
unusually conserved across parasite isolates and binds a low sulfated form of 
chondroitin sulfate A (CSA) in the placenta. Different studies have attempted to 
link a particular var gene expression with a disease phenotype. It is becoming 
evident that var group A and B/A are involved in severe childhood malaria. 
Protective immunity to severe malaria develops earlier in childhood after only few 
severe episodes pointing to a relatively conserved target antigen. This 
phenomenon makes it theoretically possible to protect non immune children 
against severe and complicated malaria by accelerating acquisition of PfEMP1 
specific immunity. 
 
Summary 
 viii 
Given the proposed importance of immunity to PfEMP1 in protection against 
malaria, it is essential that we gain a better understanding of var gene expression 
during infection. Despite substantial contribution of var genes to malaria 
pathogenesis and parasites survival, few studies on var gene transcription during 
natural infections have been carried out in field isolates. This is mainly attributed 
to technical difficulties, and the complexity and immense diversity interfering 
with most study design.  
 
For this thesis, two studies on var gene expression in naturally infected children 
with severe P. falciparum malaria from Tanzania were conducted. In the first study, 
the transcription levels of var gene groups were compared in children with severe, 
uncomplicated and asymptomatic malaria by using quantitative real-time PCR. 
Transcripts of var group A and B genes were up-regulated in children with severe 
malaria compared to patients with uncomplicated malaria. In general, the 
transcript abundances of var group A and B genes were higher for children with 
clinical malaria than for children with asymptomatic infections. var group C was 
not linked with any disease phenotype.  
 
In the second study, the genetic diversity of expressed P. falciparum var genes in 
children with severe malaria from Tanzania was determined. The var transcripts 
isolated from children with severe malaria (Blantyre score ≤ 3) were compared 
with isolates from children with asymptomatic malaria. Diversity patterns of 
dominant full-length var transcripts were determined by isolation of mRNA 
followed by magnetic bead capture through an ATS-anchor and reverse-
transcription into var cDNA. The different PCR amplified expressed sequence tags 
were cloned and sequenced. Large sequence diversity of the amplified var DBL-1α 
and the 5’ non-coding regions was observed and minimal overlapping was 
evident among the isolates providing strong evidence that the transcribed var gene 
repertoire is immense. var DBL-1α sequences isolated from AM were more diverse 
Summary 
 ix 
with more singletons (P<0.05) compared with DBL-1α sequences from SM. Unique 
var sequences that were exclusively expressed with P. falciparum isolated from 
children with SM were found. Despite the fact that var gene diversity is unlimited, 
transcripts from SM isolates were more restricted, supporting the hypothesis that 
certain PfEMP1 repertoires are involved in triggering severe infections. 
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Zusammenfassung 
 
Plasmodium falciparum ist der Hauptauslöser von Malariapathologie, Morbidität 
und Mortalität bei kleinen Kindern in Afrika südlich der Sahara. Virulenz von P. 
falciparum ist abhängig von der Expression der ‚variant surface antigens’ (VSAs, 
variable Oberflächen-Antigene) auf der Oberfläche der infizierten roten Blutzellen. 
Diese VSAs verhindern die Entwicklung einer schützenden Immunantwort und 
führen zu Zytoadhärenz der infizierten Erythrozyten an Rezeptoren des 
Endothels. Dies ermöglicht die Sequestrierung der infizierten Erythrozyten in den 
Blutkapillaren wichtiger Organe, wie z.B. im Gehirn oder in der Plazenta. 
Zytoadhärenz führt zur Rückhaltung und Anhäufung infizierter Blutkörperchen 
und damit zur Blockierung der Mikro-Kapillaren. Dies wiederum verhindert den 
Blutfluss und führt zu schweren pathologischen Komplikationen, wie z.B. zu 
zerebraler Malaria. Sequestrierung ermöglicht aber auch die 
Parasitenmultiplikation und ermöglicht es dem Parasiten nicht durch die Milz zu 
passieren, in welcher deformierte Erythrozyten aus der Zirkulation eliminiert 
werden. Diese Zytoadhärenz wird durch ein Parasiten-Protein vermittelt, dem P. 
falciparum Erythrocyte Membrane Protein 1 (PfEMP1, Erythrozyten Membran-
Protein 1). PfEMP1 gehört zur Familie der VSAs, und etwa 60 hoch-polymorphe 
var Gene kodieren für dieses Protein im haploiden Genom. Nur ein PfEMP1, 
exprimiert von einem einzelnen var Gen, ist auf der Oberfläche der infizierten 
roten Blutkörperchen exprimiert und durch Umschalten der Expression wird eine 
ausgedehnte Antigenvariation generiert mit der Möglichkeit, an verschiedenste 
Rezeptoren zu binden. Antigenvariation ist eine Strategie von P. falciparum der 
Antikörper-abhängigen Zerstörung, durch Umschalten einzelner var Gene, zu 
entgehen. Sequenzanalysen des var Genrepertoires von 3D7 zeigte eine genetische 
Struktur, welche 3 distinkte Gruppen (A, B, und C), sowie zwei Zwischengruppen 
(B/A und B/C), definiert. Die Gruppierung basiert auf der chromosomalen Lage, 
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der Genorientierung, sowie der 5’ flankierenden Sequenzen. Es wurde postuliert, 
dass diese genetische Struktur dazu beiträgt, Rekombination nur auf eine 
bestimmte var Gengruppe zu begrenzen, und somit zur strukturellen und 
funktionellen Spezialisierung der Bindung an verschiedene Endothel-Rezeptoren 
beigetragen hat. 
 
var Gensequenzen variieren substantiell innerhalb und zwischen verschiedenen 
Parasiten-Genomen. Dies wird besonders sichtbar bei der minimalen 
Überlappung des var Genrepertoires verschiedener Parasiten-Isolate, welche 
vermutlich durch die hohe inter- und intra-genische Rekombnation innerhalb der 
var Genfamilie bedingt ist. Trotz ihrer Komplexität sind die var Gene die best 
untersuchten Pathologiefaktoren bei Malaria. Verschiedene Forschungsgruppen 
haben versucht, das var Genrepertoire verschiedener Parasiten-Isolate zu 
definieren und berichten von einer riesigen globalen Diversität. Offensichtlich 
repräsentiert dies aber nur erst die Spitze des Eisberges. Und eine grosse 
Herausforderung wird es sein, zu verstehen, wie var Gendiversität und 
Selektionsdruck Malaria-Pathogenese beeinflusst, um dann entsprechende 
Interventionsstrategien zu entwickeln, die darauf beruhen, die Expression von 
PfEMP1 zu unterdrücken. 
 
Klinische und sero-epidemiologische Studien deuten darauf hin, dass schwere 
Malaria durch Parasiten ausgelöst wird, welche eine beschränkte und antigenisch 
konservierte Untergruppe von var Genen exprimieren. Diese VSAs werden häufig 
von Seren von semi-immunen Menschen erkannt, was darauf hinweist, dass die 
Expression eines bestimmten VSAs mit der Ausprägung der Krankheit assoziiert 
ist. Schwangerschafts-assoziierte Malaria (PAM, pregnancy associated malaria) 
wird inzwischen besser verstanden, und sie wurde häufig mit der Expression 
eines spezifischen var Gens, des var2csa, in Verbindung gebracht. Dieses var Gen 
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ist aussergewöhnlich stark konserviert zwischen verschiedenen Parasiten-Isolaten 
und bindet Chondroitinsulfat A (CSA) in der Plazenta. Verschiedene Studien 
haben versucht, die Expression individueller var Gene mit einem 
Krankheitsphänotyp in Verbindung zu bringen. Es gibt vermehrt Hinweise 
darauf, dass die var Gruppe A und B/A bei schwerer Kindermalaria involviert sein 
könnte. Schützende Immunität gegen schwere Malaria entsteht früher in der 
Kindheit, bereits nach wenigen schwereren Episoden, was wiederum auf wenige 
relativ konservierte Ziel-Antigene hindeutet. Diese Tatsache würde es theoretisch 
möglich machen, nicht-immune Kinder gegen schwere Malaria oder gegen 
Malaria mit Komplikationen zu schützen, in dem man die Entwicklung der 
spezifischen Immunität gegen PfEMP1 unterstützt. 
 
Wegen der Wichtigkeit der Immunität gegen PfEMP1 beim Schutz gegen Malaria, 
ist es wichtig, besser zu verstehen, welche Regeln der Expression von var Genen in 
natürlichen Infektionen zu Grunde liegen. Trotz der wichtigen Rolle, die var Gene 
in der Pathogenese und beim Überleben der Parasiten spielen, gibt es nur wenige 
Studien, die die var Genexpression in natürlichen Infektionen in Feld-Isolaten 
angeschaut haben. Der Grund hierfür liegt in technischen Schwierigkeiten und an 
der immensen Komplexität und Diversität, welche die Durchführung der meisten 
Studien limitiert.  
 
Im Rahmen dieser Doktorarbeit wurden zwei Studien über var Genexpression in 
natürlichen Infektionen bei Kindern mit schwerer Malaria in Tanzania 
durchgeführt. In der ersten Studie wurde die Expression der verschiedenen var 
Gengruppen in Kindern mit schwerer Malaria, in Kindern mit leichter klinischer 
Malaria, und in Kindern mit asymptomatischer Malaria mittels quantitativer ‚real-
time’ PCR verglichen. var Transkripte der var Gruppe A und B waren in Kindern 
mit schwerer Malaria hoch reguliert, verglichen mit Kindern mit leichter 
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klinischer Malaria. Insgesamt waren die var Gene der Gruppe A und B in Kindern 
mit klinischen Symptomen höher transkribiert, verglichen mit Kindern mit 
asymptomatischer Malaria. Die Expression der var Gengruppe C war mit keinem 
Krankheitstyp assoziiert. 
 
In der zweiten Studie wurde die genetische Diversität der exprimierten var Gene 
in Kindern aus Tanzania mit schwerer Malaria determiniert. Die var Transkripte 
wurden von Kindern mit schwerer Malaria (Blantyre score ≤ 3) isoliert und mit 
Transkripten aus Kindern mit asymptomatischer Malaria verglichen. Das 
Diversitätsmuster der dominanten ‚full-length’ var Transkripte wurde durch 
Isolation von mRNA über Bindung an Magnetkügelchen mit der ATS-Domäne 
und anschliessender reverser Transkription in cDNA bestimmt. Die verschiedenen 
PCR amplifizierten exprimierten Fragmente wurden kloniert und sequenziert. 
Dadurch wurde in den amplifizierten DBL1α und den 5’ nicht-kodierenden 
Regionen eine grosse Sequenzdiversität sichtbar. Zwischen den Sequenzen 
einzelner Isolate bestand fast keine Überlappung, was auf ein unlimitiertes 
Repertoire der exprimierten var Gene hinweist. Die DBL1α var Sequenzen aus 
asymptomatischen Malariafällen war diverser, mit einer grösseren Anzahl von 
Einzelsequenzen als die  DBL1α Domänen aus schweren Malariafällen (p<0.05). Es 
wurden spezifische var Sequenzen, die nur bei schwerer Malaria auftraten, 
gefunden. Obwohl die var Gendiversität so gross ist, war die Diversität der 
Transkripte aus schweren Malariafällen eher beschränkt, was die Hypothese 
unterstützt, dass nur eine bestimmte Anzahl spezifischer var Gene bei der 
Auslösung von schwerer Malaria beteiligt ist. 
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Chapter One 
1.0 Introduction 
 
Plasmodium falciparum malaria, besides tuberculosis and HIV, is a major global 
health problem. It accounts for more than 500 million clinical cases per year, 
mainly in children < 5 years and primigravid women in Sub-Saharan Africa 
(Breman 2001). Every 40 seconds a child dies of malaria, resulting in a daily loss of 
more than 2000 young lives worldwide. In addition to reducing quality of life, 
malaria also imposes a heavy economic burden on developing countries (Malaney 
et al 2004, Sachs & Malaney 2002). Despite extensive research efforts, no effective 
vaccine capable of conferring an adequate level of immunity has been developed 
to date. Furthermore, rapid emerging drug resistance in natural parasite 
populations and the arising of insecticide-resistant mosquitoes, highlights the 
need for new intervention strategies that are both effective in the treatment and 
prevention of the disease. 
 
Individuals living in areas of high P. falciparum transmission acquire protective 
immunity to severe malaria during early childhood after only a few symptomatic 
infections. However, they remain susceptible to uncomplicated disease and 
asymptomatic infection into adulthood. Thus, sterile immunity that prevents 
infection may never develop, but significant antidiseases immunity is acquired 
relatively rapidly. 
Clinical manifestations of falciparum malaria differ markedly from infection to 
infection, although disease symptoms often remain uncomplicated. However, in 
some cases severe complications such as cerebral malaria, severe anaemia or 
respiratory distress develop (Marsh et al 1995). The reasons why certain children 
develop life-threatening complications while others are able to tolerate very high 
parasite burdens without severe clinical symptoms remain unclear (Miller et al 
2002). 
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Severe malaria has previously been associated with expression of a restricted and 
antigenically conserved subset of variant erythrocyte antigens (Bull et al 2000, 
Nielsen et al 2002). This suggests that expression of certain surface molecules may 
be associated with specific disease manifestations. Malaria parasites causing 
clinical disease in semi immune patients express variant surface antigens (VSA) 
that correspond to the ‘holes’ in the VSA antibodies repertoire. The parasites 
expressing VSA, to which there is no pre-existing acquired immunity can multiply 
in a substantial way, leading to clinical diseases. Acquisition of protective 
immunity involves sequential closure of these holes. Immunity to severe malaria is 
relatively quick to develop after a few episodes (Gupta et al 1999), indicating the 
existence of antigenic homogeneity in parasites causing severe disease. 
 
The best characterized VSA are the var genes encoded Plasmodium falciparum 
Erythrocyte Membrane Protein 1 (PfEMP 1). There are about 60 var genes per 
haploid genome (Gardner et al 2002). PfEMP 1 is expressed in a mutually 
exclusive manner at the surface of infected erythrocyte. It mediates parasites to 
bind to host endothelium and other host cells. Sequestration in microvessels 
allows parasitized blood cells (pRBCs) to avoid clearance from blood stream by 
the spleen. Switching of the var gene expression allows the parasites to modify the 
antigenic and functional properties of parasitized erythrocytes, thereby evading 
immunity and affecting the outcome of infection. 
 
The introduction chapter of this thesis is composed of three parts. The first part 
focuses on the parasites biology; the second part highlights the clinical and 
molecular aspects of severe malaria whilst the third part explains the role of 
PfEMP1 in malaria pathogenesis. 
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1.1 Plasmodium and Malaria 
 
Malaria is caused by an infection with a protozoan parasite of the genus 
Plasmodium, which is transmitted through the bite of an infected female Anopheles 
mosquito. Of the approximately 400 species of Anopheles throughout the world, 
about 60 are malaria vectors under natural conditions, 30 of which are of major 
importance. Malaria parasites are eukaryotic single-celled microorganisms that 
belong to the genus Plasmodium. Plasmodia are members of the phylum 
Apicomplexa, characterized by the presence of an apical complex, which contains 
an apicoplast, a polar ring organizing the microtubules, the vesicles called 
micronemes, rhoptries and dense granules. The genus Plasmodium contains more 
than 100 species of which four infect humans: Plasmodium falciparum, Plasmodium 
vivax, Plasmodium ovale and P. malariae. Recently there has been an outbreak of P. 
knowlesia in Borneo, Malaysia, and reports of human infections in Asia are 
numerous (Cox-Singh et al 2008). Whether human to human transmission occurs 
is yet unknown. These major species differ morphologically, immunologically, in 
their geographically distribution, in their relapse patterns and in their drug 
responses. Of the five species of malaria parasites, P. falciparum is the most 
virulent and responsible for severe pathogenesis such as cerebral malaria (coma), 
severe anaemia, renal failure, respiratory distress, metabolic acidosis, 
hypoglycemia and lung oedema. P. falciparum is the principle cause of malaria 
death in young children and pregnant mothers in endemic countries (Breman et al 
2001). The least common malaria parasite is P. ovale, which is found throughout 
the world, natural distribution is in sub-Saharan Africa and Islands of Western 
Pacific. P. ovale has also been reported in South East Asia and South Pacific 
(Collins & Jeffery 2005). P. malariae occurs at low frequency in a patchy 
distribution worldwide. The most widespread malaria parasite is P. vivax but 
infections with this species are rarely fatal, although recent reports have linked it 
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with cerebral malaria (Kochar et al 2007). How P. vivax causes cerebral malaria 
remains a mystery. P. falciparum and P. vivax can both cause severe blood loss 
(anemia), mild anemia is more common in P. vivax infections, whereas severe 
anemia in P. falciparum malaria is a major cause of death in Africa. A characteristic 
feature of P. falciparum malaria is the ability of the parasite to invade red blood 
cells (RBCs) of all ages causing very high parasitemia, high multiplication rates 
(approximately 24 merozoites as compared to 8-10 merozoites in P. vivax) and 
enhanced growth, as well as the capacity to adhere to host endothelium 
(cytoadherence) and to non-infected RBCs (rosetting). These binding events 
eventually lead to the occlusion of the microvasculature in various tissues and 
organs, such as the brain in cerebral malaria (Miller et al 2002) hence contributing 
directly to the pathogenesis of severe malaria disease. P. ovale and P. vivax have 
dormant liver stages named hypnozoites that may remain in this organ for a 
period ranging from weeks to many years before the onset of a new round of pre-
erythrocytic schizogony, resulting in relapses of malaria infection. In some cases P. 
malariae can produce long-lasting blood-stage infections, which, if left untreated, 
can persist asymptomatically in the human host for periods extending into several 
decades. 
 
Mortality is not only the problem with malaria since morbidity in endemic 
countries leads to major socio-economic losses. In Tanzania for instance, malaria is 
the leading cause of out-patient and in-patient health service attendance for all 
ages, and is the leading cause of death in both children and adults in all regions of 
the country. Malaria is believed to be directly or indirectly responsible for about 16 
million annual malaria episodes and 100,000 to 125,000 annual deaths in Tanzania 
of whom 70–80,000 are children under-fives (Ministry of Health Government of 
Tanzania 2003).  
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1.2 Life cycle of Plasmodium falciparum 
 
The life cycle of all Plasmodium species is extremely complex and requires 
specialized protein expression for survival in both the invertebrate and vertebrate 
hosts. These proteins are required for both intracellular and extracellular survival, 
for the invasion of a variety of cell types and for the evasion of host immune 
responses. The life cycle of the malaria parasite is shown in (Figure 1) and can be 
divided into three consecutive phases of multiplication: Two phases of schizogony 
(asexual multiplication) in the vertebrate host, first in hepatocytes then in RBCs 
and one phase of sporogony (sexual multiplication) in the mosquito. Infection in 
vertebrate begins through the bite of an infected female Anopheline mosquito. 
Sporozoites released from the salivary glands of the mosquito enter the 
bloodstream, quickly reach the liver and penetrate the liver cells (hepatocytes) 
where they remain for 5-16  days for P. falciparum and undergo asexual replication 
known as exo-erythrocytic schizogony to form hepatic schizonts (Kappe et al 
2004). The mechanism of targeting and invading the hepatocytes is not yet well 
understood, but studies have shown that sporozoite migration through several 
hepatocytes in the mammalian host is essential for completion of the life cycle 
(Mota et al 2001). The receptors on sporozoites responsible for hepatocyte invasion 
are mainly the thrombospondin domains on the circumsporozoite protein and on 
thrombospondin-related adhesive protein. These domains specifically bind to 
heparan sulfate proteoglycans on the hepatocytes (Frevert et al 1993). Each 
schizont gives rise to up to 10,000s merozoites inside the hepatocyte and each 
merozoite can invade a RBC on release from the liver. In the RBC they multiply 
within 48 hours giving rise to approximately 24 merozoites for P. falciparum, which 
are released and again invade RBCs thereby maintaining the erythrocytic cycle. 
The clinical manifestations of malaria, fever and chills are associated with the 
rupture of the infected erythrocyte. Not all of the merozoites divide into schizonts, 
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as some differentiate into sexual forms, male and female gametocytes. These 
gametocytes are taken up by a female anopheles mosquito during a blood meal. 
Within the mosquito midgut, the male gametocyte undergoes a rapid nuclear 
division, producing 8 flagellated microgametes which fertilize the female 
macrogamete to form zygotes. The zygotes formed by this fertilization develop 
into motile ookinetes, which invade and traverse the midgut epithelium. Diploid 
ookinetes undergo meiosis and, on reaching the basal side of the midgut, 
transform into oocysts, thereby undergoing several round of meiosis as they 
mature. Each oocyst releases thousands of haploid sporozoites into the mosquito 
hemocoel, from where they are transported through the hemolymph and invade 
the mosquito salivary glands. Sporozoites are finally transmitted to a new 
vertebrate host during an infective bite and the Plasmodium life cycle begins again 
reviewed by Whitten et al (2006).  
 
The life cycle of Plasmodium consists of four invasive stages (a) the ookinetes 
traversing the intestinal cells in the mosquito (b) the sporozoites infecting the 
mosquito salivary glands (c) the vertebrate hepatocytes and (d) theamemaliza 
merozoites infecting the vertebrates’ erythrocytes. The sporozoites and the hepatic 
stages are called the pre-erythrocytic stages. The hepatic stage is asymptomatic in 
humans and takes approximately 5-16 days in the case of P. falciparum. Clinical 
symptoms which can be severe are solely due to the erythrocyte stages. Almost all 
antimalarial drugs except primaquine are directed against this stage (Fidock et al 
2004). 
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Figure 1. Life cycle of malaria parasite P. falciparum (Source: Wirth, 2000).  
The life cycle the Plasmodium parasite is divided between the vertebrate host ie (human) where 
asexual replication takes place (a) and the invertebrate (Mosquito) where the sexual reproduction 
occurs. Details are given in the text above. 
1.3 Clinical Aspects of Severe Malaria  
 
Severe malaria is defined as an infection with manifestation and complications 
that are potentially fatal in man causing 15 to 20% mortality in spite of effective 
drugs and correct medical aid. Severe manifestation and complications due to P. 
falciparum malaria nclude a range of clinical features such as cerebral malaria, 
severe anemia, severe respiratory distress, hypoglycemia, renal failure and 
pulmonary oedema. Cerebral malaria and severe anemia are, however, the most 
common causes of hospitalization and death, especially in malaria naïve 
individuals and children (Mackintosh et al 2004). In adults, severe malaria is 
manifested as impaired consciousness however, multi-organ failure is more 
common (WHO 2000). Normally, cerebral malaria patients progressively develop 
coma and unconsciousness. Microvasculature occlusion by clumps of pRBCs, 
RBC-pRBC rosette and other fibrillar materials are believed to be the direct causes. 
Little is known about the exact cause of the blood-brain barrier damage. 
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Severe malaria in children has been considered to be primarily due to two major 
clinical syndromes: those with impaired consciousness (regarded as being 
synonymous with cerebral malaria) and those with severe malaria anaemia; of 
which both frequently occur in the same patient (WHO 1990). Most malaria deaths 
in children were previously thought to be caused by cerebral malaria and were 
primarily neurological in origin, or caused by severe malaria anaemia as a result of 
the failure to provide a blood transfusion promptly. Over the past decade, there 
has been increasing recognition that severe malaria is a complex syndrome 
affecting many organs, and that acidosis is an important component of the 
syndrome and the best independent predictor of a fatal outcome in both adults 
and children (Newton & Krishna 1998). Factors associated with fatal outcome in 
Kenyan children with severe malaria included deep breathing or acidosis (base 
excess below -8) hypotension (systolic blood pressure < 80 mmHg), raised plasma 
creatinine (>80 mol/l), low oxygen saturation (90 %), dehydration and 
hypoglycaemia (2.5 mmol/l) (Maitland et al 2003). 
 
Acute pulmonary edema is also a common fatal complication, presenting 
interstitial edema with swollen endothelial cells and monocytes narrowing the 
capillary lumen. The edematous interstitium also contains macrophages with 
endocytes and malarial pigment (Duarte et al 1985). Renal failure is another 
important complication in severe malaria and is defined as an increase in the 
serum creatinine to above 3 mg/dL or an increase in blood urea above 40%. Half of 
the patients with renal failure present also with lung edema and 45% of these die 
(WHO 2000). 
 
Laboratory data are important for diagnosis of severe malaria. Anemia (HB < 
5g/dL, Ht < 20 %) is an inevitable consequence of severe malaria and jaundice 
(total serum bilirubin > 3mg/dL) is common to patient with renal failure and 
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parasitemia above 100,000/µL (WHO 2000). Another important aspect used to 
predict the severity of malaria is the presence of serum procalcitonin. Procalcitonin 
(PCT) is a known sepsis marker and is undetectable in healthy individual. A study 
by (Chiwakata et al 2001) concerning patients with severe malaria reported that 
the PCT concentration was found to be directly proportional to parasitemia. 
Malaria is a systemic disease whereby different systems are affected due to 
infection of the erythrocytes (Miller et al 2002). The signs and symptoms of severe 
malaria indicate a complex syndrome, established by host and parasite factors. It 
is believed that the virulence of P. falciparum is related to cytoadherence, rosetting 
and antigenic variations (Chen et al 2000). 
1.4 Molecular aspects of Severe Malaria 
1.4.1 Sequestration and Cytoadherence 
 
During the erythrocytic stage of P. falciparum, mature trophozoites and schizonts 
sequester from the blood circulation by binding to host endothelium, 
predominantly in post capillary venules of the deep tissues. This phenomenon is 
known as cytoadherence. Dysfunction of affected organs may occur with excessive 
binding due to the occlusion of blood flow that causes impaired oxygen delivery. 
Massive sequestration in the brain is believed to be the underlying cause of coma 
in cerebral malaria. The reason for the parasites to sequester is unknown. 
However, it is speculated that they grow better in an oxygen-depleted 
environment than in ambient air, and binding to the endothelium is also a way to 
circumvent spleen-dependent destruction. 
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1.4.1.1 Endothelial Receptors for Adhesion 
 
CD36 (cluster determinant 36) and thrombospodin (TSP) were the first described 
endothelial receptors that bound pRBCs (Barnwell et al 1985). MAbs specific to 
CD36 and soluble CD36 blocked the binding of pRBCs to melanoma cells and 
CD36-expressing COS cells (Barnwell et al 1985). By using similar approaches, P. 
falciparum receptors VCAM-1 (vascular cell adhesion molecule 1), ICAM-1 
(Intracellular adhesion molecule 1), and E-selectin were later identified (Berendt et 
al 1989). The affinity of P. falciparum for binding to endothelia cell receptors is 
diverse, as is their role in sequestration. ICAM-1 appears to be important and has 
been associated to cerebral malaria (Chakravorty & Craig 2005). This receptor is 
present on most microvasculature surfaces and is up-regulated by TNF-α and 
IFN-γ, important cytokines believed to contribute to severe malaria. However, in-
vitro studies have demonstrated that the affinity of most pRBCs to ICAM-1 is 
weak and synergetic cooperation with other receptors such as CD36 is necessary 
for a stable adhesion (Craig et al 1997). CD36 and TSP receptors are poorly 
distributed on brain endothelium. Platelet-endothelial cell adhesion molecule 1 
(PECAM/CD31) had been identified as yet another endothelial receptor involved 
in P. falciparum pRBC (Treutiger et al 1997). Clinical investigations in Kenya have 
revealed an association between pRBC binding to PECAM receptor and severe 
diseases, along with reports showing that fresh isolates from children with severe 
P. falciparum malaria bind to multiple receptors (Heddini et al 2001). 
 
The number of receptors associated with placental malaria is fewer compared to 
those in severe and non-severe malaria. Chondroitin sulfate A (CSA), hyaluronic 
acid (HA), non-immune IgG and a few unknown receptors are implicated 
candidates (Beeson et al 2000, Fried & Duffy 1996). CSA is the most prevalent 
receptor for pregnancy malaria as suggested by several studies (Duffy et al 2006, 
Gamain et al 2005, Tuikue Ndam et al 2005). 
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1.4.2 Rosetting  
 
Rosetting is the spontaneous binding of non-infected erythrocytes to erythrocytes 
infected with mature asexual blood stage Plasmodium parasites (Rowe 2005). Its 
association with severe malaria has been extensively studied both clinically and 
experimentally by several research groups (Carlson & Wahlgren 1992, Fernandez 
et al 1998, Rowe et al 1997). Rosetting seems to increase microvascular obstruction 
of blood flow and hide the parasitized cells thereby protecting them from 
phagocytosis, one of the main mechanisms of anti-parasitic immunity. Previously, 
it was postulated that rosetting facilitates the parasite to invade uninfected RBCs 
(Wahlgren et al 1989). However, experiments with a culture-adapted laboratory 
strain PA1 showed conclusively that there was no difference in invasion rates 
between the isogenic rosetting and non-rosetting parasites in this strain (Clough et 
al 1998). All Plasmodium spp studied so far can form rosettes invitro (Fernandez & 
Wahlgren 2002, Rowe et al 2000). Different independent studies in malaria 
endemic areas have suggested that rosetting is associated with severe malaria 
(cerebral) and anemia (Fairhurst et al 2005, Newbold et al 1997, Roberts et al 2000). 
Nevertheless, studies in Papua New Guinea and some areas in Africa failed to 
correlate rosetting capability and diseases severity (Rogerson et al 1996). Host 
genetic factors might be the reason for the discrepancy between these studies. The 
rosetting capacity of parasites originating from cases of severe malaria and 
uncomplicated malaria were compared, parasites isolated from severe malaria 
displayed much higher rosetting rates than those causing uncomplicated malaria 
(Heddini et al 2001). In a recent study rosetting rates of fresh isolates from 
Ugandan children with severe and mild malaria were determined. It was clearly 
found that the rosetting rate of infected RBCs from severe patients was higher 
than that of infected RBCs of patients with mild malaria and giant rosettes were 
observed significantly more frequent in severe isolates (Normark et al 2007). These 
findings indicated that parasites causing severe disease are phenotypically 
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different from those causing mild disease, prompting the need to focusing studies 
on the composition of rosetting parasites. It was also found that serum from 
patients with severe malaria contained a low titer of anti-rosette specific 
antibodies, while patients with uncomplicated malaria had a higher titer of anti-
rosette antibodies (Treutiger et al 1992). These observations indicate that anti-
rosetting immunity is important factor in disease outcome. 
1.4.2.1 Rosetting receptors on RBC surface 
 
Rosetting receptors are diverse. To date, four rosetting receptors have been 
identified on RBCs: ABO blood group antigens, heparin sulfate-like 
glycosaminoglycans (HS like GAGs), CD36 and compliment receptor 1(CR1) 
(Chen et al 1998, Mayor et al 2005, Rowe et al 1997, Vogt et al 2003). Stable rosettes 
require participation of multiple serum components such as non-immune human 
immunoglobulins as well as other serum proteins (Luginbuhl et al 2007, Treutiger 
et al 1999). Oligosaccharides of the ABO blood group were the first host receptors 
identified in rosetting process, mainly blood group A antigens (Barragan et al 
2000). Individuals with blood group A antigen phenotype are more frequently 
affected by severe malaria and coma than those of other blood groups.  Studies 
have shown that rosetting is reduced in blood group O RBCs compared with the 
non-O groups (A, B and AB) in P. falciparum laboratory strains (Carlson & 
Wahlgren 1992) and field isolates (Udomsangpetch et al 1993). Recent evidence 
indicates that blood group O provides protection against severe P. falciparum 
malaria through the mechanism of reduced rosetting (Rowe et al 2007, Uneke 
2007). CD36 is present in low copy numbers in mature RBCs, and it is difficult to 
accommodate its participation in rosetting. In contrast CR1 is widely distributed 
on the RBC surface, and individuals deficient in CR 1 are clinically resistance to 
severe malaria, as the parasites lose the capacity to form rosettes (Rowe et al 1997). 
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1.4.3 PfEMP 1 and var genes 
 
P. falciparum erythrocyte membrane protein 1 plays a central role in host parasite 
interaction. PfEMP1 is expressed on the surface of infected RBCs during late stage 
blood infection where they mediate parasite adhesion to host cells resulting in 
sequestration and immuno-modulation. PfEMP1 is encoded by members of the var 
superfamily of genes that is present in about 60 copies per genome. Only one var 
gene is expressed in a single parasite at a time, switching of expression from one 
variant to another changes the antigenic properties and results in antigenic 
variation (Scherf et al 1998). Switches in var gene expression correlate with 
changes in binding pRBCs (Scherf et al 1998), which seems to allow the parasites 
to establish chronic infections and sequester to different sites in the body. var 
genes are found on all chromosomes except 14. The majority of var genes are 
located in subtelomeric regions and some cluster in central parts of chromosomes 
4, 6, 7, 8 and 12 in 3D7 strain. var genes in subtelomeric regions are more 
vulnerable to recombination and presumably undergo frequent sequence 
alterations. Though the centrally located var genes are relatively conserved, gene 
recombination events affect their stability (Freitas-Junior et al 2000). As for 
sequence polymorphism, the sizes of var genes are very diverse ranging from 6-13 
kb. The classical var genes have a two-exon structure interrupted by a 1 kb var 
intron. Exon 1 encodes an extremely diverse exposed extracellular portion which 
is constituted of a semi-conserved N-terminal segment (NTS) and several different 
domains, some of which have been shown to be responsible for binding and a 
predicted transmembrane (TM) domain. The second exon encodes a more 
conserved cytoplasmic tail (acidic terminal sequence, ATS), anchoring the protein 
to the knob structure on the pRBC surface (Waller et al 2002).  
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The extracellular binding domain of PfEMP1 is highly variable. Each PfEMP1 
molecule consists of a variable number of structurally unique domains. There are 
four types of building blocks: the semi-conserved N-terminal segment (NTS) 
located on the amino terminus, the Cystein-rich InterDomain Regions (CIDR), 
cysteines-rich domain known as Duffy Binding-like (DBL) domains and the C2 
domain (Figure 2). DBL domains are homologous to P. falciparum erythrocyte 
binding antigen (EBA) and to P. vivax and P. knowlesi Duffy binding proteins 
(DBP). These molecules are involved in the invasion of the RBCs by binding to 
RBC proteins, such as to the Duffy antigen or to glycophorin A (Gaur et al 2004). 
The diverse exon1 structures of PfEMP1 variants can be categorized by their 
domain combinations, typically ranging from 2-6 DBL sequence classes (α, β, γ, δ, 
ε, and x), there are two distinct types DBLα domains (α and α1) based on the 
number of conserved cysteines and other hydrophobic residues (Robinson et al 
2003). There are only two CIDR sequence classes (α and β) and the C2 domain is 
conserved (Gardner et al 2002). Thirty-one different architectural types were 
described in the three (3D7, HB3 and IT4) sequenced parasite var repertoires 
(Kraemer et al 2007). Interestingly certain tandem domain combinations were 
consistently preserved e.g DBLα-CIDR1, DBLβ-c2, and DBLδ-CIDR. Most PfEMP1 
variants have a semi-conserved protein head structure consisting of NTS- DBLα-
CIDR1 domains (Gardner et al 2002). Sequences of DBL1α domain are relatively 
conserved compared to other domains within PfEMP1 but still highly diverse. 
DBL1α has been a target for the majority of molecular epidemiological studies of 
var gene since degenerate primers are able to amplify different sequences from 
laboratory clones and wild isolates from different places (Barry et al 2007, Bull et 
al 2005, Fowler et al 2002, Kaestli et al 2004, Kirchgatter et al 2000, Kyes et al 1997, 
Kyriacou et al 2006, Rottmann et al 2006, Taylor et al 2000a, Ward et al 1999). 
Although all var genes maintain a basic architecture, the amino acid sequence is 
highly variable when comparing PfEMP1 proteins among paralogues and across 
Chapter One 
 
 16 
parasite isolates. This suggests repertoire of PfEMP1 is virtually unlimited within 
natural parasites populations. Most PfEMP1 proteins have an overall amino acid 
identity less than 50% in individual domains even among proteins of the same 
architectural type (Kraemer et al 2007). There is minimal overlap of DBLα tags in 
population surveys of parasite isolates (Barry et al 2007). The vast antigenic 
diversity of PfEMP1 proteins in the parasite population may help to explain why 
individuals are repeatedly susceptible to P. falciparum infections and never 
develop sterilizing immunity. Despite the fact that the diversity of variant antigens 
is so large, hyperimmune human sera from distinct geographical locations are able 
to recognize pRBC and thus presumably PfEMP1 from East or West Africa 
(Aguiar et al 1992), signifying that some epitopes are semi conserved and globally 
related, possibly due to  common ancestors. 
 
1.4.3.1 PfEMP1 binding domains 
 
In vitro studies have identified a range of host receptors binding pRBCs. Different 
domains of PfEMP1 seem to have diverse binding affinities to different endothelia 
receptors. The regions responsible for the binding of PfEMP1 proteins have been 
mapped to the DBL and CIDR domains. PfEMP1 proteins have related protein 
architecture, but differ broadly in sequence, domain composition and binding 
specificity for both protein and carbohydrate substrates (Figure 2). DBL and CIDR 
domains can be divided into different sequence types on the basis of sequence 
similarity (Smith et al 2000b). Obviously domains that bind to the same host 
receptor are related. For example nearly all CIDRα type domains bind to CD36, 
whereas CIDRβ domains do not bind to CD36 (Robinson et al 2003). DBLα binds 
to heparin sulphate, heparin, CR1, and blood group A (Chen et al 1998, Rowe et al 
1997). DBLβc2 domain of a PfEMP1 has been mapped as an ICAM-1 binding 
receptor (Smith et al 2000a). In 3D7 clone, the number of PfEMP1s with potential 
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ICAM-1 binding domains is quite few (Rasti et al 2004). One could speculate that 
only a limited number of parasites can bind to this receptor. Whether these 
parasites only contribute to cerebral malaria remains to be elucidated. CSA 
binding domain has been mapped to CIDR1α, DBL3γ and DBL5δ in the PfEMP1 
protein (Buffet et al 1999, Degen et al 2000, Reeder et al 1999) 
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Figure 2. A schematic diagram of PfEMP1 protein architecture and binding 
domains  
(a) The prototypical PfEMP1 extracellular regions consist of an NTS and DBLα-CIDR1 “semi 
conserved head structure” followed by a DBL2δ-CIDR2β tandem. 
(b) Larger PfEMP1 proteins, includes the DBLβ, γ and ε types arrayed differently. Mapped 
binding traits for receptors are indicated with the domain that is responsible for binding 
(Explanation are given in the text). Adapted from (Smith et al 2001) 
 
Based on chromosomal location, gene orientation and the conserved 5’flanking 
sequences in 3D7, var genes have been grouped into three distinct groups 
commonly called A, B and C (Gardner et al 2002, Voss et al 2000) with two 
intermediate groups (B/A and B/C) Lavstsen et al (2003). var group A genes are 
best defined, and are comprised of  UpsA flanking sequences,  located in sub-
telomeric regions transcribed toward the telomere, encoding PfEMP1 with a 
complex domain structure. var group B is the largest group within the var gene 
family, they consists of telomeric genes flanked by UpsB sequences that are 
transcribed toward the centromere, and var group C are flanked by UpsC 
sequences and are located in central chromosomal regions (Figure 3). Group B/A 
genes are very similar in location and transcriptional orientation to group B genes, 
but are located further from the telomere following other var genes or 
pseudogenes. In contrast, group B/C genes have an UpsB-like 5' flanking 
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sequence, but are located in central chromosomal regions. Thus, it has been 
postulated that groups B/A and B/C represent transitional groups between the 
major groupings (Kraemer & Smith 2003). Both var group A and B/A genes are 
larger and have a more complex domain structure than other groups and encode a 
distinct protein head structure (Lavstsen et al 2003). Characteristic of P. falciparum 
var gene groups are summarized in Table 1 below 
 
Table 1: Characteristics of P. falciparum var gene groups 
var 
gene 
group 
Upstream 
sequence 
Position 
Orientation 
(direction of 
transcription) 
No. of 
genes 
in 3D7 
No. of 
DBL 
domains 
No. of 
cysteines in 
amplified 
DBL1α tag 
A UpsA Subtelomeric Telomeric 10 2-5 2 
B/A UpsB Subtelomeric Centromeric 4 4-7 2 or 4 
B UpsB Subtelomeric Centromeric 21 2-3 2 or 4 
B/C UpsB Central Telomeric 10 2-3 4 
C UpsC Central Telomeric 13 2-3 4 
Adapted from (Kyriacou et al 2006) with modifications 
 
Inter-isolate comparisons have revealed the existence of four unusual var genes: 
var1csa, var2csa, Type 3 var and var4 genes which appear in nearly all parasite 
isolates (Kraemer & Smith 2003). Type 3 var and var4, it became that they belong 
to subgroup A because they are both located in the subtelomeric region of 
chromosomes and are transcribed towards the telomere (Kraemer et al 2007). In 
field isolates var2csa appears to have semi-conserved homologues and it seems to 
play a critical role in the pathogenesis of pregnancy associated malaria. Its 
conserved sequence structure makes it a possible vaccine target against placenta 
malaria (Rowe & Kyes 2004). var4 in 3D7 P. falciparum clones has been shown to be 
highly transcribed in severe malaria patients (Jensen et al 2004). No function has 
yet been ascribed to the proteins encoded by var1csa and Type 3 var. 
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var genes are not the only gene family localized at the teleomers. The repetitive 
interspersed family (rifin) and the subtelomeric variable open reading frame 
family (stevor) are localized adjacent to the var genes (Gardner et al 2002). Both 
families show antigenic variation and are associated with the RBC membrane, 
their function is not yet clear. RIFINs have been implicated in the formation of 
rosettes between pRBC and uninfected RBCs, however this role has yet to be 
verified (Kyes et al 1999). 
 
Sequence and binding analysis of 3D7 var genes indicate recombinant CIDR 
domain based on var group A sequences do not bind to CD36, by contrast to CIDR 
domains produced on the basis of var group B and C (Robinson et al 2003). Thus, 
var gene recombination hierarchies may promote the evolution of PfEMP1 
adhesion groups with different patterns of sequestration and disease. A 
fundamental question is whether the gene organization observed in 3D7 occurs in 
other parasite isolates and contributes to a general recombination mechanism 
shaping the variant antigen repertoires.  
 
 
Figure 3. Chromosomal organization of var genes 
var genes are classified according to upstream promoter type, direction of transcription and 
binding phenotype. Most var genes are found at the subtelomeric part of P. falciparum 
chromosomes and some clustered in internal regions on chromosomes. Arrows indicate the 
direction of transcription. TAREs: telomere associated repeat elements (Details are given in the 
text). Adapted from (Kyes et al 2007) 
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1.4.3.1 Severe Malaria and PfEMP1 expression 
 
The clinical outcome of a malaria infection depends on multiple factors, including 
parasite and host polymorphisms and immune status (Mackintosh et al 2004). 
Severe malaria has previously been associated with expression of restricted subset 
of var genes that are antigenically conserved within the repertoires of the var gene 
family (Bull et al 2000, Nielsen et al 2002). Of the different malaria diseases 
syndromes, the role of PfEMP1 is best understood for pregnancy-associated 
malaria (PAM) Gamain et al (2007). In malaria endemic areas primigravidae 
women are the prime victims of placental malaria. During pregnancy, women 
who have previously developed malaria immunity become susceptible to infected 
RBCs which binds to CSA in the placenta and trigger development of PAM and 
other forms of severe disease. After one or two pregnancies, women develop 
protection to the placental form of the disease. This protection is correlated with 
development of antibodies that recognize placental parasite from different 
geographical regions, suggesting that the surface molecules expressed by placental 
infected RBCs may have unique and conserved features. VAR2CSA has been 
identified and found to be conserved across global isolates, and is transcriptionally 
up-regulated in placental isolates and parasites selected to bind CSA (Gamain et al 
2005). Disruption of var2CSA causes infected RBCs to loose their ability to bind 
CSA.  
 
Similar to PAM, parasites variants associated with severe childhood malaria 
appear to have less antigenic diversity than those associated with mild infections 
indicated by broader serological reactivity with semi immune children’s sera 
(Nielsen et al 2002). The adhesive phenotypes associated with severe childhood 
malaria are less well defined than PAM, and the extent of PfEMP1 remains to be 
characterized. Severe childhood malaria encompasses several clinical syndromes 
(severe anaemia, cerebral malaria, respiratory distress, and hypoglycaemia and 
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has been linked to sequestration of pRBC to many tissues. To determine if specific 
PfEMP1 proteins are responsible for one or more of the severe malaria syndromes 
is one of the pertinent research questions within the scientific community in search 
for vaccine target candidate. By using different approaches researchers are 
analysing var gene expression during infections, characterizing the antibody 
response to the pRBC surface, and investigating the binding properties of PfEMP1 
protein. Jensen and colleagues investigated the antibody reactivity of PfEMP1 
protein by panning 3D7 pRBCs on semi-immune children sera. UpsA var 
transcripts were found to be up-regulated suggesting that UpsA var genes might 
contain common PfEMP1 antigenic types that are expressed in early childhood 
infections, this report led to proposition that UpsA genes might be associated with 
severe malaria and probably UpsB and UpsC var genes are associated with mild 
infections (Jensen et al 2004). 
 
To date, only six studies have been carried out to investigate types of var genes 
sequences from field isolates that are expressed during disease, and patients with 
different forms severe malaria have been involved (Bull et al 2005, Kaestli et al 
2006, Kirchgatter & del Portillo 2002, Kyriacou et al 2006, Montgomery et al 2007, 
Rottmann et al 2006). These studies are complicated by the extensive variation and 
simultaneous transcription of var genes and technical difficulties such as primer 
bias and clinical definition of severe malaria. Differences in epidemiology, severe 
disease classification, and var classification make comparison across studies 
difficult. However, with larger sample sizes and strict case definition of severe 
malaria it would probably give a different picture of expressed PfEMP1 sequences 
and disease phenotype. In three studies, expressed DBLα sequence tags were 
classified by the number of cysteines encoded (Kirchgatter & del Portillo 2002) as 
well as other features (Bull et al 2005, Kyriacou et al 2006). Genes with two 
cysteines in this region (2cys/DBLα1-type) are likely to represent UpsA var genes 
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or a subgroup of B/A (Kyriacou et al 2006) whereas those of four cysteines are 
either UpsB or UpsC. The expression of (2cys/DBLα1-UpsA) sequence variant 
correlates with rosetting phenotype (Bull et al 2005), with cerebral malaria in 
Malian children (Kyriacou et al 2006) and non cerebral severe malaria in adults 
(Kirchgatter & del Portillo 2002). A study in French Guyana involving 19 severe 
malaria patients demonstrated that there were particular DBLδ var sequences 
expressed exclusively by these patients as opposed to 32 patients with mild 
malaria (Ariey et al 2001). Similar results were obtained in Brazil where parasites 
from patients with severe malaria transcribed predominantly DBL1α var 
sequences lacking 1-2 cysteines residues, while parasites from patients with mild 
malaria transcribed preferentially DBL1α var sequences without these deletions 
(Kirchgatter & del Portillo 2002). In our previous case control study in Ifakara, 
Tanzania, using quantitative Real-time PCR analysis we reported a correlation 
between expression of both UpsA and UpsB var expression and severe malaria 
cases in children (Rottmann et al 2006). In Papua New Guinea (PNG), our group 
reported only UpsB var expression correlated with severe disease (Kaestli et al 
2006). However, in PNG, 80% of the population is deficient in CR1, a major 
receptor for pRBC rosetting. Additionally in PNG, rosette phenotype does not 
relate with severe disease. Human genetic polymorphisms in cytoadhesion 
receptors may influence PfEMP1 disease associations. Strict correlations between 
any group of var genes and disease manifestation have not been found. 
 
Different parasite genotypes are potentially virulent, severe malaria syndromes 
are relatively infrequently complication of malaria infections suggesting that 
isolate-transcendent disease immunity can develop rapidly. PfEMP1 immunity is 
an important factor in the rapid development of disease immunity. The variant 
antigen within the var genes family is vast, serological evidence suggests that the 
variant antigens associated with disease may be antigenically restricted (Bull et al 
2000).  
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Figure 4. PfEMP1 expression and disease phenotype 
This schematic figure summarizes the PfEMP1 grouping and their potential role in infection and 
diseases (detailed explanation are given in the text above). Dashed and solid lines indicate 
hypothetical infection outcomes; line density represents the level of confidence in the prediction. 
Adapted from (Kraemer & Smith 2006). 
 
However, this current understanding of cytoadherence and morbidity association 
has become even more complex with new finding of Montgomery and colleagues, 
who tested PfEMP1 expression in postmortem organs and tissues. Their most 
intriguing finding was that parasites of one child expressed several var genes in a 
tissue specific manner (Montgomery et al 2007). 
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1.5 Antigenic variation of var genes 
 
Survival of the malaria parasite in human host is constantly challenged by host the 
immune system. P. falciparum has developed a process called clonal antigenic 
variation which allows the parasite to overcome immune attacks by periodically 
changing the antigenic phenotype at the surface of pRBCs as reviewed in (Kyes et 
al 2001). Switching of surface expression can alter the interaction with host tissues 
which is highly linked to pathogenicity. var genes have been shown to be 
expressed in a mutually exclusive manner at both the mRNA and protein level 
(Voss et al 2006). By limiting expression to a single var gene copy the parasite 
limits exposure to a single antigen at a time within the host’s immune system. 
Over time the immune system generates an antibody response against the surface 
of the pRBC, thus recognizing the predominantly expressed form of PfEMP1 and 
consequently selecting for subpopulations of parasites that arise via switching 
expression to different var genes. In malaria infections, especially in chronic cases, 
the peaks of parasitemia may fluctuate over time, apparently this phenomenon is 
inexhaustible in single infection, and is normally characterized by oscillations of 
peripheral parasitemia having magnitudes varying from undetectable levels to 
high parasite burden (Miller et al 1994). Recrudescence with the appearance of 
different antigenic parasites is an essential strategy for malaria parasite survival. 
Switching expression into different var genes makes the host immune response 
frequently inefficient, leading to prolonged infection. Malaria parasites challenge 
the immune system in at least two ways; through genetic recombination in the 
mosquitoes, a process which results in unlimited changes of the malaria genomic 
pool in the wild, and through the existence of several variable antigenic families.  
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Chapter Two 
2.0 General Objectives and Study Population 
2.1 Study Goal 
 
Clinical manifestations of falciparum malaria differ remarkably from infection to 
infection; disease symptoms often remain mild, in most cases only a small 
proportion of patients develop severe complications, which encompasses a variety 
of clinical syndromes such as cerebral malaria, severe malaria anaemia, metabolic 
acidosis,  respiratory distress or prostration. These syndromes may have different 
underlying pathogenic mechanisms. The reasons why certain children develop 
life-threatening complications, whilst the majorities are able to tolerate high 
parasite densities without severe clinical symptoms remain elusive.  Severe 
malaria has previously been associated with expression of a restricted and 
antigenically conserved subset of variant erythrocyte surface antigens (Bull et al 
1999), suggesting that expression of certain var genes may be associated with 
specific disease manifestations. Several sero-epidemiological studies have shown 
that antigens associated with severe disease are frequently recognized by sera 
from semi immune individuals (Bull et al 2000, Nielsen et al 2002). This suggests 
that expression of a particular surface molecule may be associated with specific 
disease manifestations.  
 
The main goal of this thesis was to explore the relationships between sequence 
and disease phenotype by analysing and comparing expressed var gene fragments 
of different Plasmodium falciparum isolated from Tanzanian children with different 
manifestations of malaria (severe and asymptomatic malaria) in order to 
determine whether there are conserved var sequences motifs that are associated 
with the severity of the disease. 
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2.2 Specific Objectives 
 
1.  To identify expressed var genes in naturally infected individuals 
 
2. To identify expressed var genes associated with severe malaria through a 
case control study 
 
3. To determine the var gene distribution in clinical and  asymptomatic cases 
 
4. To determine the phylogenic relationship of sequences generated from 
severe and asymptomatic isolates 
 
5.  To estimate the repertoire of expressed var genes 
 
2.3 Study area and population 
2.3.1 Study area 
 
These studies were carried out in Ifakara, a semi rural area in south – eastern 
Tanzania from June to September 2003 and January 2005. Ifakara is an area of 
moderate perennial P.falciparum transmission surrounded by areas of intense 
transmission. Patients with severe malaria were recruited in a pediatric ward of 
Saint Francis Designated District Hospital (StFDDH). Children with asymptomatic 
malaria were recruited from a retrospective survey in nearby villages surrounding 
the hospital. Data from the hospital showed that 40 % of the children admissions 
are due to infection with P.falciparum. Malaria is reported to account for a case 
fatality rate of 2.4 % in this hospital (Schellenberg et al 2004).  
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2.3.2 Study Population and Recruitment Criteria 
 
Ifakara Health Research & Development Centre (IHRDC) is closely linked to 
StFDDH. This link provides the basis for a comprehensive clinical surveillance 
system and allows the research activities on severe childhood illnesses. Children 
less than 5 years of age presenting severe malaria at the hospital were recruited in 
the study after obtaining the informed consent from the children’s parents or 
guardians. Severe malaria cases were defined according to the world health 
organization (WHO) criteria for severe malaria (WHO 2000). In brief, a child is 
considered to have severe malaria if had a P. falciparum positive smear as the 
primary diagnosis and no other cause for illness and in addition had one of the 
following symptoms: (1) prostration (2) respiratory distress or (3) severe anaemia. 
In this study recruitment criteria were restricted to patients admitted with cerebral 
malaria (unrousable coma with a Blantyre score ≤ 3 and no other detectable cause 
of coma). Exclusion criteria were confirmed co-infections, malnutrition (mid-
upper arm circumference [MUAC] of ≤ 12 cm), haemoglobin ≤ 5 g/dL, lactate ≥ 5 
mmol/L, glucose ≤ 2.2 mmol/L) or antimalarial treatment during the past 14 days. 
Clinical and epidemiological data were collected using inpatient forms (see 
appendix 1). The control group consisted of children with asymptomatic malaria 
(presence of P. falciparum, axillary temperature of ≤ 37.5 °C and no other 
symptoms), and were recruited by a convenience sampling in the nearby villages 
after obtained informed consent from the children’s parents or guardians. These 
children were the screened for the presence of malaria parasites by using rapid 
diagnostic test. Children with P. falciparum infection were then confirmed at 
IHRDC laboratory by Giemsa-stained blood films.  
 
2.4 Ethical Considerations 
The proposal for this study was reviewed and approved by Ifakara Health 
Research and Development Centre Institution Review Board (IRB) and the 
Medical Research Coordinating Committee of the National Institute for Medical 
Research in Tanzania. 
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The var gene family of Plasmodium falciparum encodes the variant surface antigen Plasmodium falciparum
erythrocyte membrane protein 1 (PfEMP1). PfEMP1 is considered an important pathogenicity factor in P.
falciparum infection because it mediates cytoadherence to host cell endothelial receptors. var genes can be
grouped into three major groups, A, B, and C, and the conserved var genes, var1-4, according to sequence
similarities in coding and noncoding upstream regions. Using real-time quantitative PCR in a study conducted
in Tanzania, the var transcript abundances of the different var gene groups were compared among patients with
severe, uncomplicated, and asymptomatic malaria. Transcripts of var group A and B genes were more
abundant in patients with severe malaria than in patients with uncomplicated malaria. In general, the
transcript abundances of var group A and B genes were higher for children with clinical malaria than for
children with asymptomatic infections. The var group C and var1-like transcript abundances were similar
between the three sample groups. A transcript abundance pattern similar to that for var group A was observed
for var2csa and var3-like genes. These results suggest that substantial and systematic differences in var gene
expression exist between different clinical presentations.
The particular virulence of Plasmodium falciparum is linked
to the cytoadhesion properties of infected erythrocytes in deep
vascular beds leading to multiple complications and symptoms
(19). This process of sequestration is thought to be an immune
evasion strategy to avoid splenic clearance (2, 8, 14). Infected
erythrocytes also form rosettes with uninfected erythrocytes
(27) or form larger groups involving platelets, called clumps
(25). P. falciparum erythrocyte membrane protein 1 (PfEMP1),
encoded by the var gene family and expressed on the surfaces
of infected erythrocytes, mediates binding to host endothelial
receptors and is an important target for protective immunity
(1, 7, 9, 13, 31, 34). Each parasite possesses 50 to 60 var gene
copies, and switching between surface expression of the various
var gene products results in antigenic variation while maintain-
ing or changing adhesion properties (12, 31). Immunity pre-
venting severe malaria and death develops naturally in exposed
populations. In areas of intense transmission, the main burden
of malaria morbidity and mortality is among children between
6 months and 5 years of age (32). Adults are often infected
asymptomatically, and severe disease is rare.
It has been shown that parasites from patients with severe
malaria express a different subset of surface antigens that are
more frequently recognized by sera from malaria-exposed in-
dividuals, including young children, than parasite antigens
from older children with mild malaria (5, 23). It has also been
shown that this subset of surface antigens is serologically con-
served among different geographical regions (24), and it is
therefore crucial to identify the molecular phenotype of such a
subset to develop a disease-ameliorating vaccine.
Linking PfEMP1 expression to disease outcome is inherently
difficult due to the extensive inter- and intragenomic variation
in var genes. Previous studies predominantly relied on reverse
transcription-PCR using degenerate primers, with subsequent
cloning and sequencing (4, 17). While these studies have shown
that the transcription of certain DBL1 domains is associated
with either severe malaria or rosette formation, they have been
unable to identify a clear correlation between var gene groups
and disease outcomes.
Sequencing of the 3D7 genome revealed that P. falciparum
parasites contain 50 to 60 var genes that can be grouped into
three major groups, A, B, and C, and the single-copy in-
tergenomic conserved var genes, var1 and var2csa, according to
sequence similarities in both noncoding and coding sequences
(12, 18, 22, 37). Evidence is emerging for the existence of
subgroups of var group A, namely, type 3 var (18) and type 4
var (12, 15) genes, referred to here as var3 and var4, respec-
tively. The functional relevance of this genetic structuring is
indicated by the fact that CIDR domains of group B and C
PfEMP1 variants bind to CD36, in contrast to CIDR domains
of group A variants (26). Parasites selected for chondroitin
sulfate A and human bone marrow endothelial cell binding in
vitro dominantly express var2csa and var4, respectively (15,
29), also supporting the notion of functional genetic substruc-
turing.
The genetic organization of var genes was exploited to de-
* Corresponding author. Mailing address: Swiss Tropical Institute,
Socinstrasse 57, CH 4002 Basel, Switzerland. Phone: 41-61-284 8116.
Fax: 41-61-284 8101. E-mail: hans-peter.beck@unibas.ch.
† M.R. and T.L. contributed equally to this work.
3904
sign primers targeting the conserved regions defining var1-3
genes and group A, B, and C var genes. Using these primers in
quantitative reverse transcription-PCR, the transcript abun-
dances of var genes were measured in parasites collected from
P. falciparum-infected Tanzanian children with asymptomatic
malaria (AM), uncomplicated malaria (UM), and severe ma-
laria (SM). Our data demonstrate an increase in transcript
abundance for group A and B var genes in parasites causing
severe malaria compared to that in parasites causing uncom-
plicated malaria.
MATERIALS AND METHODS
Study design and population. The study was conducted in Ifakara, a semirural
area in southern Tanzania, from June to September 2003. Ifakara is an area of
moderate perennial P. falciparum transmission surrounded by areas of more
intense transmission.
Of all children seeking medical treatment, 40% were admitted to the hospital
due to infection with P. falciparum. Malaria is reported to account for a case
fatality rate of 2.4% in this hospital (30). Samples were collected from children
(aged 4 to 59 months) presenting with malaria at the hospital. Severe malaria
cases were defined according to the World Health Organization criteria for
severe malaria (38). Uncomplicated malaria was defined as the presence of
asexual P. falciparum, an axillary temperature of 37.5°C, or symptoms of head-
ache or myalgia but no other signs of severe malaria. Exclusion criteria were
confirmed coinfection, malnutrition (mid-upper-arm circumference [MUAC]
of 12 cm), or antimalarial treatment during the last 14 days. Asymptomatic
patients (presence of P. falciparum, axillary temperature of 37.5°C, and no
other symptoms) were age-matched as closely as possible to the patients with
severe cases by convenience sampling in the same area in January 2005. P.
falciparum infection was determined by Giemsa-stained blood films, and para-
sitemia was counted as parasites per 200 white blood cells. Ethical clearance for
this study was obtained from the Ifakara Health Research and Development
Centre’s scientific review board and the Medical Research Coordinating Com-
mittee of the National Institute for Medical Research in Tanzania.
Blood samples. After obtaining written informed consent from parents, 1 to 2
ml of venous blood from children was collected in EDTA tubes. Erythrocytes
were separated from serum by centrifugation and washed with 40 ml phosphate-
buffered saline, 5 volumes of TRIzol reagent (Invitrogen) was added to the
erythrocyte pellet, and the sample was frozen at 70°C. Samples were collected
from 52 patients with SM, 56 patients with UM, and 19 AM children. 3D7
parasite lines were generated as described elsewhere (33).
DNA, RNA, and cDNA. Genomic DNAs were isolated from infected red blood
cells (100 l blood was frozen after adding 2 volumes of 6 M guanidine HCl, 50
mM Tris, pH 8.0, 20 mM EDTA) with a QIAamp blood kit (QIAGEN), and total
RNAs were extracted by using TRIzol reagent (Invitrogen) twice, as recom-
mended by the manufacturer, and treated with DNase I (Invitrogen) for 30 min
at 37°C. The absence of DNA in RNA samples was confirmed by stable base
fluorescence after 40 cycles of real-time PCR with seryl-tRNA synthetase prim-
ers (29). Reverse transcription was performed using Superscript II (Invitrogen)
and random hexamer primers in a total volume of 40 l according to the
manufacturer’s recommendations. Hereafter, two different real-time PCR meth-
ods were used to quantify var transcript abundance, namely, a SYBR green-
based assay and a minor groove binder (MGB) probe-based assay.
Validation of SYBR green method and quantification of var gene transcript
abundance. Quantitative real-time PCR using Quantitect SYBR green PCR
master mix (QIAGEN) was performed on a Rotorgene thermal cycler system
(Corbett Research) as previously described, using the seryl-tRNA synthetase
(primer pair p90) and fructose-bisphosphate aldolase (primer pair p61) genes as
endogenous controls (23). Primers targeting var gene groups A, B, and C were
designed based on sequence similarities in the 3D7 var repertoire (22). The
majority of var genes are flanked by conserved upstream region upsA, upsB, or
upsC. Primer pairs B1 and B2 target the conserved upstream region of var B
genes, whereas C1 and C2 target the upstream region of var C genes. Attempts
to design primer pairs targeting upsA with sufficient amplification in the SYBR
green assay were unsuccessful. In strain 3D7, grouping into groups A, B, and C
is also maintained in the coding sequences for DBL and ATS. This was ex-
ploited to design primer pairs A1, targeting DBL of group A var genes; A2 and
A3, targeting exon 2 of group A var genes; and BC1 and BC2, targeting exon 2
of both B and C var genes. Additional primers were designed to target conserved
regions of var1 and var2csa 5 untranslated regions (UTRs) and var3 coding
regions (pvar1utr, pvar2utr, and pvar3). Primers designed to target var4 genes in
quantitative reverse transcriptase PCR amplified fragments with the expected
melting temperature (Tm) for 3/20 genomic DNAs from field samples only, and
this analysis was therefore left out subsequently. Seven annotated genes in 3D7
were predicted not to be targeted by any of these primer pairs. Primers are shown
in Table 1, and the 3D7 genes expected to be amplified by the respective primers
are listed in Table 2. The primers were validated as follows. Initially, all
primers were tested on 10-fold dilutions of 3D7 genomic DNA (gDNA). All
primers amplified fragments of the expected size and Tm, and sequencing of one
PCR clone from each amplification reaction revealed an expected target se-
quence. All primers had amplification efficiencies (E) between 1.85 and 2 [E 
10(1/slope of 10-fold-dilution gDNA standard curve)] (data not shown). Cycle threshold
(CT) values for primers targeting multiple genes were compared to those ob-
tained with the control primer p90, targeting a single-copy gene. The observed
	CTi
	CTi-obs-3D7  CTi  CTp90) was compared to the expected value estimated
from the number of predicted genes targeted in 3D7. A 	CT value reduction of
1 represents a duplication of targeted gene copies, and the estimated 	CTi-estt 
log(no. of targeted genes)/log(2) (Table 2). Most primer pairs amplified as ex-
pected; the primers were then tested on gDNAs from 20 field isolates, and the am-
plification results were compared to the p90 CT values (	CTi-obs-field 
n20	CTi  CTp90) (Table 2). All primer pairs yielded fragments with the sizes and
Tms expected from the amplifications of 3D7 gDNA, and all primers amplified with
similar efficiencies (95% confidence interval for (n 20)[CTi  CTp90], 0.8) from all
field isolates, with no significant difference (t test) between DNAs from severe
and uncomplicated malaria cases. The amplification efficiency for field isolate
gDNA was similar to that for 3D7 gDNA for most primer pairs, except C1, C2,
and BC2, indicating that these primers targeted fewer genes in field isolates than
in 3D7 and might reflect that a larger variation in var group C gene copy numbers
exists among parasites from naturally infected individuals. However, none of the
primer pairs showed any significant difference in amplification efficiencies be-
tween DNAs from severe and uncomplicated malaria cases.
Next, primers targeting var groups were tested on cDNAs from isogenic but
phenotypically distinct 3D7 parasites with known differential var transcript abun-
TABLE 1. SYBR green primers
Primer pair
Sequence (5–3)
Forward Reverse
A1 TTGGGRAATBTGTTAGTTAYRGCAA CTGCAAAACTKCGWGCAAG
A2 AACCCATCTGTRRATGATATACCTATGGA GTTCCAASGATCCATTRGATGTATTA
A3 AGGTAATGTTTTAGATGATGGTAT ACCAGAATATACATTATTTGATACATA
B1 CATCCGCCATGCAAGTATAA CGTGCACGATTTCGATTTTT
B2 ATCAAGGTAATTTCATACATATGTGATA GTCCGTGCACGATTTCGATTTT
C1 CACATCGATTACATTTTAGCGTTT TGTGGTAATATCATGTAATGG
C2 GTAGCGACAACCACGRYATCATGG CATTGTTAACATAGTCTACCATTA
BC1 GACAAAACTTTCACCCAATAGA AATGATCGGTGTAACCACTATC
BC2 CATCTGTTGCAAATTTATTCCAAATAC TCAGTAGTATCAGACATAAATGCATA
pvar1utr TGGCACATCTTTGGTATAAAA AAACCTTTATATTCCTGTAAAATTCA
pvar2utr CACGACATTAACAATACATGCAGA CATTGCATTCACAGACATTGG
pvar3coding CGTAAAACATGGTGGGATGA GGCCCATTCAGTTAACCATC
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dance patterns. These were nonmanipulated 3D7UM and 3D7SM selected on
hyperimmune serum (15). The transcription measured by group-specific primers
was compared to predicted changes calculated from absolute quantifications
using gene-specific primers. There was a clear association (R 0.904; P 0.0008
[Pearson correlation]) between results obtained with gene-specific and group-
specific primers (Fig. 1).
Assessment of Tms of fragments generated from cDNAs from collected
field samples showed that all primers amplified fragments with the expected
Tms in 90 to 99% of all included samples (not shown), indicating that the
primers targeted var sequences conserved in the parasite isolates. The CT
values for the two internal control genes showed with cDNAs from field
samples that reliable quantification could be performed from the collected
samples 	CTp90(, )  21.2 and 2.6; 	CTp61(, )  19.0 and 2.5]. As ex-
pected, there was a negative association between parasitemia and control
gene p90 CT values (representing the overall amount of cDNA) (regression
coefficient
[log2(parasitemia/blood sample volume): CTp90]
, 0.58; P  0.005).
Validation of MGB method and quantification of var transcript abundance.
Quantitative real-time PCR using MGB probes was performed using an ABI
PRISM 7200 sequence detection system (Applied Biosystems) as described by
Kaestli et al. (16), with few modifications. Briefly, cDNAs were synthesized from
total RNA, and a primary PCR with 16 cycles over the var 5 UTR-DBL1 target
sequence was performed prior to real-time PCR for var groups A, B, and C.
Primers and probes targeting upsA, -B, and -C for the MGB probe assay were
described by Kaestli et al. (16) (upsA-probe, upsB-probe, and upsC-probe). The
seryl-tRNA synthetase internal control gene was used for relative quantification
without prior amplification. The primers and probe were designed using Primer
Express software 2.0 (Applied Biosystems) and had the following sequences:
primer p90Probe_for, 5-ACCTCAGAACAACCATTATGTGCTT-3; primer
p90Probe_rev, 5-TGTGCCCCTGCTTCTTTTCTAA-3; and p90Probe, 5-6-
carboxyfluorescein-AGGTTACCACTCAAATACGCTGGATTCTCATCTTG-
6-carboxytetramethylrhodamine–6-carboxyfluorescein-3.
Data analysis. After all samples had been subjected to real-time PCR, the data
set was cleaned for subsequent statistical analysis. Data points were not consid-
ered if the Tm diverged more than 1°C from the expected value or if the CT value
was above 30. Transcript abundances were compared between clinical groups
after normalization to internal controls (yielding 	CT values) (Fig. 2). Based on
these, x-fold changes were calculated by the 		CT method (see Table 4). Com-
parisons between groups were made with one-way analysis of variance and
Intercooled Stata 8.0 analysis software.
RESULTS
Sample collection and clinical data. Samples were collected
from 52 children admitted to hospital with SM and 56 children
with UM. var gene transcription analysis was performed on
cDNAs from 42 SM and 52 UM cases. Twelve samples from 19
children with asymptomatic P. falciparum infections collected
during a village survey could be analyzed for var transcript
abundance. Clinical characteristics of all children from whom
cDNAs were available are presented in Table 3.
Comparison of var transcript abundance profiles. The var
group A transcript abundance was lowest in AM cases, higher
in children with UM, and highest in children suffering from SM
(Fig. 2; Table 4). Similar findings were obtained with primers
targeting the upsB upstream region, whereas data obtained
with primers targeting group C var genes indicated that group
C var genes were transcribed at the same level in the three
groups of children.
The BC1 primer pair was predicted to predominantly am-
plify fragments of B var genes, whereas BC2 primers were
expected to amplify a smaller subset of genes consisting of
group B, BC, and C var genes (Table 2). The BC1 primer
results showed that the targeted genes were transcribed at
higher levels by SM parasites than by UM or AM parasites. No
significant changes were observed in transcription of genes
targeted by the BC2 primer pair.
TABLE 2. Technical characteristics of var group primers for SYBR green real-time PCRa
Characteristic
Value or description for indicated primer pair
A1 A2 A3 B1 B2
Target region Grp A DBL1 Group A exon 2 Group A exon 2 upsB upsB
Targeted genes in 3D7 predicted
by alignments
PFD1235w, MAL7P1.1,
PF08_0141, PF11_0008,
PFD0020c, PF11_0521,
PF13_0003, PFA0015c,
MAL6P1.314,
PFI1820w
PFD1235w, MAL7P1.1,
PF08_0141, PF11_0008,
PFD0020c, PF11_0521,
PF13_0003, PFA0015c,
MAL6P1.314,
PFI1820w
PF11_0521, PFD1235w,
MAL7P1.1, PF13_0003,
PFD0020c, PF11_0008
MAL6P1.1, PF07_0139,
PF08_0142, PF10_0001,
PF10_0406, PF11_0007,
PF13_0001, PF13_0364,
PFA0005w, PFA0765c,
PFB0010w, PFB1055c,
PFC0005w, PFC1120c,
PFD0005w, PFD1245c,
PFE0005w, PFI0005w,
PFI1830c, PFL0005w,
PFL0935c, PFL2665c
MAL6P1.1, PF07_0139,
PF08_0142, PF10_0001,
PF10_0406, PF11_0007,
PF13_0001, PF13_0364,
PFA0005w, PFA0765c,
PFB0010w, PFB1055c,
PFC0005w, PFC1120c,
PFD0005w, PFD1245c,
PFE0005w, PFI0005w,
PFI1830c, PFL0005w,
PFL0935c, PFL2665c
Coverage in 3D7 (group) All A genes, including
var3 types
All A genes, including
var3 types
All A genes, excluding
var3 types
All B genes All B genes
Fragment Tm (°C) in 3D7 77.2 73.6 72.1 75.4 75.6
Fragment length (bp) 110–120 100 160 260 190
Fragment Tm (°C)
b in field isolates
(SD) [no. of PCR-negative
genomes/total]
77.2 (0.4) [0/20] 73.7 (0.2) [0/20] 72.2 (0.4) [0/20] 75.1 (0.4) [0/20] 75.3 (0.4) [0/20]
	CTi-estimated-3D7 gDNA [log(no. of
targeted genes)/log(2)]
3.3 3.3 2.6 4.5 4.5
	CTobserved-3D7 gDNA
CTi  CTp90) 2.0 2.5 1.9 3.7 3.9
	CTi-mean-observed-field gDNA [(CTi  CTp90)
(95% CI)]c
1.2 (0.4) 1.9 (0.3) 1.9 (0.3) 4 (0.2) 3.6 (0.2)
a The following 3D7 var genes were not targeted by any primer pair: PFD0635c, PF07_0050, PFL1955w, MAL7P1.55, MAL6P1.4, MAL6P1.316, and PFL0020w
(three BA and four BC genes).
b Mean Tm based on real-time PCR on 20 gDNA and 108 cDNA field isolates.
c 95% confidence intervals based on real-time PCR on gDNAs from 20 field isolates. The design and validation of primers and probes for the MGB real-time PCR
assay were described by Kaestli et al. (16).
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The primer pairs targeting the var1 and var2csa (Table 1)
gene family showed no significant difference in transcript abun-
dance between the cohorts, although a trend of increased
var2csa transcript abundance with increased severity of disease
was observed. In contrast, primers targeting the var3 family
showed significantly higher transcript abundance in SM than in
AM samples and a trend of higher transcript abundance with
increased severity of disease (Fig. 2). var3 belongs to the group
A var genes, and a correlation between the transcript abun-
dances of var3 and group A var genes would be expected. The
strongest correlation of var3 transcript abundance was found
with transcripts measured by A2 (Rpvar3:A2  0.482; P 0.0012
[Spearman rank]).
High transcript abundances of group A and B var genes are
associated with severe disease. The association between tran-
script abundance and clinical presentation of malaria was
tested in logistic regression models in which the dependent
variable was the clinical presentation (SM or UM) and the
independent variables were age, MUAC, parasitemia, sex, and
transcript abundance measured by the respective primer pair.
The logistic regression models were built for primer sets ex-
hibiting statistically significant differences in transcript abun-
dance (Table 4) and showed that young age and increased
MUAC significantly increased the risk of severe disease. No
significant association was found for parasitemia and sex (data
not shown). According to the model, the risk of severe malaria
is increased 20 to 61% with a twofold increased var group A or
var group B transcript abundance (Table 5).
Seven severe cases were classified as cerebral malaria due to
Blantyre scores of 3 (data not shown). Parasites from these
children showed a trend towards a larger abundance of var
group A transcripts than those for all other clinical cases (for
upsA-probe, P  0.1660; for A2 primer, P  0.0077). Primer
pairs A1 and A3 showed no difference in transcript abundance
between the groups (data not shown).
Associations of var transcript abundance with other clinical
features. Linear regression models showed that increased var
group B transcript abundances measured by both primer pairs B1
and B2 were positively associated with parasitemia. This was also
the case when corrected for age [R(parasites/200 leukocytes):	CT(B1/B2)
226/223; P  0.045/0.019; an increase of parasitemia by 226
parasites/200 leukocytes resulted in a twofold increase in var
group B transcript abundance (1 CT value decrease)]. In contrast,
there was a nonsignificant trend for var group C transcript abun-
dance, as measured by C1 or C2 primers, to be negatively corre-
lated with parasitemia [R(parasites/200 leukocytes):	CT(C1/C2)  224/
207; P 0.091/0.074). There was also no association between var
group A transcript abundance and parasitemia, but var group A
transcript abundance tended to decrease with age among the UM
cases (Rage (months):	CT(A1/A2/A3)  1.58/1.67/1.72; P  0.050/
0.058/0.081). No such trends were found with var group B or C.
DISCUSSION
Studies on the development of natural acquired immunity
have suggested a genetic structuring of the PfEMP1 protein
family leading to niche characteristics with regards to host
receptor binding (6, 7, 9, 13). This is supported by var expres-
sion analyses of in vitro manipulated parasites (15, 31). The
present study aimed to analyze the expression of var genes in
naturally infected individuals presenting with different forms of
malaria. Based on the sequence of the P. falciparum clone 3D7,
it appears that most var genes fall into one of three main
groups, A, B, and C, according to both coding and noncoding
regions. Four interclonally conserved var genes (var1-4) have
also been identified. This genetic structuring might reflect
TABLE 2—Continued
Value or description for indicated primer pair
C1 C2 BC1 BC2 pvar1utr pvar2utr pvar3
upsC subtype upsC subtype Group B and C exon 2 Group B and C exon 2 var1 5 UTR var2 5 UTR var3 coding
PFD0625c, PFL1960w,
PF07_0048,
PFD0630c,
PF07_0049,
PF07_0051,
PFD0615c,
PFD1015c
PFD0615c, PF07_0051,
PFD0995c, PFD1000c,
PF07_0049, PFD1015c,
MAL6P1.252
PF08_0142, MAL6P1.1,
PFA0765c, PFC1120c,
PFC0005w, PFE0005w,
PF10_0406, PFB1055c,
MAL7P1.56,
PF08_0140, PF13_0364,
PF13_0001, PFL2665c,
PFI0005w, PFB0010w,
PF11_0007, PF07_0139,
PFD1005c, PFD1000c,
PF08_0107, PFD0005w,
PFL0005w, PFD1015c,
PFI1830c, PF07_0050,
PF10_0001
MAL7P1.50, PF07_0048,
PF08_0103,
PF08_0106,
PFA0005w,
PFD1245c, PFL0935c,
PFL1950w
PFE1640w PFL0030c PFA0015c, MAL6P1.314,
PFI1820w
8/13 C 7/13 C 17/22 B, 4/13 C, 1/4 BA,
2/9 BC
4/9 BC, 3/22 B, 1/13 C var1 var2 var3
74.1 73.5 75.9 75.5 69.6 74 75.5
106 120 110 170 87 184 155
74.2 (0.4) [0/20] 73.5 (0.3) [0/20] 75.9 (0.3) [0/20] 75.6 (0.3) [0/20] 69.6 (0.2) [0/20] 74.3 (0.4) [0/20] 75.6 (0.2) [0/20]
3 2.8 4.7 3 0 0 1.6
2.2 0.7 4.5 1.67 2.8 0.8 1.8
0.3 (0.8) 0.9 (0.5) 4.55 (0.2) 0.7 (0.3) 2.6 (0.2) 0.3 (0.3) ND
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functional differences of the encoded PfEMP1 proteins, a no-
tion that is supported by observations with regards to CD36
binding properties of CIDR domains (26), differences in sur-
vival rates in vivo (21), and variant surface antigen serotypes of
genotypically identical parasites with diverse PfEMP1 expres-
sion profiles (15, 29). However, only a few studies have aimed
to directly correlate var/PfEMP1 expression in naturally in-
fected individuals with different presentations of malaria. One
study showed that parasites from Chinese children suffering
from cerebral malaria expressed larger PfEMP1s than did par-
asites from other malaria patients (3). This may indicate an
involvement of group A genes in severe malaria, as large size
is characteristic of but not unique to group A PfEMP1s (22).
PfEMP1 variants of group A were also associated with se-
vere malaria in a study with Brazilian children. The dominant
DBL1 transcripts were determined by their amplification fre-
quencies upon reverse transcription-PCR using degenerate
primers (17). However, it has been shown to be difficult to
reliably reproduce results using this approach (10). Bull et al.
(4) used a similar approach to study var gene expression in 12
clinical isolates from Tanzania. Although they were able to
identify unique short DBL sequence markers for var group A
that correlated with the formation of rosettes, no association
between var group expression and disease outcome was found.
Recently, Kaestli et al. (16) analyzed parasites from Papua
New Guinean children with asymptomatic, uncomplicated, or
severe malaria infections by using quantitative real-time PCR
to investigate changes in the proportion of var A, B, or C
transcripts, using primers targeting the corresponding up-
stream regions. This study showed a significant increase in
proportions of var group B transcripts in clinical cases, whereas
var group C transcript levels were increased in asymptomatic
cases. No particular involvement of var group A was reported.
The above-mentioned primers and probes were also applied
in the present study, but to allow for relative comparisons to
internal control genes, a new set of primers with specificity for
the three main groups (A, B, and C) and var1-3 was designed.
By using these primers, var transcript levels were measured in
cDNAs from 106 Tanzanian children with asymptomatic, un-
complicated, or severe P. falciparum infections.
Similar to the results of the study by Kaestli et al. (16), a
larger transcript abundance of var group B genes was observed
with an increasing degree of disease severity. Importantly, a
similar pattern of transcript abundance was found for the var
genes of group A (including var3). Conversely, var genes of
group C were found to be transcribed at the same level in all
sample groups. The differential transcript abundance patterns
determined with the BC1 and BC2 primers corresponded to
the transcript abundance patterns measured by B and C group-
specific primers, respectively. These conclusions were sup-
ported by data generated by two quantitative PCR methods
with primers targeting both the 5 and 3 ends of the genes.
Although we cannot exclude the possibility that the difference
in PfEMP1 expression patterns in asymptomatic children and
younger symptomatic children is due to the marked age dif-
ference or the severity of infection, the data suggest that var
group C genes are not involved in severe childhood malaria.
The fact that no var gene group was detected at higher tran-
scription levels in AM and UM than in SM samples is puzzling.
This could be explained in several ways. Firstly, the categori-
zation of patients into AM, UM, or SM is operational, and
other host and parasite factors, including other variant surface
antigens, might play equally important roles in disease out-
come. Secondly, since the current knowledge of the global var
sequence repertoire is limited, unknown transcripts not tar-
geted by our primers may be excluded from the analysis. Fi-
nally, there is a possibility that the present primers result in
biased amplification of a subset of predicted target genes. In
particular, the last case might be true for the var group C
primer pairs C2 and BC2, as indicated by the relatively large
differences between estimated and observed CT values for the
3D7 genomic DNA amplifications. Alternatively, group A or B
var genes might be expressed in relatively larger abundance
than var group C genes. This explanation would assume that
not only the type of adhesion ligand, but also the amount of
ligand, determines the adhesion phenotype. Future studies will
test this hypothesis.
In logistic regression models, there was a statistically signif-
icant association between the risk of developing severe malaria
and the transcript abundance of group A or B var genes. Thus,
a twofold increase in var group A or B transcript abundance
was associated with an increase of 20 to 61% in the risk of
developing severe malaria. This observation does not indicate
any difference between var group A and B transcript abun-
dances in relation to disease severity. However, some indica-
tions of functional differences in group A and B var genes may
be found in the linear regression models of var transcript
abundance and clinical features. The association of increased
parasitemia with var group B transcript abundance suggests
that the parasites expressing these genes caused the severe
FIG. 1. Differences in var transcript abundance (x-fold changes)
between 3D7UM and antibody-selected 3D7SM parasites (15). Tran-
script abundance was measured by using primers targeting var gene
groups (white) or primers targeting single var genes (black) and are
summarized corresponding to var gene groups. A twofold change in var
transcript abundance (dashed lines) was arbitrarily defined as the cut-
off for biologically significant changes in var transcript abundance.
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infections in these children. In contrast, the lack of association
between var group C transcription and parasitemia or clinical
presentation supports a previous finding which suggested that
group C var genes may be involved in establishing chronic
infections (16). Similar to the case for var group B transcripts,
a positive correlation between var group A transcript abun-
dance and parasitemia would be expected in these data and in
previous findings indicating the involvement of group A var
FIG. 2. Transcript abundances of var gene groups in parasites from children with AM and from children suffering from UM or SM. Transcript
abundances are shown relative to the average abundances in uncomplicated cases (	CT values). Panel A shows var group A transcript abundances
measured with primers A1-3 in quantitative PCR and with upsA-probe in the MGB assay. Similarly, panels B and C show the transcript abundances of
group B and C var genes, respectively. Panel D shows the transcript abundances measured with primers BC1 and BC2, targeting group B and C genes.
Panel E shows transcript abundances measured with primers targeting the conserved var genes var1-3. Boxes outline 25th to 75th percentiles, with
medians indicated as a line inside each box and whiskers illustrating the 5th and 95th percentiles. Horizontal lines with asterisks below the plots indicate
statistically significant differences in transcript abundance between groups (one-way analysis of variance; P  0.05 after Bonferroni correction).
TABLE 3. Clinical and parasitological details of subjects
Parameter
Value for indicated groupa Significant relationship(s)
between groups (P)bAM (n  12) UM (n  52) SM (n  42)
Mean age (mo) 46 (38, 54) 30 (26, 34) 28 (24, 32) AM  UM/SM (0.001)*
Sex (no. of males/no. of females) 6/6 22/30 18/24
Mean parasitemia (parasites/200
leukocytes)
336 (144, 527) 867 (1,067, 2,206) 2,105 (1,883, 3,230) AM  UM  SM (0.001)*
Mean PCV (%) 29.28 (25.60, 32.95) 27.98 (26.32, 29.64) 25.37 (23.34, 27.4) AM  UM/SM (0.001)*
Mean lactate (mmol/liter) 3.82 (2.79, 4.84) 2.67 (2.4, 2.9) 2.9 (2.6, 2.3) AM  UM (0.02)*
Mean glucose level (mmol/liter)
(95% CI)
4.97 (4.22, 5.71) 5.1 (4.62, 5.58) 5.24 (4.68, 5.81) 0.491*
No. of days of illness Not applicable 2.6 (2.3, 2.9) 2.8 (2.5, 3.1) 0.526**
Mean MUAC (cm) Not determined 15.96 (15.02, 15.71) 15.36 (15.56, 16.36) 0.01**
No. of patients with prostration/
total no. of patients
0/12 40/42
No. of patients with impaired
consciousness, coma, or
neurological alterations
(Blantyre score of 3)/total
no. of patients
0/12 0/52 7/42
a Values in parentheses are 95% confidence intervals.
b *, analysis of variance/Kruskal-Wallis test; **, t test.
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genes in severe malaria (3, 15, 17). The lack of such an asso-
ciation might be explained if group A PfEMP1 variants confer
the strongest cytoadhesion in naı¨ve individuals only and if
group A variants only dominate in first malaria infections.
Since the average age of the children enrolled in this study was
29 months, most children would have undergone several,
sometimes severe, infections and would have developed some
immunity against PfEMP1 variants of group A. This is sup-
ported by a trend towards a lower var group A transcript
abundance with increasing age in UM cases.
The observed trend of more abundant var group A tran-
scripts in cerebral malaria cases than in all other cases might
indicate that these var genes play a specific role in cerebral
malaria. var2csa has been identified as the main chondroitin
sulfate A binding ligand in pregnancy-associated malaria (28).
The difference seen in var2csa transcript abundance between
the disease groups was therefore unexpected. However, for all
samples, the var2csa transcript abundance was100-fold lower
(data not shown) than that reported for placental parasites
(35) or parasites selected in vitro on CSA (29). In addition,
while var2csa transcription appears to be controlled by similar
mechanisms to those controlling group A var genes (11), the
translation of var2csa transcripts, unlike that of other var tran-
scripts, seems to be controlled by translation of an upstream
open reading frame (22; K. W. Deitsch, personal communica-
tion). Thus, var2csa is most likely not responsible for the dis-
ease outcomes of these children.
var1-like genes are unique among var genes because they are
highly conserved between parasite genomes and appear to be
controlled by a unique 5 region (36), which might indicate a
specialized function for var1 products similar to the var2csa
gene in pregnancy-associated malaria. However, the similar
abundances of var1 transcripts in all three groups gave no
indications of the function of var1 products. This, together with
the observed constitutive var1 transcription throughout the
intraerythrocytic stages in isogenic but phenotypically different
parasite lines (20, 21, 29), leaves the function of var1 molecules
enigmatized.
In conclusion, the data presented here show an association
between disease outcomes and the transcription of var sub-
types in African areas where malaria is endemic. Of specific
importance, the association between severe malaria in young
children and var group A and B transcription is demonstrated
and supports the notion that a vaccine based on selected
PfEMP1 molecules might be feasible.
ACKNOWLEDGMENTS
We express our thanks to Boniface Idindili and Wilbert Manyilizu
for the recruitment and assessment of patients, Irene Kasiga for clin-
ical supervision, and the staffs of the Saint Francis Designated District
Hospital Ifakara and the Ifakara Health Research and Development
Centre for their field assistance. We highly appreciate the cooperation
of the parents and children who were willing to participate in this
study. The PlasmoDB database (http://www.plasmodb.org) has been a
valuable resource for this work, and the database developers and
researchers who made their data available are thanked.
This study was supported by the Swiss National Science Foundation
(grant number 3100 AO 104043/1) and by grants from the Danish
Medical Research Council (no. 22-02-0220) and the Commission
of the European Communities (grant no. QLK2-CT-1999-01293)
(EUROMALVAC).
REFERENCES
1. Baruch, D. I., B. L. Pasloske, H. B. Singh, X. Bi, X. C. Ma, M. Feldman, T. F.
Taraschi, and R. J. Howard. 1995. Cloning the P. falciparum gene encoding
PfEMP1, a malarial variant antigen and adherence receptor on the surface
of parasitized human erythrocytes. Cell 82:77–87.
2. Berendt, A. R., D. J. Ferguson, and C. I. Newbold. 1990. Sequestration in
Plasmodium falciparum malaria: sticky cells and sticky problems. Parasitol.
Today 6:247–254.
3. Bian, Z., and G. Wang. 2000. Antigenic variation and cytoadherence of
PfEMP1 of Plasmodium falciparum-infected erythrocyte from malaria pa-
tients. Chin. Med. J. 113:981–984.
4. Bull, P. C., M. Berriman, S. Kyes, M. A. Quail, N. Hall, M. M. Kortok, K.
Marsh, and C. I. Newbold. 2005. Plasmodium falciparum variant surface
antigen expression patterns during malaria. PLoS Pathog. 18:1.
5. Bull, P. C., M. Kortok, O. Kai, F. Ndungu, A. Ross, B. S. Lowe, C. I. Newbold,
and K. Marsh. 2000. Plasmodium falciparum-infected erythrocytes: aggluti-
nation by diverse Kenyan plasma is associated with severe disease and young
host age. J. Infect. Dis. 182:252–259.
6. Bull, P. C., B. S. Lowe, M. Kortok, and K. Marsh. 1999. Antibody recogni-
tion of Plasmodium falciparum erythrocyte surface antigens in Kenya: evi-
dence for rare and prevalent variants. Infect. Immun. 67:733–739.
7. Bull, P. C., B. S. Lowe, M. Kortok, C. S. Molyneux, C. I. Newbold, and K.
Marsh. 1998. Parasite antigens on the infected red cell surface are targets for
naturally acquired immunity to malaria. Nat. Med. 4:358–360.
8. David, P. H., M. Hommel, L. H. Miller, I. J. Udeinya, and L. D. Oligino.
1983. Parasite sequestration in Plasmodium falciparum malaria: spleen and
antibody modulation of cytoadherence of infected erythrocytes. Proc. Natl.
Acad. Sci. USA 80:5075–5079.
9. Dodoo, D., T. Staalsoe, H. Giha, J. A. Kurtzhals, B. D. Akanmori, K. Koram,
S. Dunyo, F. K. Nkrumah, L. Hviid, and T. G. Theander. 2001. Antibodies to
variant antigens on the surfaces of infected erythrocytes are associated with
protection from malaria in Ghanaian children. Infect. Immun. 69:3713–3718.
10. Duffy, M. F., J. C. Reeder, and G. V. Brown. 2003. Regulation of antigenic
variation in Plasmodium falciparum: censoring freedom of expression?
Trends Parasitol. 19:121–124.
11. Freitas-Junior, L. H., R. Hernandez-Rivas, S. A. Ralph, D. Montiel-Condado,
TABLE 4. Comparison of var group transcript abundances in
parasites from patients with SM or UM
Primer pair Fold change
a
(by 		CT method)
Confidence
interval
P value
(t test)
A1 1.6 0.6, 3.9 0.3067
A2 2.6 1.2, 5.6 0.0175
A3 2.6 1.2, 5.6 0.0148
UpsA-probe 4.3 1.6, 11.5 0.0051
B1 2.7 1.5, 4.9 0.0014
B2 2.5 1.4, 4.5 0.0020
UpsB-probe 2.8 1.2, 6.5 0.0208
C1 0.8 0.4, 1.5 0.4779
C2 1.1 0.6, 2.1 0.6836
UpsC-probe 1.1 0.4, 3.1 0.8494
BC1 1.7 1.2, 2.4 0.0050
BC2 1.1 0.6, 1.8 0.7928
Pvar1utr 1.1 0.5, 2.7 0.4375
Pvar2utr 2.0 0.8, 4.8 0.1383
Pvar3coding 2.6 0.7, 10.2 0.1611
a Transcript abundance in SM parasites/transcript abundance in UM parasites.
TABLE 5. Logistic regression model showing the risk of severe
malaria for a twofold increase in transcript abundance of
specific var gene groups after correcting for the
effects of age, MUAC, parasitemia, and sex
Primer pair Odds ratio 95% Confidence interval P
A2 1.28 1.06, 1.56 0.012
A3 1.37 1.08, 1.75 0.010
upsA 1.35 1.02, 1.79 0.037
B1 1.47 1.08, 2.00 0.014
B2 1.52 1.14, 2.04 0.006
BC1 1.61 1.06, 2.44 0.023
upsB 1.20 0.93, 1.56 0.170
3910 ROTTMANN ET AL. INFECT. IMMUN.
O. K. Ruvalcaba-Salazar, A. P. Rojas-Meza, L. Mancio-Silva, R. J. Leal-Silvestre,
A. M. Gontijo, S. Shorte, and A. Scherf. 2005. Telomeric heterochromatin
propagation and histone acetylation control mutually exclusive expression of
antigenic variation genes in malaria parasites. Cell 121:25–36.
12. Gardner, M. J., N. Hall, E. Fung, O. White, M. Berriman, R. W. Hyman,
J. M. Carlton, A. Pain, K. E. Nelson, S. Bowman, I. T. Paulsen, K. James,
J. A. Eisen, K. Rutherford, S. L. Salzberg, A. Craig, S. Kyes, M. S. Chan, V.
Nene, S. J. Shallom, B. Suh, J. Peterson, S. Angiuoli, M. Pertea, J. Allen,
J. Selengut, D. Haft, M. W. Mather, A. B. Vaidya, D. M. Martin, A. H.
Fairlamb, M. J. Fraunholz, D. S. Roos, S. A. Ralph, G. I. McFadden, L. M.
Cummings, G. M. Subramanian, C. Mungall, J. C. Venter, D. J. Carucci,
S. L. Hoffman, C. Newbold, R. W. Davis, C. M. Fraser, and B. Barrell. 2002.
Genome sequence of the human malaria parasite Plasmodium falciparum.
Nature 419:498–511.
13. Giha, H. A., T. Staalsoe, D. Dodoo, C. Roper, G. M. Satti, D. E. Arnot, L.
Hviid, and T. G. Theander. 2000. Antibodies to variable Plasmodium falcip-
arum-infected erythrocyte surface antigens are associated with protection
from novel malaria infections. Immunol. Lett. 71:117–126.
14. Howard, R. J., and J. W. Barnwell. 1984. Roles of surface antigens on
malaria-infected red blood cells in evasion of immunity. Contemp. Top.
Immunobiol. 12:127–200.
15. Jensen, A. T., P. Magistrado, S. Sharp, L. Joergensen, T. Lavstsen, A.
Chiucchiuini, A. Salanti, L. S. Vestergaard, J. P. Lusingu, R. Hermsen, R.
Sauerwein, J. Christensen, M. A. Nielsen, L. Hviid, C. Sutherland, T.
Staalsoe, and T. G. Theander. 2004. Plasmodium falciparum associated with
severe childhood malaria preferentially expresses PfEMP1 encoded by group
A var genes. J. Exp. Med. 199:1179–1190.
16. Kaestli, K., I. A. Cockburn, A. Corte´s, K. Baea, J. A. Rowe, and H.-P. Beck.
Virulence of malaria is associated with differential expression of Plasmodium
falciparum var gene subgroups in a case-control study. J. Infect. Dis., in press.
17. Kirchgatter, K., and H. A. Portillo. 2002. Association of severe noncerebral
Plasmodium falciparum malaria in Brazil with expressed PfEMP1 DBL1
alpha sequences lacking cysteine residues. Mol. Med. 8:16–23.
18. Kraemer, S. M., and J. D. Smith. 2003. Evidence for the importance of
genetic structuring to the structural and functional specialization of the
Plasmodium falciparum var gene family. Mol. Microbiol. 50:1527–1538.
19. Kyes, S., P. Horrocks, and C. Newbold. 2001. Antigenic variation at the
infected red cell surface in malaria. Annu. Rev. Microbiol. 55:673–707.
20. Kyes, S. A., Z. Christodoulou, A. Raza, P. Horrocks, R. Pinches, J. A. Rowe,
and C. I. Newbold. 2003. A well-conserved Plasmodium falciparum var gene
shows an unusual stage-specific transcript pattern. Mol. Microbiol. 48:1339–
1348.
21. Lavstsen, T., P. Magistrado, C. C. Hermsen, A. Salanti, A. T. Jensen, R.
Sauerwein, L. Hviid, T. G. Theander, and T. Staalsoe. 2005. Expression of
Plasmodium falciparum erythrocyte membrane protein 1 in experimentally
infected humans. Malar. J. 4:21.
22. Lavstsen, T., A. Salanti, A. T. Jensen, D. E. Arnot, and T. G. Theander. 2003.
Sub-grouping of Plasmodium falciparum 3D7 var genes based on sequence
analysis of coding and non-coding regions. Malar. J. 2:27.
23. Nielsen, M. A., T. Staalsoe, J. A. Kurtzhals, B. Q. Goka, D. Dodoo, M.
Alifrangis, T. G. Theander, B. D. Akanmori, and L. Hviid. 2002. Plasmodium
falciparum variant surface antigen expression varies between isolates causing
severe and nonsevere malaria and is modified by acquired immunity. J. Im-
munol. 168:3444–3450.
24. Nielsen, M. A., L. S. Vestergaard, J. Lusingu, J. A. Kurtzhals, H. A. Giha, B.
Grevstad, B. Q. Goka, M. M. Lemnge, J. B. Jensen, B. D. Akanmori, T. G.
Theander, T. Staalsoe, and L. Hviid. 2004. Geographical and temporal
conservation of antibody recognition of Plasmodium falciparum variant sur-
face antigens. Infect. Immun. 72:3531–3535.
25. Pain, A., D. J. Ferguson, O. Kai, B. C. Urban, B. Lowe, K. Marsh, and D. J.
Roberts. 2001. Platelet-mediated clumping of Plasmodium falciparum-in-
fected erythrocytes is a common adhesive phenotype and is associated with
severe malaria. Proc. Natl. Acad. Sci. USA 98:1805–1810.
26. Robinson, B. A., T. L. Welch, and J. D. Smith. 2003. Widespread functional
specialization of Plasmodium falciparum erythrocyte membrane protein 1
family members to bind CD36 analysed across a parasite genome. Mol.
Microbiol. 47:1265–1278.
27. Rowe, A., J. Obeiro, C. I. Newbold, and K. Marsh. 1995. Plasmodium falciparum
rosetting is associated with malaria severity in Kenya. Infect. Immun. 63:2323–
2326.
28. Salanti, A., M. Dahlback, L. Turner, M. A. Nielsen, L. Barfod, P. Magistrado,
A. T. Jensen, T. Lavstsen, M. F. Ofori, K. Marsh, L. Hviid, and T. G. Theander.
2004. Evidence for the involvement of VAR2CSA in pregnancy-associated ma-
laria. J. Exp. Med. 200:1197–1203.
29. Salanti, A., T. Staalsoe, T. Lavstsen, A. T. Jensen, M. P. Sowa, D. E. Arnot,
L. Hviid, and T. G. Theander. 2003. Selective upregulation of a single
distinctly structured var gene in chondroitin sulphate A-adhering Plasmo-
dium falciparum involved in pregnancy-associated malaria. Mol. Microbiol.
49:179–191.
30. Schellenberg, D., C. Menendez, J. Aponte, C. Guinovart, H. Mshinda, M.
Tanner, and P. Alonso. 2004. The changing epidemiology of malaria in
Ifakara Town, southern Tanzania. Trop. Med. Int. Health 9:68–76.
31. Smith, J. D., C. E. Chitnis, A. G. Craig, D. J. Roberts, D. E. Hudson-Taylor,
D. S. Peterson, R. Pinches, C. I. Newbold, and L. H. Miller. 1995. Switches
in expression of Plasmodium falciparum var genes correlate with changes in
antigenic and cytoadherent phenotypes of infected erythrocytes. Cell 82:101–
110.
32. Snow, R. W., J. A. Omumbo, B. Lowe, C. S. Molyneux, J. O. Obiero, A.
Palmer, M. W. Weber, M. Pinder, B. Nahlen, C. Obonyo, C. Newbold, S.
Gupta, and K. Marsh. 1997. Relation between severe malaria morbidity in
children and level of Plasmodium falciparum transmission in Africa. Lancet
349:1650–1654.
33. Staalsoe, T., M. A. Nielsen, L. S. Vestergaard, A. T. Jensen, T. G. Theander,
and L. Hviid. 2003. In vitro selection of Plasmodium falciparum 3D7 for
expression of variant surface antigens associated with severe malaria in
African children. Parasite Immunol. 25:421–427.
34. Su, X. Z., V. M. Heatwole, S. P. Wertheimer, F. Guinet, J. A. Herrfeldt, D. S.
Peterson, J. A. Ravetch, and T. E. Wellems. 1995. The large diverse gene
family var encodes proteins involved in cytoadherence and antigenic varia-
tion of Plasmodium falciparum-infected erythrocytes. Cell 82:89–100.
35. Tuikue Ndam, N. G., A. Salanti, G. Bertin, M. Dahlback, N. Fievet, L.
Turner, A. Gaye, T. Theander, and P. Deloron. 2005. High level of var2csa
transcription by Plasmodium falciparum isolated from the placenta. J. Infect.
Dis. 192:331–335.
36. Vazquez-Macias, A., P. Martinez-Cruz, M. C. Castaneda-Patlan, C. Scheidig, J.
Gysin, A. Scherf, and R. Hernandez-Rivas. 2002. A distinct 5 flanking var gene
region regulates Plasmodium falciparum variant erythrocyte surface antigen
expression in placental malaria. Mol. Microbiol. 45:155–167.
37. Voss, T. S., J. K. Thompson, J. Waterkeyn, I. Felger, N. Weiss, A. F. Cowman,
and H. P. Beck. 2000. Genomic distribution and functional characterisation of
two distinct and conserved Plasmodium falciparum var gene 5 flanking se-
quences. Mol. Biochem. Parasitol. 107:103–115.
38. World Health Organization, Communicable Diseases Cluster. 2000. Severe
falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 94(Suppl. 1):S1–S90.
Editor: W. A. Petri, Jr.
VOL. 74, 2006 EXPRESSION OF var GENE GROUPS IN TANZANIAN CHILDREN 3911
Chapter Four 
 
 39 
 
 
 
 
 
 
 
 
 
 
 
Chapter Four 
 
Genetic Diversity of Expressed Plasmodium falciparum var 
genes from Tanzanian children with Severe Malaria 
Chapter Four 
 
 40 
Chapter Four 
Genetic Diversity of Expressed Plasmodium falciparum var genes 
from Tanzanian children with Severe Malaria 
 
Joseph Paschal Mugasa1, Weihong Qi2, Sebastian Rusch2, Matthias Rottman2 and 
Hans-Peter Beck2* 
 
1Ifakara Health Research and Development Centre, P.O.BOX 53, Ifakara, Morogoro, 
Tanzania 
 
2Swiss Tropical Institute, Socinstrasse 57, Postfach 4002 Basel, Switzerland 
 
 
 
*Corresponding address 
Swiss Tropical Institute 
Socinstrasse 57 
CH 4002 Basel  
Tel.: +41-61-284 8116, Fax: +41-61-284 8101 
E-mail address: hans-peter.beck@unibas.ch (HP Beck) 
 
 
 
 
 
 
 
 
This article will be submitted to the International Journal of Parasitology 
 
Chapter Four 
 
 41 
Abstract 
Severe malaria has been attributed to the expression of a restricted subset of the 
var multi-gene family, which encodes for Plasmodium falciparum erythrocyte 
membrane protein 1 (PfEMP1). PfEMP1 mediates cytoadherence to a variety of 
host cell receptors and cause sequestration of infected erythrocytes in post 
capillary venules of the vital organs such as the brain or placenta which is a key 
element in the pathology of malaria. var genes are highly diverse, and can be 
classified in three major groups (upsA, B and C) and two intermediate groups 
(B/A and B/C) based on the genomic location, gene orientation and the upstream 
sequences. We have shown previously that var group A and B are up-regulated in 
clinical malaria compared to children with asymptomatic infections. We studied 
subsequently the genetic diversity of expressed var genes associated with severe 
childhood malaria. By use of biotinylated magnetic beads tagged the reverse 
complement of the conserved exon 2, full-length var mRNA was isolated and 
reverse transcribed into var cDNA. Different N-terminal domain tags were 
amplified by PCR, cloned and sequenced from children isolates with severe (SM) 
and asymptomatic malaria (AM). Our analyses shows high sequence diversity of 
the amplified var DBL-1α and upstream regions with minimal overlap among the 
isolates, providing strong evidence that var gene repertoire is immense and 
indefinite in high endemic areas. var DBL-1α sequences from AM isolates were 
more diverse with more singletons (p<0.05) than those from SM cases. 
Furthermore, few var DBL-1α sequences from SM patients were rare and restricted 
suggesting that certain PfEMP1 variants are predisposed for inducing severe 
infection.  
 
Keywords: Plasmodium falciparum; severe malaria; var genes; PfEMP1; Repertoire; 
Diversity.  
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1. Introduction 
 
Plasmodium falciparum malaria infections continue to be the primary cause of 
morbidity and mortality in many developing countries, with an estimated 1.5 -2.7 
million deaths annually (Breman & Holloway 2007). The burden of disease is 
greatest in children < 5 years old where, much of the mortality is attributable to 
severe malaria. Despite extensive research efforts there is no vaccine to date. 
Vaccine development is encouraged by the fact that children living in endemic 
areas attain conditional immunity to severe malaria after a relatively few number 
of episodes during childhood. However, the genetic diversity between different 
parasites isolates poses an obstacle for vaccine development. 
 
Severe malaria, a life threatening form of the disease, is believed to be mediated by 
cytoadhesion of P. falciparum- infected erythrocytes to a variety of host cell 
receptors on the endothelial cells of the host. This causes sequestration into vital 
organs such as post-capillary venules of the brain, kidneys, lungs or placenta 
(Miller et al 2002). Plasmodium falciparum expresses a number of proteins on the 
surface of infected erythrocytes that play a key role as both virulence factors in 
malaria pathology by mediating cytoadherence, and as targets for naturally 
acquired immunity (Bull & Marsh 2002, Kyes et al 2001). The virulence of P. 
falciparum has been associated with the expression of P. falciparum erythrocyte 
membrane protein 1 (PfEMP1) on the surface of infected erythrocytes. PfEMP1 is 
large 200-400 kDa, highly polymorphic antigen, encoded by a family of ~ 60 var 
genes per haploid genome (Gardner et al 2002). The var genes present a two-exon 
structure encoding a conserved C terminus that contains a predicted 
transmembrane region and a polymorphic extracellular N terminus. This part is 
composed of a number of cysteine-rich domains that are involved in sequestration 
of the parasite in the microvasculature (Baruch et al 1995, Smith et al 1995, Su et al 
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1995). The duffy binding like-domain α (DBLα) is the most conserved domain 
within the var gene domains. It is located in the N-terminal head structure of 
PfEMP1, and was found to mediate rosetting and cytoadherence (Chen et al 1998, 
Rowe et al 1997). A range of host receptors appear to be involved in binding such 
as heparin, heparin sulfate, complement receptor 1 (CR1) and blood group A 
antigen (Chen et al 1998, Mayor et al 2005, Vogt et al 2003). Rosetting and 
endothelial binding are closely associated with severe falciparum malaria 
(Fairhurst et al 2005, Rowe et al 2000).  
 
var genes have been classified into three major groups (A, B and C) and two 
intermediate groups (B/A and B/C) based on the presence of one of the three 
conserved 5' upstream sequences (UpsA, B or C), position and orientation of the 
gene within a chromosome (Lavstsen et al 2003, Voss et al 2000). Severe malaria 
has been associated with expression of a restricted and antigenically semi 
conserved subset of variant erythrocyte surface antigens (Bull et al 2000, Nielsen et 
al 2002). Of the different malaria diseases syndromes, the role of PfEMP1 protein is 
best understood for pregnancy-associated malaria (PAM) Gamain et al (2007). 
 
Few studies have investigated the expression of var genes in field isolates 
representing different forms of severe malaria (Ariey et al 2001, Bull et al 2005, 
Kaestli et al 2004, Kirchgatter & del Portillo 2002, Kyriacou et al 2006). These 
studies suggested that the transcription patterns of var genes vary between 
different malaria manifestations. Differences in epidemiology, severe disease 
classification, and var classification have also made comparison between studies 
difficult. Using quantitative real time reverse transcription PCR (qRT-PCR), we 
have previously shown that group A and B var transcripts were up-regulated in 
children with clinical malaria as opposed to asymptomatic infections from 
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Tanzania (Rottmann et al 2006) qRT- PCR is a standard method for detection and 
quantification of genes expression levels (Bustin 2000), however, this technique is 
not informative in studying genetic diversity of genes. Given the proposed 
importance of immunity to PfEMP1 in protection against malaria, it is essential 
that we gain a better understanding of diversity of this molecule at the sequence 
level and how such diversity influences the development of protective immunity. 
In this study, we examined the diversity of expressed PfEMP1 repertoires in 
parasite populations isolated from children with severe malaria. 
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2. Materials and Methods 
 
2.1 Sample collection 
Samples used in this study were collected in a severe malaria (SM) case control 
study that has been described in details previously (Rottmann et al 2006). Briefly, 
children aged <59 months admitted with severe malaria at Saint Francis 
Designated District Hospital (StFDDH), Ifakara, Tanzania were recruited into the 
study after the informed consent was obtained from children’s parents or 
guardians. One to two ml of venous blood from each child was drawn into an 
EDTA tube (Vacutainer, Becton Dickinson, Rutherford, NJ, USA). Between 50 – 
100 µL of this whole blood was then mixed with 2 volumes of 6 M guanidine HCl, 
50 mMTris pH 8.0, 20mM EDTA and kept at -20 °C for gDNA isolation. The 
remaining RBCs were separated from serum by centrifugation and washed with 
40 ml phosphate buffered saline, 5 volume of TRIzol reagent (Invitrogen) were 
added to the RBC pellet before preservation at -70 °C until later use.  
 
Exclusion criteria were confirmed co-infections, malnutrition (mid -upper arm 
circumference [MUAC] of ≤ 12 cm), haemoglobin ≤ 5 g/dL, lactate ≥ 5 mmol/L, 
glucose, ≤ 2.2 mmol/L) or antimalarial treatment during the last 14 days. A total of 
52 patients with SM were recruited. Eight patients met the inclusion criteria and 
were grouped into cerebral malaria according to WHO guidelines (WHO 2000) 
and the modified Blantyre coma score ≤ 3 (Molyneux et al 1989). In nearby villages 
children of the control group were recruited with asymptomatic malaria (AM) i.e 
presence of P. falciparum, axillary temperature of ≤ 37.5 °C and no other symptoms. 
Informed consent was sought from the children’s parents or guardians, children 
aged < 59 months were screened for P. falciparum infection by using a rapid 
diagnostic test (RDT), Paracheck® Pf (Orchid Biomedical Systems, Goa, India). 
Participating children who were found positive by RDT later had their infection 
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status confirmed microscopically by Giemsa-stained thick and thin blood films at 
IHRDC laboratory. A total of 19 children with AM were recruited. Ethical 
clearance for this study was obtained from the Ifakara Health Research and 
Development Centre and the Medical Research Coordinating Committee of the 
National Institute for Medical Research in Tanzania. 
 
2.2 DNA extraction and genotyping 
Genomic DNA was extracted from frozen blood using Qiamp kit (Qiagen) by 
following the manufacturer’s instructions. The minimum number of genotypes 
per isolate was evaluated by Genescan as described by Falk et al (2006) and 
confirmed by genotyping PCR with MSP2 primers as described by Felger et al 
(1993), briefly, 1 µL of purified genomic DNA was used in a 20 µL primary PCR 
reaction, followed by restriction fragment length polymorphism (RFLP) of the 
nested PCR product to record the number of infecting strain per isolate. 
 
2.3 Isolation of full-length var transcripts and RT- PCR 
For total RNA extraction blood pellets in TRIzol were thawed on ice. TRIzol 
(Invitrogen) was pre-warmed to 37 °C and used by following the manufacturer’s 
protocol. Extraction with TRIzol was performed twice, to decrease DNA 
contamination. RNA was treated with 3 U of RQ1 RNase-Free DNase (Promega), 
followed by the second extraction with TRIzol. Full-length var mRNA with an 
acidic terminal sequence (ATS) was isolated by using magnetic beads tagged with 
an anti-ATS oligonucleotide as previously described with modifications (Kaestli et 
al 2004). Briefly, RNA was dissolved in (5 mmol/L Tris/0.5 mmol/L EDTA), and 
mixed with binding buffer (0.5 mol/L LiCl, 1 mmol/L EDTA, 10 mmol/LTris, pH 
7.5), 15 mmol/L DTT, 40 U RNase OUT (Invitrogen) and 1 pmol of biotinylated  
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oligonucleotide complementary to the conserved sequence in ATS domain (Biotin-
5'- GGTTC(A/T)A(A/G)TAC(C/T)ACTTC(A/T)AT(C/T)CCTGGT(A/G)CAT 
ATATATCATTAATATCCAATTCTTCATA(C/T)TCACTTC(T/G)GA 
(A/T/G)GA-3') incubated at a temperature gradient from 65 °C to 4 °C over 30 
minutes. Meanwhile 150 mg of Dynabeads M-280 streptavidin (Dynal Biotech, 
ASA, Oslo, Norway) was washed as suggested by manufacturer, dissolved in 5.5 
mmol/L LiCl and added to the beads-ATS-mRNA hybrid. The mixture was 
uniformly mixed by rotating for 30 min at 37 °C. The biotinylated beads-ATS-
mRNA complex was washed three times with washing buffer (10 mmol/L Tris, 1 
mmol/L EDTA, 0.15 mol/L NaCl, pH 7.5) and 1 time with 10 mmol/L Tris. Reverse 
transcription (RT) into single stranded cDNA was performed on captured mRNA, 
primed by random hexamere oligonucleotides in the concentration of 300 ng 
(Invitrogen) using Sensiscript (Qiagen), reverse transcriptase, following the 
manufacturer’s instructions in a final volume of 20 µL. A second RNA aliquot was 
equally treated except that reverse transcriptase was omitted in the RT-step; this 
sample served as a control for proving the absence of gDNA. After RT, cDNA was 
treated with RNaseA (Promega) and 1 µL was used for various PCRs. 
 
2.4 Amplification of var sequences 
The DBL-1α domain of var genes was amplified from 1 µL cDNA template by PCR 
with the Advantage cDNA polymerase mix (CLONTECH) using primer sets 
shown in Table 1 to generate a PCR product of about ~ 400- 500 bp in length. PCR 
was performed in 25 µL 1.5 mM MgCl2,  200 µM dNTP mix, 1 µM each primer. 
The cycling conditions were 30 cycles of 94 °C for 30 s, 1 min at the annealing 
temperature specified in (Table 1) and for 70 s at 68 °C. To study the genetic 
diversity of the untranslated upstream sequences, three different PCRs were 
carried out on cDNA using designed degenerate primers based upon sequence 
alignments of 3D7 var genes. Primers were designed to amplify the homology 
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blocks in upstream sequences (5' UTR, 200bp region on upsA, 400 bp and 440 bp 
for upsB and upsC, respectively) and the reverse primer was chosen from 
homology block H of the first DBL-1α domain (Kraemer et al 2003). The primers 
were tested on genomic DNA from the 3D7 isolate. Amplification of DBLα-CIDRβ 
fragments was done by using primers shown in Table 1. Controls minus reverse 
transcriptase were amplified in parallel in each reaction to control for gDNA 
contamination. If a PCR product was obtained in the control, the positive sample 
was excluded from the analysis.  
 
2.5 Cloning and sequencing 
An aliquot of 5 µL of each PCR product was visualized in a 1% agarose gel, the 
remaining PCR product was purified by using the NucleoSpin® Extract II 
(Macherey & Nagel). The eluted DBL-1α fragments were cloned into the pGEM-T 
vector (Promega) according to the manufacturer’s instructions and transfected into 
Escherichia coli SURE cells (Stratagene). Untraslated upstream regions and DBL-1α-
CIDR1 products were cloned into the pCR®4-TOPO (Invitrogen) and transformed 
into TOP10 cells. This vector was more efficient for large fragments (> 1 kb) and 
low concentrated PCR products (< 5 ng/µL). From each clinical isolate an average 
of 50 white colonies that were found to be positive by PCR screening were 
processed for sequencing (Perfectprep® Plasmid 96 Vac Direct Bind kit, 
Eppendorf). The size of the insert was checked in purified plasmids using 
restriction enzymes NotI and NcoI (New England BioLab) for pGEMTs plasmids. 
EcoRI (New England BioLab) was used for TOPO following manufacturer’s 
instructions. Sequencing was carried out using the T7 and SP6 primers for pGEM-
T vector, whereas M13 forward and reverse primers for the pCR®4-TOPO using 96 
capillary automated sequencing systems 3700 (Applied Biosystems). A multiple-
sequence alignment of sequences derived from the same clinical isolate was 
carried out to allow the exclusion of PCR derived mutations. Two sequences were 
considered to be identical when ≥ 96 % amino acid sequence identity was detected. 
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2.6 Sequence analysis 
DNA sequences were assembled and analyzed using ContigExpress in the Vector 
NTI Advance™ 10 software (Invitrogen) and BLAST from the National Centre for 
Biotechnology information webpage: (http://www.ncbi.nlm.nih.gov/BLAST/). 
BLAST analysis against the 3D7 genome database was performed at P. falciparum 
GeneDB webpage: (http://www.genedb.org/genedb/malaria/) and PlasmoDB 5.4 
(https://www.pasmoDB.org). The DNA sequences were translated using 
RevTrans1.4 (Wernersson & Pedersen 2003). Amino acids were aligned with either 
CLUSTALW 1.8 or MUSCLE (Edgar 2004) using default parameters and edited 
with Bioedit version 7.09 with minor manual adjustment where necessary. 
Sequences were further categorized into sequence types (STs) by BLASTCUT 
analysis (Altschul et al 1990) by which sequences sharing ≥ 96 % sequence identity 
were assigned the same ST. 
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2.7 Phylogenetic analysis 
Phylogenetic analyses were conducted on multiple sequence alignment of the 3 
most dominant sequences from each isolates. Because var genes are subject to 
intra-genic recombination (Freitas-Junior et al 2000), synonymous substitutions are 
likely saturated and DNA sequence analysis would be quite noisy in constructing 
phylogenetic trees (Russo et al 1996). Therefore, we used protein sequences rather 
than nucleotide sequences. Two methods were employed in constructing the 
phylogenic trees. Neighbour-Joining (NJ) trees were constructed by using MEGA 
4.0 (Tamura et al 2007). The reliability of internal branches for NJ was assessed 
with 1000 bootstrap pseudoreplicates using ‘pairwise deletion option’ of amino 
acid sequences with p-distance. SplitsTree4 version 4.7 was used to construct the 
phylogenetic network (Huson & Bryant 2006) using the Neighbour-Net distances 
transformation and equal angle splits transformation. 
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3. Results 
 
3.1 Sample collection and clinical data 
A total of 15 children were used in the analysis of the present study 8 of which 
were found to have SM with cerebral manifestation, Blantyre score ≤ 3 and 7 
children with asymptomatic P. falciparum malaria (12 children were dropped from 
analysis as they were confirmed negative for P. falciparum microscopically). 
Clinical and epidemiological assessments of isolates from SM and AM are 
presented in Table 2. There was a significant difference in age between the two 
groups AM: median 52, range 24-59, SM: median 28.5, range 14-40 (P=0.02, 
Kruskal-Wallis test). There was a highly significant differences in parasitemia 
between clinical categories (P=0.0012, Kruskal-Wallis test).  
 
3.2 Multiplicity of infection 
msp2 genotyping indicated that 87.5% (7/8 SM isolates) had multiple clone P. 
falciparum infections (2-4 clones) with an average of 2.6 infecting clones. All 
isolates from AM children had multiple infections (2 or 3) with an average of 2.4 
infecting clones (Table 3a). 
 
3.3 DBL-1α sequences types generated  
A total of 665 var DBL-1α clones (~ 400-500 bp) were successfully sequenced. Of 
these, 305 sequences were originating from AM children (Table 3a) and were 
assembled into 224 Sequence types (STs) ie distinct DBL-1α sequences. The 
remaining 360 sequences from SM children were assembled into 300 STs. AM 
patient samples had more singletons (p<0.05) than SM isolates. Assembled STs 
showed an extreme diversity in sequence reflecting the high recombination and 
mutation rates in the DBL-1α domain. Multiple-sequence alignment of the DBL-1α 
sequences showed conserved islands of homology. The dominant sequence from 
each isolate was blasted against the 3D7 genome. The blasted sequence was 
assigned the name of the identified 3D7 gene with the high scoring segment pair 
(Table 3a). 
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3.4 Upstream sequences  
Three hundred and thirty sequences were generated from var upstream regions 
and 103 sequences from DBLα-CIDRβ fragments (Table 3b). Generally, the PCR 
amplification and cloning efficiencies were low in some isolates. This highlights 
the high diversity of var genes in field isolates, as primers designed were based on 
3D7 var genes and these might not amplify sequences from natural isolates. More 
than one distinct sequence was detected in each isolate. All isolates showed a 
predominant upstream sequence (Table 3b). The predominant sequence from each 
isolate (5’ UTR-DBL-1α or the DBL-1α fragment) was blasted against the 3D7 
genome. UpsA fragments were found to have higher scoring against 3D7 var gene 
both in DBL-1α and the entire upsA type 5' UTR-DBL-1α fragment in contrast to 
var group B and C. This provides evidence that var group A are more conserved 
between field isolates and 3D7 genome.   
 
3.5 Distribution of DBL-1α expressed sequence tags 
The number of distinct transcribed DBL-1α var gene sequences detected per isolate 
varied from 8 to 25 (Table 3a). All isolates showed a predominant sequence as well 
as minor transcripts and unique sequence types. In cluster analysis some of the 
DBL-1α sequences were found to be shared among isolates (i.e overlapping). A 
number of transcripts were found in both groups (SM & AM) and others were 
specifically found either in SM or in AM isolates. Some sequences were unique to 
a particular isolate and were not found in other isolates. The distributions of the 
STs in our 15 isolates are shown in Figure 1. There was no significant difference in 
the number of distinct DBL-1α sequences per isolate detected in both clinical 
groups AM: median 20, range 8-25, SM: median 17.5, range 12-23, (P=0.72, 
Kruskall-Wallis test). 
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3.6 Distribution of DBL-1α expressed sequences tags in clinical isolates 
All sequences generated were classified into six DBL-1α sequence tag groups by 
using text string software in Ms Excel and Perl which was kindly provided by Dr 
Pete Bull (KEMRI, Kilifi, Kenya). This classification of DBL-1α sequence tags was 
previously explained in detail by (Bull et al 2005). In short, it is based on counting 
the number of cysteine-residues within the tagged region, and in a set of sequence 
motifs at 4 positions of limited variability (PoLV 1-4). Figure 2 shows the 
distribution of PoLV/cys groups in clinical isolates. Analysis of DBLα sequences 
generated in the present study corresponded well with the cysteine/PoLV 
grouping Figure 3 shows the proportional distribution of PoLV motifs between the 
clinical isolates. Sequence “signature tags” and the group of the dominant 
sequence from each isolate are shown in Table 3. A significant association of Cys2 
sequence tags (groups 1-3) with SM isolates (p < 0.0001, CMH test), with an odds 
ratio of 2.5 (95% C.I = 1.78 - 3.4) was observed. These findings support previous 
reports that DBL-1α sequences associated with severe disease have a reduced 
number of cysteines (Bull et al 2005, Kirchgatter & del Portillo 2002, Kyriacou et al 
2006). A two sample test of proportion was used to test whether expressed PoLV 
motifs are associated with a particular disease phenotype SM or AM (p<0.0001). A 
range of expressed PoLV motifs were found strongly associated with severe 
malaria in PoLV1 (LDLY and MFKR), PoLV2 (FREY and LRVE), PoLV3 (NAIT 
and RAIT) and in PoLV4 (LTNL and PTNL).  
 
3.7 Cumulative diversity of DBL-1α sequences in clinical isolates 
To estimate the size of the var gene repertoire in the parasite population under 
study, the rate of how distinct DBL-1α sequences changed was simulated with 
increasing sample size. This simulation was performed separately for AM and SM, 
as well as the combined data (AM & SM). The empirical plots were fitted by a 
linear function. The curves did not plateau with the DBL-1α sequences generated 
from the Ifakara area (Figure 4). The repertoire of expressed var genes was 
Chapter Four 
 
 54 
unlimited, thus, var gene diversity in this local population seems to be immense 
and unrestricted. However, a minimal overlap among var genes was found in 
different isolates. A similar finding has been reported Barry et al (2007) for the 
cumulative DBL-1α sequences from genomic DNA in the Amele, PNG, and for the 
global population, where in more than 1000 sequences from 59 isolates plus the 
entire 3D7 var repertoire the saturation point of the var gene repertoires could not 
be reached. 
 
3.8 Phylogenetic analysis 
To study the sequence diversity between the SM and AM groups, a phylogenetic 
network was constructed using the 3 most dominant DBL-1α variants expressed 
from each SM or AM isolate. The analyzed sequences clustered in two distinct 
groups. The majority of the DBL-1α isolates from severe malaria clustered 
together and belonged to var group A and B/A. AM isolates formed another 
cluster mainly consisting of var B, B/C or C (Figure 5). To further study 
relationships between sequences, 9 DBL-1α sequences from the 3D7 genome were 
incorporated, 3 from each group A, B and C in the phylogenetic tree construction. 
Among the sequence included was var group A (PF11_0008) which has been 
shown to be highly transcribed in the NF54 isolate (Lavstsen et al 2005) and var 
group B (PF10_0406) which has been detected previously as a major transcript in 
3D7B2 and 3D7B1 samples (Peters et al 2002).  
 
The DBL-1α sequences analyzed were found to cluster into two distinct clades. 
The majority of SM isolates and the 3D7 DBL-1α sequences clustering together 
belonged to var group A and B/A. AM isolates and the other remaining 3D7 DBL-
1α sequences formed another cluster majority belonging to var group B, B/C or C 
(Figure 6). These findings again support the hypothesis that SM is caused by a 
restricted subset of var gene family that belongs to var group A or B/A whilst the 
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non severe form of malaria is attributed to other var gene groups. Similarly the 
phylogenetic approach by Kyriacou et al (2006) when comparing DBL-1α 
sequence tags from Mali, identified var group A and B/A to be more frequent 
among parasites isolated from children with cerebral malaria than those of 
hyperparasitemia patients.  
 
A multiple-sequence alignment of 3 dominant upsA sequences from clinical 
isolates together with upsA sequences from the 3D7 genome showed the existence 
of short islands of homology, conserved in all isolates suggesting that they might 
be structurally important. Phylogenetic analysis of the three upsA dominant 
sequences from clinical isolates and the 3D7 upsA sequences, showed an even 
distribution among clinical isolates (Figure 7). Two different methods for 
phylogenetic tree construction were used (MEGA 4.0 and SplitsTree 4.7). Both 
methods yielded similar tree topologies.  
 
4. Discussion 
Studies on var genetic diversity are important in understanding malaria 
pathogenesis and feasibility for designing a disease intervention such as a vaccine 
or other therapeutic approach. In the present study, we examined var gene 
expression from clinical isolates of children with severe malaria and asymptomatic 
infections from Tanzania. Dominant expression of one particular var gene was 
found, together with less abundant variant transcripts and unique sequences in 
each isolate. However, the dominant sequences differed between the isolates. This 
suggests that each parasite contains its own form of var gene variants. This has the 
consequences that exposure to multiple infections and hence var gene products do 
not necessarily confer immunity to future malaria infections (Fowler et al 2002, 
Trimnell et al 2006). 
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By analyzing the expressed var genes repertoires in severe malaria cases versus 
asymptomatic controls, we have shown that the diversity within the var gene 
family is enormous with minimal degree of overlaps between isolates. Recently, 
Kyriacou et al (2006) have found a minimal overlap in var genes repertoires after 
they analyzed the expressed sequence tags from Malian children with malaria 
infections. However, Albretch et al (2006) reported huge overlapping var gene 
repertoires in the Western Amazon isolates. var repertoires of natural parasite 
populations found within specific geographical regions showed a degree of 
overlapping, suggesting the circulation of a similar var gene repertoire. This has 
important implications for the acquisition of long-term immunity by the exposed 
individuals (Barry et al 2007). 
 
The diversity of var genes within a natural P. falciparum population in a particular 
geographical region is difficult to define, and it is also difficult to assess whether 
the diversity is constant due to functional constrain on this molecule, fluctuating 
or constantly turning over, and how fast the turnover rate of the PfEMP1 
repertoires could be. Changes in the var repertoire are believed to be due to high 
allelic and ectopic recombination rates of var genes in field isolates (Conway et al 
1999, Freitas-Junior et al 2000, Taylor et al 2000b) which are influenced by 
transmission intensity. The diversity of the PfEMP1 repertoire of parasites in a 
given geographical area is a key factor in the development of clinical immunity. 
The vast antigenic diversity and complexity of var gene repertoires in parasite 
populations may explain why individuals are repeatedly susceptible to P. 
falciparum infections and never develop sterilizing immunity. The antigenic 
variation and high switching rate of var gene expression are effective mechanisms 
adopted by P. falciparum to evade the host’s immune system, for their survival and 
effective transmissions.  
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In our study, several sequences were observed more frequently than other 
sequences within individual patients. Whether this is due to the primer and 
cloning bias or whether it can be explained by presence of multiple infections as 
was the case in most of the patients remains open. Consistent with previous 
studies of var gene diversity (Bull et al 2005, Fowler et al 2002, Kirchgatter et al 
2000, Kyriacou et al 2006, Taylor et al 2000b), the variability of the DBL-1α and 
upstream sequences within an isolate was found to be similar to different isolates 
in all the groups (SM &AM). Nevertheless, AM isolates were more diverse as 
reflected by the presence of more singletons. This suggests that var genes 
associated with asymptomatic infection have an enormous repertoire which could 
explain the difficulty to acquire immunity to mild or asymptomatic malaria. 
 
Isolates from children with severe malaria were predominantly found to 
transcribe var genes with a DBL-1α domain that had a reduced number of cysteine 
residues which is the characteristic of var group A or B/A. Similar results have 
been reported previously from other research groups in Mali, Kenya and Brazil 
(Bull et al 2005, Kirchgatter & del Portillo 2002, Kyriacou et al 2006). These results 
highlight that severe malaria is caused by a restricted subset of var genes and 
probably var group A and B/A are involved in severe disease. This finding 
supported our previous study, in which we had shown by quantitative PCR that 
var group A was up regulated in children with cerebral malaria (Rottmann et al 
2006). However, most studies on var gene family have been relying on the use of 
DBL-1α fragments (Kyes et al 1997). DBL-1α primers amplify only a small 
fragment of the var gene that is more conserved than other var domains and that is 
found in most of PfEMP1 proteins. Due to the complex nature of var genes it has 
been difficult to clone and sequence larger fragments. Larger fragments of the var 
genes would provide additional information on understanding var gene 
transcription and its association to disease phenotype. 
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Clustering analysis revealed several “unique sequences” of var gene were 
transcribed only in isolates from patients with severe malaria. Expression of these 
“unique sequences” in a patient who lacks a pre-existing antibody response 
against this variant might trigger the development of severe malaria. Once 
exposed to these virulent var genes individuals living in endemic areas may 
acquire immunity to severe malaria. In areas of high endemicity this might 
happen early in life after a relatively few number clinical episodes. Comparisons 
of PoLV motifs distribution between the clinical groups, 8 motifs were identified 
which were highly associated with severe disease. Recently, Normark et al (2007) 
identified 15 DBL-1α sequence degenerate motifs pertinent to severe disease states 
and 3 motifs associated with high rosetting after analysing 93 patients with well 
characterized disease state based on the MOTIFF algorithm. These findings also 
support the hypothesis that disease phenotypes are correlated with the expression 
of certain PfEMP1 variants and motifs, which is relevant information for vaccine 
development and understanding disease pathogenesis. 
 
The distribution of PF11_0008, a group A var gene, which previously has been 
identified in the 3D7 genome and the isogenic isolate NF54 (Lavstsen et al 2005), 
was found in three SM isolates (ISM11, ISM33, ISM48) and in one AM sample 
(IAM17), although in low frequencies. This is an indication that the var genes of 
laboratory strains are shared among the field isolates.  
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In conclusion, we have shown that the var family is highly diverse in natural P. 
falciparum populations, however, the diversity was more restricted in severe 
malaria than in asymptomatic isolates, and this finding suggests a fundamental 
role played by different subset of var transcripts in disease syndromes. Further 
studies for analysis of this molecule are required from many geographical regions 
with well defined malaria infections. This approach might provide the basis for 
vaccine or chemotherapy targets. To gain better understanding of var gene 
diversity and function future work should be focused on analysis of full length 
sequences and the analysis of protein function and immunological responses. 
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6. Tables 
 
Table 1 Oligonucleotide primers used for amplification of different fragments of var genes 
 
var Gene region 
Size of 
amplified 
product Tanneal 
Name of 
primer Primer sequence Source 
DBL1α ~500 54 
DBLα-5' 
DBLα-3' 
5'-GCACGAAGTTTTGCAGATAT(A/T)GG-3' 
3'-AA(A/G)TCTTC(T/G)GCCCATTCCTCGAACCA-5' (Kaestli et al 2004) 
DBL1α-CIDR 1.5 kb 52 
DBLα-5' 
CIDR1.1-3' 
CIDR1.2-3' 
5'-GCACGAAGTTTTGCAGATAT(A/T)GG-3' 
3'-T(C/G/T)TAGTAATTTATC(A/C/T)ATTGT-5' 
3'-T(C/G/T)TAATAAGAATTCGATTGC-5' (Kaestli et al 2004) 
upsA 5'UTR- DBL1α 1.2 kb 54 
up sA- 5 ' 
DBLα-3' 
5'-ATTA(C/T)ATTTGTTGTAGGTGA-3' 
3'-AA(A/G)TCTTC(T/G)GCCCATTCCTCGAACCA-5'  
upsB 5'UTR- DBL1α 1.3 kb 52 
17DBLα-5' 
DBLα-3' 
5'-ATGTAATTGTTGTTTTTTTTTTTGTTAGAA TATTTA AA-3' 
3'-AA(A/G)TCTTC(T/G)GCCCATTCCTCGAACCA-5'  
psC 5'UTR- DBL1α 1.3 kb 54 
5B1-5' 
DBLα-3' 
5'-CACATATARTACGACTAAGAAACA-3' 
3'-AA(A/G)TCTTC(T/G)GCCCATTCCTCGAACCA-5' 
(Voss et al 2000) 
(Kaestli et al 2004) 
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 Table 2 Clinical and epidemiological assessment of isolates from severe and asymptomatic malaria 
Isolate Sex 
Age 
(months) 
Days 
between 
symptoms 
and 
treatment 
Parasitemia 
(parasites/200 
leukocytes) 
Temperature 
(°C) 
MUAC 
(cm) PCV % 
Lactate 
mmol/L 
Glucose 
mmol/L 
Blantyre 
score 
Severe           
ISM2 M 40 3 3120 38.6 17 27 2.5 2.3 2 
ISM3 M 36 2 2574 39.7 17 16 2.4 5.9 3 
ISM11 M 33 2 7344 37.0 17 30 4.5 3.7 3 
ISM16 M 16 3 2484 38.6 14 26 2.1 2.7 3 
IMS33 F 24 3 1316 37.4 16 22 3.1 3.0 2 
ISM48 M 36 2 4713 38.9 17 31 3.0 5.0 3 
ISM49 M 14 4 1907 39.9 16 23 1.8 6.6 3 
ISM51 F 16 4 9999 40.0 16 21 5.0 8.4 2 
Asymptomatic           
IAM5 M 24 NA 830 36.7 ND 20 3.4 5.8 NA 
IAM7 F 33 NA 704 36.6 ND 14 3.3 3.9 NA 
IAM10 M 59 NA 70 37.5 ND 22 2.4 4.2 NA 
IAM11 F 56 NA 68 36.7 ND 23 4.6 4.4 NA 
IAM12 F 47 NA 690 36.4 ND 26 4.5 8.0 NA 
IAM17 M 59 NA 360 37.3 ND 28 2.5 4.9 NA 
IAM18 F 52 NA 360 37.3 ND 18 3.1 4.3 NA 
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 A – Not applicable, ND – Not determined  
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Table 3a Summary of analysed sequences of different transcribed var DBL1α 
sequences 
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Severe        
ISM 2 48 42 23 PF08_0141 A LFLG-IREY-KAIT-2-LTNL 2 
ISM 3 48 41 22 PFF0010w B/A LYLD-FREY-KAIT-2-PTNL 3 
ISM 11 60 50 20 PFD1005c B/C LFIG-LRED-KALT-4-PTYF 2 
ISM 16 48 36 18 PFD0020c A MFKR-LRED-RAIT-2-PTNL 1 
ISM 33 60 50 15 PFF0010w A LFLG-VREY-KAIT-2-LTNL 3 
ISM 48 48 47 12 PF08_0141 A MFLG-IREY-KALT-2-PTNL 3 
ISM 49 48 44 17 PFL1830c B LYLG-LRED-KAIT-4-PTYF 3 
Asymptomatic        
IAM 5 48 46 25 PF08_0141 A MFLG-IREY-KALT-2-PTNL 3 
IAM 7 48 45 8 PFL 1830c B LYLG-LRED-KALT-4-PTYF 2 
IAM 10 48 38 23 PFD0615c C LFIG-LRED-EAIT-4-PTNF 3 
IAM 11 48 43 15 PFL2665c B LYRG-LRED-NAII-3-LTNF 3 
IAM 12 48 45 20 PFL1955w B/C LYLG-LRED-KAIT-4-PTYF 2 
IAM 17 48 46 24 PFA0005w B LYLG-LRED-EAIT-4-PTYF 2 
IAM 18 48 42 16 PFA0005w B LYLG-LRED-KAIT-4-PTYF 2 
 Total 66
5 
     
MOI- Multiplicity of infections 
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Table 3b Summary of analysed upstream sequences transcribed by different 
isolates 
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ISM 2 48 19 4 PFD0625 C PFD0625 C 5B1 
ISM 33 48 26 8 MAL7P1.56 C MAL7P1.56 C 
IAM 18 48 39 10 PFA0005w B PFA0005w B 
ISM 49 48 27 6 PFL0005w B PFL0020w B/A 
17DBL 
ISM 3 48 29 3 PFD10005c B/C PFD0020c A 
ISM 11 48 35 5 PF08_0141 A PFD0020c A 
ISM 51 48 39 13 PFL0020w B/A PFD0020c A 
DBL-CIDR 
IAM 17 48 31 4 PFE1640w var 1  PFE1640w var 1 
ISM 2 48 18 6 PFD0020c A PFD0020c A 
ISM 3 60 44 5 PF08_0141 A PFD1235w A 
ISM 11 48 35 5 PFD0020c A PFD0020c A 
ISM 16 60 45 3 PFD0020c A PFD0020c A 
ISM 49 60 48 3 PFL1820w A PFE1640w var 1  
upsA 
ISM 51 48 40 7 PFD0020c A PFD0020c A 
  Total 665      
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7. Figure Legends 
 
Figure. 1 Distribution of unique sequence types (STs) of DBL1α in clinical isolates 
Blue columns represent STs found in multiple samples from both AM and SM 
groups. Red columns represent STs found in multiple samples within the SM 
group. Pink columns represent STs found in multiple samples within the AM 
group. Yellow columns represent STs specific to each individual isolate 
 
Figure. 2 Distribution of DBL-1α sequences into cys/PoLV groups by clinical 
status. 
SM DBL-1α sequences had more than 50% Cys2 sequence tags (1-3 groups) 
compared to 27 % in AM isolates 
 
Figure. 3 Distribution of PoLV motifs within clinical isolates SM (red bars) and in 
AM (white bars) 
 
Figure. 4 Cumulative diversity curves for DBL-1α sequences from Ifakara. 
The cumulative curve for DBL-1α was determined by simulation of the number of 
unique sequences as a function of the number of patient samples as a function of 
the number of patient samples. For each number of patient samples the statistics 
value were obtained from simulations of all possible sample combinations 
 
Figure. 5 Phylogenetic network showing the comparison of 3 dominant DBL-1α 
sequence tags transcribed from clinical isolates, generated using Neighbour-Net 
(Bryant & Moulton 2004). Sequences transcribed by isolates with severe malaria 
(ISM, blue) and asymptomatic malaria (IAM, red) are compared. The sequences 
fall into two major clades separated with dotted line, the upper cluster formed 2 
subgroups of sequences isolated from severe patients, one with group A and the 
remaining var group B/A homology to 3D7. Isolates from asymptomatic patient 
majority of the sequences clustering together and were homology to group B, B/C 
and C of 3D7 genome 
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Figure. 6 Phylogenetic comparison of DBLα from 3D7 genome and 3 dominant 
DBLα sequence tags transcribed from each clinical isolates. A neighbor-joining 
tree was generated based amplified DBL-1α fragments. The bootstrap consensus 
tree inferred from 1000 replicates (Felsenstein 1985), using pairwise deletion of 
amino acid sequences with p-distance. Phylogenetic analyses were conducted in 
MEGA4 (Tamura et al 2007). Sequences transcribed by isolates from children with 
severe malaria (ISM, pink), asymptomatic malaria (IAM, black) and 3D7 genes 
(group A, red; group B, blue; group C, green.  
 
Figure. 7 Phylogenetic comparison of var group A from 3D7 genome and 3 
dominant var group A amplified from clinical isolates. A neighbor-joining tree was 
generated based upon the predicted protein start site in the N-terminal segment 
(NTS) domain to the first DBL-1α H block. The bootstrap consensus tree inferred 
from 1000 replicates (Felsenstein 1985), using pairwise deletion of amino acid 
sequences with p-distance. Phylogenetic analyses were conducted in MEGA4 
(Tamura et al 2007). Sequences transcribed by isolates from children with severe 
malaria (ISM, blue), asymptomatic 
  
Chapter Four 
 
 72 
Figure 1 
0
5
10
15
20
25
30
35
40
45
IAM
10
IAM
11
IAM
12
IAM
17
IAM
18
IAM
5
IAM
7
ISM
11
ISM
16
ISM
2
ISM
3
ISM
33
ISM
48
ISM
49
ISM
51
Clinical isolates
U
n
iq
u
e 
se
qu
en
c
es
 
(S
Ts
)
 
Figure 2 
 
.   
 
Chapter Four 
 
 73 
Figure 3 
 
 
 
 
Figure 4 
y = 12.404x + 12.889
R2 = 0.995
0
50
100
150
200
250
0 2 4 6 8 10 12 14 16
no. samples (IAM + ISM)
n
o
.
 
u
n
iq
u
e 
se
qs
min
max
mean
median
Linear (mean)
 
Chapter Four 
 
 74 
Figure 5 
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Figure 7 
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Chapter Five 
5.0 General Discussion and Conclusion 
 
Plasmodium falciparum is unique among parasites that cause malaria in humans 
due to its ability to induce cytoadhesion of infected red blood cells. This property 
is a consequent of the exposure of PfEMP1 protein on the surfaces of infected cells. 
The resulting adhesive properties are believed to be the major virulence 
determinants of P. falciparum infections. PfEMP1 plays a large role in host-parasite 
interactions.  
 
Despite years of research, very little is known about changes that occur in the host-
parasite relationship as naturally acquired antimalarial immunity develops. 
Molecular tools for measuring changes in the parasite as it adapts to the 
development of clinical immunity in vivo are still lacking. Such a tool would 
provide a powerful means of dissecting the protective components of host 
response, a first step in the identification of new vaccine candidates. One of the 
limitations of studying host-parasite interaction has been possible to overcome by 
using parasite isolates from peripheral blood, since there is no equivalent or useful 
animal model system for mimicking cytoadherence in the host. It is possible to 
argue though that parasites isolated from peripheral blood might not reflect what 
is happening in deep tissue and organs of the host.  
 
Both clinical and sero-epidemiological studies have shown that parasites from 
patients with severe malaria express a different subset of surface antigen that are 
more frequently recognized by sera from malaria exposed individuals, including 
young children, than parasite antigens from older children with mild malaria (Bull 
et al 2000, Nielsen et al 2002). It has been shown that this subset of surface antigens 
is serologically conserved among different geographical regions (Nielsen et al 
2004). Therefore, it is critical to identify the molecular phenotypes and the genetic 
diversity of such a subset in-order to develop a disease ameliorating vaccine or for 
other therapeutic interventions.  
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In this research, two studies on var gene expression during malaria infection are 
described. In the first study, the differential expression levels of PfEMP1 encoded 
by var gene group A, B, or C were quantified. The real-time quantitative PCR 
procedure was used to compare the distribution of var gene transcripts of var 
group A, B and C among children with asymptomatic malaria (AM), 
uncomplicated malaria (UM) and severe malaria (SM). In the second study, the 
case definition of severe malaria was restricted by using children with cerebral 
malaria (Blantyre coma score ≤ 3). The genetic diversity of expressed var genes 
from children with severe malaria was compared with that of children with 
asymptomatic malaria infection.  
 
Both studies were carried out in Ifakara, a semi-rural area, in Kilombero valley, in 
Southern Tanzania. Ifakara is an area of moderate perennial P. falciparum 
transmission surrounded by areas of more intense transmission. Malaria is known 
to be the leading cause of morbidity and mortality in children under age of 5 years 
(Schellenberg et al 2004). 
 
5.1 Differential Expression of var gene Groups 
 
Transcripts of var group A and B genes were more abundant in patients with 
severe malaria than in those with mild malaria. It was clearly demonstrated that 
the transcript abundances of var group A and B gene were higher for children with 
clinical malaria than for children with asymptomatic infections. var group C had 
no association with any clinical manifestation.  
 
Recent studies on var gene transcription and malaria severity in clinical isolates 
have yielded conflicting results. Differences in epidemiology, var classification, 
and severe disease characterization make comparison across studies difficult. 
Chapter Five 
 
 80 
Severe malaria encompasses a variety of clinical syndromes (i.e cerebral malaria, 
severe anaemia, respiratory distress and prostration). These syndromes may have 
different underlying cytoadherent properties of parasites and different pathogenic 
mechanisms. Significant associations between var gene groups and clinical disease 
may be masked unless strictly defined clinical groups are assessed along with 
suitable control groups (Kurtzhals et al 2001). This represented one of the major 
challenges in the first study as we considered severe malaria as a single entity to 
facilitate the analysis. Large sample size and strict clinical definition of severe 
malaria should provide strong evidence of a particular var gene group expression 
with a particular subset of severe malaria syndrome. In the study, peripheral 
blood samples were used to examine P. falciparum var gene transcription profiles 
in clinical isolates. There is a big debate whether parasites circulating in peripheral 
blood adequately represent the sequestered parasites, and the disease associated 
phenotype. Ideally, studies aimed at examining the relationship between var gene 
transcription and a particular disease syndrome would preferably examine 
sequestered parasites. However, these are only accessible in postmortem samples, 
and conducting such studies are technically and ethically challenging. There is 
controversial data on phenotypes of circulating parasites and adhering parasites 
from human placental studies. Two studies reported identical binding phenotype 
in the placental and in the peripheral circulation (Ofori et al 2003, Tuikue Ndam et 
al 2004), whereas other studies showed antigenically distinct parasites (Beeson et 
al 1999, Fried & Duffy 1996). Three recent studies from Malawi (Dembo et al 2006, 
Dobano et al 2007, Montgomery et al 2006) indicates that sequestered parasites are 
usually similar to those in peripheral circulation, and that parasite genotypes in 
cerebral malaria patients are homogenously distributed throughout the body. In 
another study, (Montgomery et al 2007) by using pediatric postmortem samples 
showed that the var genes expressed in the brain, lungs and heart are subsets of 
var transcripts found in the spleen, which might represent peripheral circulation. 
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Yet, the exact proportion of sequestered parasites present in peripheral circulation 
remains uncertain. Thus, although we hypothesize that severe malaria is 
maintained by a homogenous parasite population expressing multi-adhesive 
variant surface antigens (VSA), or parasites expressing a VSA subset, which 
mediates sequestration independent of endothelial receptors it might be quite 
challenging to identify these.  
 
5.2 Genetic Diversity of Expressed Plasmodium falciparum var genes 
 
This study showed a wide genetic diversity of the var gene with minimal overlaps 
between isolates. DBL-1α sequences from SM had a reduced number of cysteines 
residues, and most belonged to var gene group A and B/A with homology to 3D7. 
Detailed analysis of the sequences showed all isolates had a predominant 
sequence as well as minor transcripts and unique sequence types. Although, the 
dominant transcript differed between isolates, it is uncertain whether the 
dominance of particular var genes within a patient truly reflected the differential 
expression levels, or whether it is due to biased amplification, cloning or unequal 
distribution of circulating stages. For either of these assumptions to be true, we 
would expect that the same bias would be observed in all patient isolates and 
therefore we would not see a different dominant sequence in each isolate. The 
differences in var transcripts in each isolate suggest that each parasite genome has 
its own form of var gene repertoires. This has an implication for acquiring long-
term protective immunity. Infection with a particular strain of P. falciparum does 
not necessarily give protection to subsequent infections. The DBL-1α and 
upstream sequences variability within an isolate were similar to that found 
between different isolates regardless of the group (AS or SM). This suggests that 
the level of diversity detected is representative of all the possible sequence 
diversity existing within each isolate. Using the collector’s curve analysis on all 
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DBL-1α sequences generated, the total repertoire of var gene sampled from a local 
population of Ifakara area was estimated. This is a region of circa 50 km in 
diameter surrounding the St Francis Designated District Hospital, where the study 
subjects were recruited. The analysis showed that the var gene repertoire in the 
sampled population is unlimited as the saturation point could not be reached. This 
result indicates a vast amount of var gene diversity in the Ifakara area, and is 
evidence for the vast archive of antigenic diversity in P. falciparum and this might 
explain why immunity to malaria is non-sterilizing and develops slowly. Whether 
this is the representation of the var gene diversity of Ifakara or Tanzania in general 
still remains to be elucidated. Whether increased sample size and inclusion of 
more than only one var gene domain would have helped to elucidate the total var 
gene diversity is a challenge to be solved. However, the var genes were found to 
have an unlimited repertoire in this study, and further cluster analysis revealed 
that AM isolates were more diverse with more singletons compared to SM 
isolates. This shows that the diversity of var genes within SM patients was more 
restricted, hence could explain why immunity to severe childhood malaria 
develops earlier after a few episodes. 
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5.3 Conclusions 
 
The pathogenesis of falciparum malaria involves complex interactions of host and 
parasite factors, further complicated by the fact that antigenic and adhesive 
properties of circulating parasites may be quite different to those sequestered. The 
increased body of evidence has demonstrated that circulating parasites represent 
the sequestered parasites. Despite the importance of var genes in malaria 
pathogenesis, most of the expression studies have been done either on in vitro 
cultured field isolates or on reference strains. In in vitro cultures, the parasites are 
grown without the selective pressure of the host’s immune system, therefore no 
changes of their intrinsic phenotype occurs, consequently becoming homogeneous 
with respect to the PfEMP1 variant expressed (Frank et al 2007, Peters et al 2007). 
Scherf et al observed subtelomeric deletion in cultured isolates which resulted into 
loss of functional genes. (Scherf et al 1992). Our studies on var gene transcriptions 
on naturally infected children were performed without culturing the parasite 
isolates, therefore, providing a good insight of the complex nature of this family of 
genes. 
 
The diversity of var genes is massive and encourages broader analysis of var 
subpopulations from other geographical areas with different malaria 
epidemiology. It will be important to define the total var gene repertoire in a given 
geographical area or globally, to facilitate the analysis of temporal changes over 
time or as new P. falciparum strains invade endemic areas. It might seem 
unreasonable to use the var genes family as the basis of vaccine or therapeutic 
targets owing to its extraordinarily high polymorphism and complex nature. 
However, var2csa is a promising vaccine candidate for pregnancy-associated 
malaria (Avril et al 2006, Rogerson et al 2007). With better understanding of var 
gene diversity and function, we might be able to take advantage of specific var 
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subtypes associated with severe malaria, since the var gene family remains the best 
defined factor contributing to malaria pathogenesis. The completion of human and 
P. falciparum genomes, high throughput methodologies and reverse genetics, along 
with clinical data from different epidemiological settings will hopefully lead to a 
better understanding of the role of these complex interactions in different clinical 
syndromes. Most studies of var genes have focused on small fragments of DBL1α 
domain. With the high throughput technologies for sequencing available (Solexa 
and 454 life science), broader analysis of full-length var genes, the analysis of 
protein function and immunological responses will provide invaluable 
information toward new opportunities for interventions to treat or prevent severe 
malaria. 
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Appendix 1: INPATIENT FORM 
 
IDENTIFICATION 
 
1 Date admitted (dd/mm/yy)  |__|__| / |__|__| / |__|__|  
2 Hospital number  |__|__|__|__|__|__|__|__| 
3 Study number                                       | __|__|__|__|/ 
|__|__|__| 
4 Child's first name |__|__|__|__|__|__|__|__|__|__| 
5 Date of birth (dd/mm/yy) 
Age (Months) 
|__|__| / |__|__| / |__|__| 
 |__|__| 
7 Sex (1=male, 2=female) |__| 
8 Mother's first name |__|__|__|__|__|__|__|__|__|__| 
9 Father's first name |__|__|__|__|__|__|__|__|__|__| 
10 Family name of father |__|__|__|__|__|__|__|__|__|__| 
11 Village |__|__|__|__|__|__|__|__|__|__| 
12 Balozi |__|__|__|__|__|__|__|__|__|__| 
12(a) Mwenyekiti wa Kitongoji |__|__|__|__|__|__|__|__|__|__| 
HISTORY 
13 Fever (1=yes, 2=no / no days) |__| / |__|__| 
14 Cough (1=yes, 2=no / no days) |__| / |__|__| 
15 Dyspnoea (1=yes, 2=no / no days) |__| / |__|__| 
16 Child sucking / drinking 1=more than usual, 2=less than usual, 3=as usual) 
 
|__| 
17 
 
17(a) 
 
17(b) 
 
 
Diarrhoea (1=yes, 2=no / no days) 
     If no, go to question 20 
Have you given any oral treatment to this diarrhoea 
episode?  (1=yes,  2=no) 
Which one (probe) 
(1=porridge, 2=plain water, 3=ORS, 4=others 
 
|__| / |__|__| 
 
|__| 
 
|__| 
18      Nº of stools in the last 24 hours |__|__| 
19      Stool type (1=Watery, 2= bloody, 3=mucoid)  |__| 
20 Dysentery (1=yes, 2=no / no days) |__| / |__|__| 
21 Vomiting (1=yes, 2=no / no days) |__| / |__|__| 
22 Has the child fitted during this illness? (1=yes, 2=no) 
     If no, go  to Q25 
|__| 
  96 
23 No of seizures within the last 24 hours |__|__| 
24 Other significant history ______________________________________________________ 
25 Has the child been seen at any health unit for that illness? (1=yes,2=no)  |__| 
26 If yes, where? __________________________________________________________________ 
27 Treatment given: 
A  |__|__ d  |__|__| 
B 
 |__|__
| 
 
e 
 
|__|__| 
C 
 |__|__
| 
 
f 
 
|__|__| 
EXAMINATION 
General 
28 Height (cm) |__|__|__| 
29 Weight (kg) |__|__| : |__| 
30 Axillary temperature(oC) |__|__| : |__| 
31 Pallor (1=yes, 2=no) |__| 
32 Jaundice (1=yes, 2=no) |__| 
33 Skin rash (1=scabies, 2=other (mild), 3=other (severe), 4=none) |__| 
34     Visible pus in ears ? ( 1= yes, 2 = no)  |__| 
35      Oral candidiasis (1=yes, 2= no)  |__| 
Respiratory  & Cardiovascular 
36 Pulse (timed over full minute) |__|__|__| 
37 Respiratory rate (time  over full minute) |__|__|__| 
38 Nasal flaring (1=yes, 2=no) |__| 
39 Indrawing (1=yes, 2=no) |__| 
  40   Crackles/creps/bronchial breathing (1= yes, 2=no)                                           __| 
41 Wheeze/ronchi (1=yes, 2=no) |__| 
42 Gallop rhythm (1=yes, 2=no) |__| 
43 Hepatomegaly (1=yes, 2=no /length cm) |__| / |__|__| 
44 Splenomegaly (1=yes, 2=no /length cm) |__| / |__|__| 
Nutritional & Hydration Status 
  97 
45 Flaky paint skin (1=yes, 2=no) |__| 
46 Orange hair (1=yes, 2=no) |__| 
47 Visible wasting (1=yes, 2=no) |__| 
48 Oedema (1=general, 2=face, 3=periphery, 4=other, 5 =none) |__| 
49 Mucous membranes (1=moist, 2=dry, 3=very dry) |__| 
50 Skin pinch goes back (1=quickly, 2=slowly, 3= very slowly) |__| 
51 
 
52 
Level of consciousness (1=well/alert, 2=restless/irritable, 3=lethargic/unconscious) 
 
Dehydration (none=1, some =2, severe=3) 
       
|__| 
 
Neurological 
53 Fontanelle (1=normal, 2=sunken, 3=bulging, 4=na) |__| 
54 Position (1=decerebrate, 2=decorticate, 3=opisthotomia, 4=normal) |__| 
55 Neck stiffness (1=yes, 2=no) |__| 
56 Can the child sit down?  (1=yes, 2=no) |__| 
57 Eye movements (0=not directed, 1=directed) |__| 
58 Verbal response (0=none, 1=inappropriate cry, 2=appropriate cry) |__| 
59 Motor response (0=none, 1=withdraw from pain, 2=localises pain) |__| 
60 Has the child had a convulsion in the last hour or anticonvulsant treatment in the 
last  
 
|__| 
61(a) 
 
 
61(b)
Provisional diagnosis by OPD Clinician                                                                                         
 
Provisional diagnosis by IHRDC Clinician 
|__|__|/|_
_|__| 
 
 
LABORATORY AND COMPLEMENTARY INVESTIGATIONS 
61 Microcapillary tube and blood slides sent to IC lab? (1=yes, 2=no) |__| 
62      Sample brady number? (affix sticker here) 
63 Blood glucose (mg/dl) |__|__|__| 
64 Hospital PCV on admission (%) |__|__| 
65 Initials of admitting officer |__|__| 
AT DISCHARGE 
66 Hospital parasitaemia on admission (1=positive, 0=negative) |__| 
67 Chest x-ray taken (yes=1 ,no=2) |__| 
  98 
68      If yes (normal=1 ,abnormal=2) |__| 
69 LP done (1=yes, 2=no) |__| 
70      If yes (normal=1,abnormal=2) |__| 
71 Has the child received a blood transfusion during admission? (1=yes, 2=no) |__| 
72      Date of transfusion |__|__| / |__|__| / |__|__| 
73 
 
73(a
) 
     What was the last hospital PCV recorded before transfusion? 
      
      Hospital PCV on discharge 
|__|__| 
 
|__|__| 
 74 Final diagnosis 1:______________________________________________ |__|__|__| 
75 
 
75(a
) 
Final diagnosis 2:______________________________________________ 
 
Final diagnosis 3:______________________________________________ 
|__|__|__| 
 
|__|__|__| 
 76 Date of discharge (dd/mm/yy) |__|__| / |__|__| / |__|__| 
77 Outcome: (Alive=1, dead=2, absconded=3, 4=transferred) |__| 
78 Treatment received during admission: 
A  |__|__|  d  |__|__| 
B 
 
|__|__| 
 
e 
 
|__|__| 
C 
 
|__|__| 
 
f 
 
|__|__| 
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 Appendix 2: Analysed sequences 
 
2.1 DBL-1α multiple alignments of predominant sequences from IAM 
isolates 
 
F8IAM10  ARSFADIGDIVRGKDLFLG---------NTYESAQRDELEKNLKTIFEKIYNDVTNGSNA 51 
F5IAM10  ARSFADIGDIVRGKDLYLGG--------NNKEKKRRDELEKNLKKIFEKIKGD--NNSKL 50 
C4IAM11  ARSFADIGDIIRGKDIFIG-------------NKKKDKLEENLKTIFGKIYEKLNGAKEY 47 
A8IAM5   ARSFADIGDIVRGRDLYSG-------NSKE---KKKRCLENKLKEIFGDIYKDVTKNNR- 49 
A10IAM11 ARSFADIGDIVRGKDLYLG-------NKKKNQAREKEKLENKLKEYFEKIYNSLES---- 49 
A3IAM12  ARSFADIGDIIRGKDLYLGKKKK-QNETKTE--TEREKLEQKLKEIFAKIHSEVTSTSGN 57 
F2IAM18  ARSFADIGDIIRGKDLYLGKKKKKQNETKTE--TEREKLEQKLKEIFAKIHSEVTSTSGN 58 
D5IAM5   ARSFADIGDIIRGKDLYLEKKKKKQNETKTE--TEREKLEQKLKEIFAKIHSEVTSTSGN 58 
E1IAM7   ARSFADIGDIVRGKDLYLG------YDEKEK--EQRKKLEKNLKEIFTQIYNDVT-TNGK 51 
F7IAM17  ARSFADIGDIVRGKDLYLG------YDDKEK--KRREKLENKLKEISTQIHEDVT-KNG- 50 
E2IAM18  ARSFADIGDIIRGKDLYLG-------NPQES--AQRIILEKNLKKYFQQIHNDVT-SSGR 50 
F10IAM10 ARSFADIGDIIRGKDLFIGYD--------EKDRKEKKQLQQNLKNIFGKIHSEVTNG-SN 51 
H6IAM18  ARSFADIGDIVRGKDLYIGN----------RKEKEKEELQKNLKSIFKKIYGELKNGKTN 50 
F3IAM17  ARSFADIGDIVRGKDLFYGN---------PQEKKQRKELDKKLKEVFGKIHEGLKNG--- 48 
H8IAM7   ARSFADIGDIVRGRDLYFGKRKK---KNQKETETEREKLEKNLKDIFKKIYGELSRTSTN 57 
A5IAM12  ARSFADIGDIIRGKDLYLG-------DNRKDRE-QKVKLENKLKEIFAKIHENLGTQDAI 52 
A7IAM11  ARSFADIGDIIRGKDLYRG--------NSKEKD----NLEKKLIEYFQKIHGGL-TGDAQ 47 
A2IAM12  ARSFADIGDIIRGKDLYLDH------------EPGKQHLEERLETMFQNIQYNNTELKDI 48 
F12IAM17 ARSFADIGDIIRGKDLYLDH------------EPGKQHLEERLETMFQNIQYNNTELKNI 48 
F6IAM7   ARSFADIGDIVRGKDLFLGH------------KQGKQKLEASLKTMFQNILSTIDQLKRL 48 
D4IAM5   ARSFADIGDIVRGTDMFLGS------------NKEKGKIENSLQNIFKNIKKNNKKLKDL 48 
         **********:** *::                     ::  *     .*           
F8IAM10  E--AAKERYKGDADNNYFQLREDWWTANRATIWEAITC--DVHGSDYFRPTCS-MNGSGA 106 
F5IAM10  S--TLKD----D------QIREYWWALNRETVWEAMTC--KAEG-AYFHATCS-MNGSGA 94 
C4IAM11  Y--QDKN------GGNFLKLREDWWALNRNDVWKAMTCSEDLKNSSYFHATCIDRKGSCS 99 
A8IAM5   ---ALQARYT-DNKN-YYKLREDWWDANRETVWKAITCGSA--GGKYFRKTCAGG---TS 99 
A10IAM11 ---SIKSQYD-DEANNFFKLREDWWALNREEVWKAITCGHP--DGTYFRNTCAGG---TT 100 
A3IAM12  NKEVLKARYD-GDGDNYYQLREDWWDANRLDVWKAITCGAP-HGAQYFRQTCNDDG-TSS 114 
F2IAM18  NKEVLKARYD-GDGDNYYQLREDWWDANRLDVWKAITCGAP-HGAQYFRQTCNDDG-TSS 115 
D5IAM5   NKEVLKARYD-GDGDNYYQLREDWWDANRLDVWKAITCGAP-HGAQYFRQTCNDDG-TSS 115 
E1IAM7   NVDALKTRYN-DDTPDFFKLREDWWDANRETVWKALTCDHRLGGSQYFRPTCGSKAKTAT 110 
F7IAM17  ----AEARYN-DDTGDFFQLREDWWTANRSTIWEAITCNAG-GGNRYFRQTCGS----GN 100 
E2IAM18  N--GVKDRYK-DTDKNFFQLREDWWYANRETVWKAITCNAQ--GFDYFRQTCGDDEKTAT 105 
F10IAM10 A-EAAKARYK--DTTDFYQLREDWWDANRETVWEAITCG-AAGG-TYFRATCSDEENKST 106 
H6IAM18  G-EAAKVHYQE-DGQNYYKLREDWWTANRETVWEAITCN-AGGG-TYFRGTCGKND---T 103 
F3IAM17  ---KAKERYK--DTTNYYQLREDWWTANRETVWKAITCA-AKVGDTYFMESRTNSY---K 99 
H8IAM7   GRNGELQERYEDKDGNYLKLREDWWTANRDQVWKAITCDAR-DNAQYFRATCAGEQ---- 112 
A5IAM12  G-------HYEDAKKNYYKLREDWWTANRGTVWKAITCGAG-KHDKYFRKTCNGGS---- 100 
A7IAM11  T-------HYNDKSGNFFKLREDWWDANRQEIRNAIICDVP-EDAKYLEQSDGSQSG--- 96 
A2IAM12  P---------------LPKVREYWWALNRDQVWKAITCHAG-KDDAYFRNSSGGEY---K 89 
F12IAM17 P---------------LPKVREYWWALNRDQVWKAITCHAG-KDDAYFRNSSGGEY---K 89 
F6IAM7   S---------------INAVREYWWEIKRQEVWKAITCSAG-EDDTYSKYLGDRTT---G 89 
D4IAM5   T---------------DKQIREYWWALNRKEVWKALTCSVP-YEAYYFTYKSDNFR---T 89 
                                :** **  :*  : :*: *        *              
  100 
F8IAM10  QANNKCRCTKSSGAK-DGEVNIVPTYFDYVPQYLRWFEEWAEDL 149 
F5IAM10  QANNKCRCDKEKAGKGSGDVTIVPTHFDYVPQFLRWFEEWAEDL 138 
C4IAM11  QAKDKCRCKDEKGTN----TDQVPTYFDYVPQYLRWFEEWAEDL 139 
A8IAM5   LTEDNCRCAANI---------DPPTYFDYVPQYLRWFEEWAEDL 134 
A10IAM11 PTPNKCRCATN----------DAPTNFDYVPQYLRWFEEWAEDL 134 
A3IAM12  RAIHQCRCQKKDGTH---DSDQVPTYFDYVPQYLRWFEEWAEDL 155 
F2IAM18  RAIHQCRCQKKDGTH---DSDQVPTYFDYVPQYLRWFEEWAEDL 156 
D5IAM5   RAIHQCRCQKKDGTH---DSDQVPTYFDYVPQYLRWFEEWAEDL 156 
E1IAM7   QTPSQCRCSDN----------QVPTYFDYVPQFLRWFEEWAEDL 144 
F7IAM17  WTKDKCRCDDKP-------NTDPPTYFDYVPQYLRWFEEWAEDL 137 
E2IAM18  RVKDKCRCDGD----------QVPTYFDYVPQFLRWFEEWAEDL 139 
F10IAM10 LASNKCRCAGKNA-------DQVPTNFDYVPQYLRWFEEWAEDL 143 
H6IAM18  WTREDCRCDGSN---------VVPTYFDYVPQYLRWFEEWAEDL 138 
F3IAM17  FSGDKCGHNDDN----------VPTNLDYVPQYLRWFEEWAEDL 133 
H8IAM7   RTKGYCRCNGDKPDN-DMVNIDPPTYFDYVPQYLRWFEEWAEDL 155 
A5IAM12  PTKGYCRCNGDQPND-HKANIDPPTHFDYVPQFLRWFEEWAEDL 143 
A7IAM11  SHQTKCRCHSG----------SVLTNFDYVPQYLRWFEEWAEDL 130 
A2IAM12  FTSGYCGRNEGK----------VPTNLDYVPQHLRWFEEWAEDL 123 
F12IAM17 FTSGYCGRNEGK----------VPTNLDYVPQHLRWFEEWAEDL 123 
F6IAM7   VSHGQCGHMDEN----------VPTHFDYVPQFLRWVEEWAEDL 123 
D4IAM5   FSGYWCGHYEGA----------PPTNLDYVPQFLRWFEEWAEDL 123 
 
2.2 DBL-1α multiple alignments of predominant sequences from SM 
isolates 
A1ISM49  ARSFADIGDIVRGRDLFLGNTY-------ESAQRDQLDKK----LKEIFTQIYNDVTTN- 48 
C4ISM16  ARSFADIGDIIRGRDLFYGNTQ-------EKTKRKQLDKK----LKDIFGDIYKELRKN- 48 
D2ISM49  ARSFADIGDIVRGKDPFYGNPD-------EIKQRQQLEDK----LKEIFQKIHDKLDS-- 47 
A3ISM11  ARSFADIGDIVRGRDIFRGNDE-------EKKKRDELDDK----LKKIFGKIHGGLTG-- 47 
A1ISM16  ARSFADIGDIIRGKDLYLGYDDE------EKSRRKQLDDK----LKDIFKEIHDDVTTN- 49 
E5ISM48  ARSFADIGDIVRGKDLYLGYDDK------EKKRREKLENK----LKEIFTQIHEDVTKN- 49 
E2ISM3   ARSFADIGDIIRGKDLYLGYDQK------EKDRRDELEKN----LKTIFGKIHSDVTSG- 49 
A5ISM49  ARSFADIGDIIRGKDLYLGKKKKKQNETKTETEREKLEQK----LKEIFAKIHSEVTSTS 56 
ISM11F10 ARSFADIGDIIRGKDLFIGNNK-----------RDKLEKQ----LKEYFKNIYDNLN--- 42 
F1ISM3   ARSFADIGDIIRGKDLFRGYNEK------DRKEKEQLQDS----LKNIFKEIYDDVTSDK 50 
B5ISM11  ARSFADIGDIIRGKDLFRGYDYE------EKNRREQLEEN----LKTIFGNIYEELREEQ 50 
G12ISM3  ARSFADIGDIIRGKDLYLDHEPG----------KQHLEER----LERIFENIKK------ 40 
A10ISM2  ARSFADIGDIIRGKDLHLDHEPG----------KQHLEER----LERIFENIKK------ 40 
ISM51C11 ARSFADIGDIIRGKDLYLDHEPG----------KQHLEER----LERIFANIQK------ 40 
F9ISM33  ARSFADIGDIIRGKDLYLDHEQG----------NNRLEAR----LKTIFQNIQN------ 40 
E8ISM51  ARSFADIGDIIRGKDLFLGHEQR----------KKYLEAR----LEAMFDNIKK------ 40 
H9ISM33  ARSFADIGDIIRGKDLFLGHEQR----------KKYLEAR----LEAMFDNIKK------ 40 
G5ISM48  ARSFADIGDIVRGTDMFLGSNKE----------KEKIENS----LQNIFKNIKK------ 40 
C9ISM2   ARSFADIGDIVRGKDLYLGDKGE----------KKKLEKN----LKDIFKQIHEKLTDP- 45 
A1ISM2   ARSFADIGDIIRGKDLFLGHKEQ----------KKKLQEN----LEKIFNKFKT------ 40 
E6ISM51  ARSFADIGDIVRGRDMFL-PNKD----------DKVQKG-----LQVVFEKINNGLKKI- 43 
F8ISM33  ARSFADIGDTVKGKDMFK-PNDA----------DKVEKG-----LQVVFGKIYKSLPSP- 43 
C1ISM16  ARSFADIGDIVRGKDMFK-RNEE----------DAVQKG-----LRAVFKKINDNLKVK- 43 
E9ISM48  ARSFADIGDIVRGKDLFLGNNDN----------DKVKKEKLQNNLKSIFAKIYKELKLE- 49 
         ********* ::* * .                    .      *.  * .:         
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A1ISM49  -------G-KKPALQKRYKKDGKDPDFFKLREDWWYANRQEIWKAITCKV----ENAQYF 96 
C4ISM16  -------G-KKGELQKRYQKDG-DKDFFQLREDWWEENRETVWKAITCDAP---PDAQYF 96 
D2ISM49  ------------KAQARHQHDAP--DYYQLREDWWTANRATVWKAITCDDDKKLASASYF 93 
A3ISM11  ------------DAQTHYQDDAKK-NFYQLREDWWTANRATIWEAITCKAD---TGNAYF 91 
A1ISM16  -------GKNWQTLKKRYEGDTD-GNYYKLREDWWTANRATIWEALTCDDDNKLAGAHYF 101 
E5ISM48  -------G-----AEARYNDDT--GDFFQLREDWWTANRSTIWEAITCNAG---GGNRYF 92 
E2ISM3   -------K-NAEELKARYNGDKN-NDFFKLREDWWEANRETIWRAITCGHP----GGTYF 96 
A5ISM49  -------GNNKEVLKARYDGDGD--NYYQLREDWWDANRLDVWKAITCGAP---HGAQYF 104 
ISM11F10 -------GAQKHYSDD--DKGTK--NYYQLREDWWALNRQEIWKALTCES----GGGRYF 87 
F1ISM3   N------GKNAEELKERYGQDSP--NFYKLREDWWNANRLDVWKAITCKAE----NAQYF 98 
B5ISM11  TKRKRAKPKNGQALQARYKKDGD--NFFKLREDWWYANRLEVWKAITCHAG---KDDAYF 105 
G12ISM3  ---------------KNNNNELNNLSLDKFREYWWALNRVQVWKAITCRAE---EKDIYS 82 
A10ISM2  ---------------KNNNNELNNLSLDKFREYWWALNRVQVWKAITCRAE---EKDIYS 82 
ISM51C11 ---------------ENG--DINTLKPEEVREYWWALNRVQVWKAITCRAE---EKDIYS 80 
F9ISM33  ---------------KNKS-PLDKLSLDKFREYWWALNRVQVWKAITCGAT---MNDIFS 81 
E8ISM51  ---------------NNKK-QLGELSTAQVRGYWWALNRDQVWKAITCGAT---MNDISF 81 
H9ISM33  ---------------NNKK-QLGELSTAQVREYWWALNRGQVWKAITCGAT---MNDISF 81 
G5ISM48  --------------NNKKLKDLTDK---QIREYWWALNRKEVWKALTCSVP---YEAYYF 80 
C9ISM2   -------------RAKDHYKDEKDGNLFQLREDWWTANRDQVWKAITCNAP---YKAWYF 89 
A1ISM2   -----------------IYAGLEDVAIDDIREYWWALNREDVWKAITCKAP---TGADYF 80 
E6ISM51  -------------GINAYNDG--SGNYSKLREVWWNVNRDQVWRAITCSAP---GDVNYF 85 
F8ISM33  -------------AKKHYPDGDKSGNYVKLREDWWTANRDQVWRAITCSAP---GDVNYF 87 
C1ISM16  -------------EISDYDND---PNYYKLREDWWNVNREQVWRAITCYIP---YYVNYF 84 
E9ISM48  -------------KNSDYKDDDIDGNYYKLREDWWTVNRDQVWKALTCFAD---GSEEYF 93 
                                     ..*  **  **  :*.*:**             
A1ISM49  KDTCSTG-----GHYEKCRCNGDQPKSGKGGDVNIVPTYFDYVPQYLRWFEEWAEDL 148 
C4ISM16  RGTCGDNEKTATQTPSQCRCNDDQ-----------VPTYFDYVPQYLRWFEEWAEDL 142 
D2ISM49  RETCGGDGKTGTQAKRQCRCEDAN--------ANQVPTYFDYVPQYLRWFEEWAEDL 142 
A3ISM11  RATCGGSGETPLVTPSQCRCKKNDG----GDDADQVPTYFDYVPQYLRWFEEWAEDL 144 
A1ISM16  RQTCGSNAKSATQASNKCRCSDKVN-TDPP-------TYFDYVPQFLRWFEEWAEDL 150 
E5ISM48  RQTCGS----GNWTKDKCRCDDKPN-TDPP-------TYFDYVPQYLRWFEEWAEDL 137 
E2ISM3   RKTCVG----ENETQNNCRCDDKPK-SGKPREVNIVPTYFDYVPQYLRWFEEWAEDL 148 
A5ISM49  RQTCND-DGTSSRAIHQCRCQKKDG----THDSDQVPTYFDYVPQYLRWFEEWAEDL 156 
ISM11F10 RETC---AGGTSRTQDDCRCRTND-----------VPTYFDYVPQYLRWFEEWAEDL 130 
F1ISM3   RNACSKG---TTPTNEKCHCIDET-----------VPTYFDYVPQYLRWFEEWAEDL 141 
B5ISM11  RKSGYR-----EFEFTDGHCGNKDG---------TVPTNLDYVPQHLRWFEEWAEDL 148 
G12ISM3  KTTDN----GKLLLWNY-NCGHHVNK--------DVPTNLDYVPQFLRWFEEWAEDL 126 
A10ISM2  KTTDN----GKLLLWNY-NCGHHVNK--------DVPTNLDYVPQFLRWFEEWAEDL 126 
ISM51C11 RIA------GDTTIWND-NCGHHVNQ--------DVPTNLDYVPQYLRWFEEWAEDL 122 
F9ISM33  KNIRN----SRTTLFYY-KCGHYVYK--------DVPTNLDYVPQFLRWFEEWAEDL 125 
E8ISM51  KNIGN----GKLLLWNE-KCGHGDYN---------LLTNLDYVPQFLRWFEEWAEDL 124 
H9ISM33  KNIGN----GKLLLWNE-KCGRGDYN---------LLTNLDYVPQFLRWFEEWAEDL 124 
G5ISM48  TYKSD----NFRTFSGY-WCGHYEG---------APPTNLDYVPQFLRWFEEWAEDL 123 
C9ISM2   MHSED----NKQLFSDY-KCGHYEG---------SPLTNLDYVPQFLRWFEEWAEDL 132 
A1ISM2   VYKSG----SLLNFSSD-RCGHNNND--------GPLTNLDYVPQFLRWFEEWAEDL 124 
E6ISM51  RKISG----DTRTFENAGKCRRHDN---------KVPTNLDYVPQFLRWFEEWAEDL 129 
F8ISM33  RKESD----GSYVFSNRGPCGRNET---------DVPTNLDYVPQYLRWFEEWAEDL 131 
C1ISM16  KKTSD----NTIVFTNDGKCGHYEG---------APPTNLDYVPQFLRWFEEWAEDL 128 
E9ISM48  IQSEN----NTQLFSNP-KCGHEQG---------TVPTYLDYVPQFLRWFEEWAEDL 136 
                            *                 * :*****.*********** 
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2.3 upsA multiple sequence alignment of predominant sequences from 6 
isolates 
 
ISM51upsAG3 TTTATTATATTTGTTGTAGGTGAAAAATATATGAATTTTACAGGAATATAAGGGTTTATT 60 
ISM49upsAF3 TTTATTACATTTGTTGTAGGTGAAAAATATATGAATTTTACAGGAATATAAGGGTTTATT 60 
ISM16upsAG6 TTTATTATATTTGTTGTAGGTGAAAAATATTCGATTTTTAATCGAATAATAGGGTTTATT 60 
ISM11upsAH5 TTTATTATATTTGTTGTAGGTGAAAAATATTCGATTTTTAATTGAATATTAGTGTTTATT 60 
ISM2upsAB12 TTTATTATATTTGTTGTAGGTGAAAAATATGTAAATTTTAATTGAATATTAATCTTTATT 60 
ISM16upsAE10TTTATTATATTTGTTGTAGGTGAAAAATATTCGATTTTTAATCGAATAATAGGGTTTATT 60 
ISM3upsAC6  TTTATTACATTTGTTGTAGGTGACAAATATATGAATTTTACAGGAATATAAGGGTTTATT 60 
ISM49upsAF8 TTTATTACATTTGTTGTAGGTGACAAATATATGAATTTTACAGGAATATAGGGGTTTATT 60 
IAM17upsAA3 TTTATTACATTTGTTGTAGGTGAAAAATATATGAATTTTACTGGAATATAAGTGTTTATT 60 
IAM17upsAD3 TTTATTATATTTGTTGTAGGTGAAAAATATATGAATTTTACAGGAATATAAAGGTTTATT 60 
ISM49upsAG3 TTTATTATATTTGTTGTAGGTGAAAAATATATGAATTTTACAGGAATATAAAGGTTTATT 60 
ISM11upsAG9 TTTATTATATTTGTTGTAGGTGACAAATATATGAATTTTACAGGAATATAAGGGTTTATT 60 
ISM3upsAB11 TTTATTATATTTGTTGTAGGTGACAAATATATGAATTTTACAGGAATATAAGGGTTTATT 60 
ISM3upsAD6  TTTATTACATTTGTTGTAGGTGATGAATGTATGGATTTTACATGAATACAGTTGTTTATT 60 
ISM2upsAD10 TTTATTATATTTGTTGTAGGTGAGAAATATATGAATTTTACATGAATATGAGGATTTATT 60 
ISM16upsAE3 TTTATTATATTTGTTGTAGGTGAAAAATATGTGAATATTACATGAATAACAGGGTTTATT 60 
ISM2upsAD3  TTTATTATATTTGTTGTAGGTGAAAAATATTCGATATTTATTTGAATATTAGGGTTTATT 60 
IAM17upsAB7 TTTATTATATTTGGTGTAGGTGAAAAATATTCGATTTTTAATCGAATAATAGGGTTTATT 60 
            ******* ***** *********  *** *       ***   *****      ****** 
 
ISM51upsAG3 AACAATATATAATAATAATGATTATTAGCATGAAAAAATAATAT-TGTTTTCACATAATA 119 
ISM49upsAF3 AACAATATATAATAAGAATGATTATTAGCATGAAAAAATAATAT-TGTTTTCACATAATA 119 
ISM16upsAG6 TACAATATTTGATTGTCATATTTATTACTATGAAGAACCAATAC-TGTTTTCACCATATA 119 
ISM11upsAH5 TACAATATTTGATTGTCATGTTTATTACTATGAAGAACTAATAC-TGTTTTCACCATATA 119 
ISM2upsAB12 AACAATATATATTAATAATGTTTATTACCATGAAGAATTAATAT-GGTTTTCACATAATA 119 
ISM16upsAE10TACAATATTTGATTGTCATATTTATTACTATGAAGAACTAATAC-TGTTTTCACCATATA 119 
ISM3upsAC6  AATTATATATAATAATCATGTTTATTACCATGAAAAAACAATAT-TGCTTCCACAATGTA 119 
ISM49upsAF8 AATTATATATAATAATCATGTTTATTACCATGAAAAAACAATAT-TGCTTCCACAATGTA 119 
IAM17upsAA3 AACAATATATTATAATAATGTTTATTACTATGAAAAAATAATAT-TGTTTTCACATAATA 119 
IAM17upsAD3 AACAATATATAATAATCATGATTATTACCTTGGAAAAATTATAT-TGTTTTCGCAATATA 119 
ISM49upsAG3 AACAATATATAATAATCATGATTATTACCTTGGAAAAATTATAT-TGTTTTCGCAATATA 119 
ISM11upsAG9 AATTATATATAATAATCATGTTTATTACCATGAAAAAACAATAT-TGCTTCCACAATGTA 119 
ISM3upsAB11 AATTATATATAATAATCATGTTTATTACCATGAAAAAACAATAT-TGCTTCCACAATGTA 119 
ISM3upsAD6  AACAATATGTAATAATCATATTTATTACCATGAAGAAATAATAT-TGTTTTCACGATATA 119 
ISM2upsAD10 AACATTATTTAATAATCATGGTAATTACCATGAAGAAATAATATATTTTTTAACAATATA 120 
ISM16upsAE3 AATATTATATCATTACCATATTTATTAGTAGGAAAAAATAATGT-AGTTTTGAGAATATA 119 
ISM2upsAD3  AACAATATCTGATTATAATGTTTATTGCGTTTAAGAAATAATAC-TGTTTTTACAATATA 119 
IAM17upsAB7 TACAATATTTGATTGTCATATTTATTACTATGAAGAACTAATAC-TGTTTTCACCATATA 119 
             *   *** *  *    **  * ***       * **   **      **        ** 
ISM51upsAG3 ATGATAGTTTTTGT----AAAATATATTTAGAGGATATATATTGGTTATAATAATTGTAA 175 
ISM49upsAF3 ATGATAGTTTTTGT----AAAATATATTTAGAGGATATATATTGGTTATAATAATTGTGA 175 
ISM16upsAG6 ATGTTAATATTTTT----AAAATATATTTAAAGGAAATGAATTGGTTATAATAACTGTAA 175 
ISM11upsAH5 ATGTTAATATTTTT----AAAATATATTTAGAGGAAATGAATTGGTTATAATAATTGTGA 175 
ISM2upsAB12 ATGATAATTTTTGT----AAAATATATTTAGAGGATATATATTTGTTATAATAATTGTAA 175 
ISM16upsAE10ATGTTAATATTTTT----AAAATATATTTAAAGGAAATGAATTGGTTATAATAACTGTAA 175 
ISM3upsAC6  ATAATAATATATTT----AAAATATATTTAGTGCATATATATTGATTATAATAATTGTTA 175 
ISM49upsAF8 ATAATAATATATTT----AAAATATATTGAGATTGTATATATTGATTATAATAATTGTTA 175 
IAM17upsAA3 ATGATAGTTTTTGT----AAAATATATTTAGAGGATATATATTGGTTATAATAATTGAAA 175 
IAM17upsAD3 ATAATAATATATTT----AAAATATATTTAGGGGACATAAATTGATTATAATAATTGCAA 175 
ISM49upsAG3 ATAATAATATATTT----AAAATATATTTAGGGGACATAAATTGATTATAATAATTGCAA 175 
ISM11upsAG9 ATAATAATATATTTTTTTGAAATATATTTAGTGCATATATATTGATTATAATAACTGAAA 179 
ISM3upsAB11 ATAATAATATATAT----AAAATATATTGAGATTGTATATATTGATTATAATAATTGTTA 175 
ISM3upsAD6  ATCATAATGGTTTT----AAACTATTTTTAGAGGATATTTATTGATTACAATAATTTTAA 175 
ISM2upsAD10 ATAATCATATTTTA----AAAATATGTTTAGAGGAAATATATTGGTTAAATTAATTATAA 176 
ISM16upsAE3 ATAGTACTATAATT----AAAATATATTTAGAAGAAATATATGGGTTATAATAATTATAA 175 
ISM2upsAD3  ATGATAATGATTTT----AAAATATATTTAGCGGAAACGAATTGGTTATAATAATTGTAA 175 
IAM17upsAB7 ATGTTAATATTTTT----AAAATATATTTAAAGGAAATGAATTGGTTATAATAACTGTAA 175 
            **  *  *           ** *** ** *      *   **   *** * *** *   * 
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ISM51upsAG3 TGTATTAGTATAAATTATTTAAATACTTTGTTAT--AAAAATGGGGACAGGTTCATCA-- 231 
ISM49upsAF3 CGTTATATTATAGATTATTTTAATAGTTTGTTAT--TAAAATGGGGGGAGGACATACA-- 231 
ISM16upsAG6 TCTTATAGTATAGATGTTTTATACATTGCGTTAT--AAAAATGGGGTCACAACCATCA-- 231 
ISM11upsAH5 CGTTATATTATAGATTATTTTAATAGTTCGTTAT--AAAAATGGGGACAGGTTCATCA-- 231 
ISM2upsAB12 TGTTATAGTACAGATGTTTTATATATTACGTTAT--AAAAATGGGGACAGGTTCATCA-- 231 
ISM16upsAE10TCTTATAGTATAGATGTTTTATACATTGCGTTAT--AAAAATGGGGTCACAACCATCA-- 231 
ISM3upsAC6  TGTATTAATATATATTATTTAAATATTTTATTAT--AAAAATGGGGAATACAAAATCA-- 231 
ISM49upsAF8 TGTATTAATATATATTATTTAAATATTTTATTAT--AAAAATGGGGAATACACAATCATT 233 
IAM17upsAA3 TGTCTTAATATAGATTATTAAAATATTTTATAAT--CAAAATGGGAGCATCACAATCA-- 231 
IAM17upsAD3 TGTATTAATACATAATATTTAAATATTTTATTAT--AAAAATGGGGAATACAGAATCATC 233 
ISM49upsAG3 TGAATTAATACATAATATTTAAATATTTTATTAT--AAAAATGGGGAATGAACAATCATC 233 
ISM11upsAG9 TGTCTTAGTATAAATTATTTAAACATTTTGTTAT--AAAAATGGGGAATGCAACATCATC 237 
ISM3upsAB11 TGTATTAATATATATTATTTAAATATTTTATTAT--AAAAATGGGGGATACAAAATCA-- 231 
ISM3upsAD6  TGTCTTAGTATAGATTATTAAAATATTTTATAAT--CAAAATGGGATCATCGCATTCA-- 231 
ISM2upsAD10 TATCATAGTATAGGATATTTAAATAGATTGATATTAAAAAATGGGATCACAAGAATCT-- 234 
ISM16upsAE3 TGTTATAGTATACATTATTTAAATTTTTTAATAT--CAAAATGGGGGGAAATTCTTCA-- 231 
ISM2upsAD3  TGTTATAGTATAGATGTTTTAAATATTACATTAT--AAAAATGGGGTCACAATCATCA-- 231 
IAM17upsAB7 TCTTATAGTATAGATGTTTTATACATTGCGTTAT--AAAAATGGGGTCACAACCATCA-- 231 
                 ** ** *     **   *         **   ********           *    
ISM51upsAG3 --ACTCCT----TCGGTTCCAAAAGAT---GTTAAAAATGAAAGTCACAACAGTGCCAGA 282 
ISM49upsAF3 --AAGCAT-------GTTCAAGTTGTT---GACATAAAGGAAAGTCCTAACAGCGCTAGA 279 
ISM16upsAG6 --AAACCT----TCGAAACCAAGTGTT---GATACAAATGAAAGTCACAAAAGTGCCCGA 282 
ISM11upsAH5 --ATTCCT----TCGGTTCCAAAAGAT---GTTAAAAATGAAAGTGAGAAAAGTGCCAGA 282 
ISM2upsAB12 --ACTCCT----TCGGTTCCAAAAGAT---GTTACAAATGAAAGTCACAAAAGTGCCAGA 282 
ISM16upsAE10--AAACCT----TCGAAACCAAGTGTT---GATACAAATGAAAGTCACAAAAGTGCCAGA 282 
ISM3upsAC6  --ACGCCT----TCGGTTCCAAAAGAT---GTTAAATATGAAAGTCACAAAAGTGCCAGA 282 
ISM49upsAF8 AAATGAAG----AGGAGGCTAAAACCCCTAGTTTAACA-GAAAGTCACAACAGTGCCAGA 288 
IAM17upsAA3 --AAACCT----TCGAAACCAAGTGTT---GATACAAATGAAAGTCACAACAGTGCAAGG 282 
IAM17upsAD3 ATTAGAG-----GGAGAGGCTAGAAGCCCTAGTATAATAGAAAGTGAGAACAGTCCAAGA 288 
ISM49upsAG3 ATCATCA-----GAGGGGGATAAAATTCCTAGTATAATAGAAAGTGAGAACAGTCCAAGA 288 
ISM11upsAG9 AACATCATCAGAGGGGGAGATGAAATCCCTTTTATAAAAGATAGTGAGAACAGTCCGAGA 297 
ISM3upsAB11 --ACGCCT----TCGGTTCCAAAAGAT---GTTAAATATGAAAGTCACAACAGTGCCAGA 282 
ISM3upsAD6  --ACAAAT----GATACTAAAAGTCCT---ACTCTAAGTGAAAGTCACAAGAGTGCCAGA 282 
ISM2upsAD10 --AAACCT----GTGGATACAAGCGAT---GTTAAAAATGAAAGTCACAACAGTGCTAGA 285 
ISM16upsAE3 --AAAGGT----GCTCCTACATACTAT---AC---AAATGAAAGTGAAAAAAGTGCCAGA 279 
ISM2upsAD3  --AAACCT----TCGGAACCTAGTGTT---GATACAAATGAAAGTCACAAAAGTGCCAGA 282 
IAM17upsAB7 --AAATCT----TTGGAACCAATTGTT---GATACAAATGAAAGTCACAAAAGTGCCAGA 282 
                                               *   ** ***   ** **  *  *  
ISM51upsAG3 AATGTTTTGGAAAATATTGGAAAATGGATAAAAGATGAGATTAATAAAAATAGTAAT--- 339 
ISM49upsAF3 AATGTTTTGGAAAATATTGGAATAGAAATATATAATGAGGAAAAAAAAAAAGTGAATGGA 339 
ISM16upsAG6 AATGTTTTGGAAAATATTGGAATAGAAATATATAAGGAAATAGAAAAAACGATTCCA--- 339 
ISM11upsAH5 AATGTTTTGGAAAATATTGGAAAATGGATAAAAGATGAGAGAGTAAAATCGAGTAAA--- 339 
ISM2upsAB12 AATGTTTTGGAAGAAATTGGAAAAAAGATAAAAGATAAGACAGAAAAAGGGAATAAC--- 339 
ISM16upsAE10AATGTTCTGGAAAATATTGGAAGCGCCATAAAAGATAAGAGGCAAATTGAGAGTAAA--- 339 
ISM3upsAC6  AATGTTCTGGAAAAAATTGGACTAGAAATATATAA---GGAAATAGAAAAAACGATTCCA 339 
ISM49upsAF8 AATGTTTTGGAAAATATTGGAATAGGAATATATAATGAGGAAAAAAAAAATGTAAATAAA 348 
IAM17upsAA3 GGTGTTTTGGAAGAAATTGGAAAAAAGATAAAAGATAAGACAGAAAAAGAGAGTAAA--- 339 
IAM17upsAD3 AATGTTTTGGAACGTTATGCCAAAAATATAAG---ACAGGCATCAAAAGCTGAAAATGAA 345 
ISM49upsAG3 AATGTTTTGGAACGTTATGCCAAAAATATAAG---ACAGGCATCAAAAGATGAAAATGAA 345 
ISM11upsAG9 AATGTTTTTGAACGTTATGCCGAACATATAAAGAAACAGGCAGAAAATGATGCAAAAAAA 357 
ISM3upsAB11 AATGTTTTGGAAGATATTGGTAAAGGAATAAAAGATAAAGTAACAAAGGATGCAGAAAAA 342 
ISM3upsAD6  AATGTTCTGGAAAACATTGCCCAAGATATAAGGAAACAAGTGCAAAAAGATGCACAAAAA 342 
ISM2upsAD10 AATGTTTTTGAATACATTGCAGAAATAATAAGCAACGAGGTAAAAGAAAATGCTGAAAAA 345 
ISM16upsAE3 AACGTTTTGGAAAATTTCGCAAAAGATATAAAAGGAAAAGCGTCAAATGACGCAAATAGG 339 
ISM2upsAD3  AATGTTTTGGAAAATATTGGAAGAAAAATAAAAGATAGAGCATCGAGTGATGCAAAAAAT 342 
IAM17upsAB7 AATGTTTTGGATGTTCTTGCAGAAGATGTAAAGAAACAGGCAGAAAAAGCTGCTGAAAGT 342 
               *** * **       *         **                               
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ISM51upsAG3 CATACAAATAAATTGGAAGGCACATTAAGAGAGGCAAGATTTCTTGATGGCTTGCATAAG 399 
ISM49upsAF3 TATACAAGTCAATTGAGAGGCGATTTATCAAGCGCACGATTTCATGATGGCTTGCACAAG 399 
ISM16upsAG6 CATAAAGATCAATTGATAGGCGTATTAAGAAATGCAAGATTTGCTGATCGATTGTATAAG 399 
ISM11upsAH5 TATATAAATAGATTAAAAGGTAATTTATCAAATGCAATATTCATTGATGGATTGAGTAGA 399 
ISM2upsAB12 TATGACGGGAAATTGAAAGGAAAATTATCAAATGCAAAATTTGCTGATGGCTTGTATAAG 399 
ISM16upsAE10CATAGTGAAATATTGAAAGGCACATTATCAAAAGCACAATTTCTTGATGGCTTGCATAAG 399 
ISM3upsAC6  TATAATAGTGAATTGATAGGCACATTATCAAACGCCCAATTTCATGATGGCTTGCGCAAG 399 
ISM49upsAF8 TATGCAAGTCAATTGCGAGGCAATTTATCAAGAGCAACATTTTGTGATGTCTTTTGTGAT 408 
IAM17upsAA3 CATGAAAGGCAATTGAAAGGAAAATTATCAAATGCAAAATTTGCTGATCGATTGTATAAG 399 
IAM17upsAD3 CATGTGGATTCGTTGAAAGGGGATTTAACGAAAGCAGAATTTCGTGGTGGTCCTTCTACG 405 
ISM49upsAG3 CATGTGGATTCGTTGAAAGGGGATTTAACGAAAGCAGAATTTCGTGGTGGTCCTTCTACG 405 
ISM11upsAG9 TATGCAAGTTCTTTGAAAGGAGATTTGAAGAGAGCAAAATTTAATCATGATTTTTTTA-- 415 
ISM3upsAB11 CATGTAAGTTCTTTGAAAGGAAATTTATTACAAGCACAATTTTATCA-TGCGTACTCTAT 401 
ISM3upsAD6  CATAGTAGCTCTTTGAAAGGATATTTGTCACAAGCAAAATTTCATCAGCCCTTATTAAAG 402 
ISM2upsAD10 CATGATAAATCTTTGCAAGGAAATTTTAAGAAAGCACAATTTCATCAGCGCTTATTAAGG 405 
ISM16upsAE3 CATGGAAAAATTTTGAAAGGAAATTTGAGGCAAGCAAAATTTTATCA-TGATTTTTCAAA 398 
ISM2upsAD3  TATAGAAGTTATTTGAAAGGAAATTTGGGGAATGCACAATTTTATCA-TGAGTACTCTAA 401 
IAM17upsAB7 TATGAAAATGAATTGAAAGGAAAATTAGAAGAAGCATCATTTTGTGA-TGCTTATTGTGA 401 
             **         **   ***    **       **   ***   *                
ISM51upsAG3 GCAGCTCGTGGGGACATAAAATATGGTCCTCAAGATTCGTGTAGTCTTGATCACAAATTC 459 
ISM49upsAF3 GCAGCTGATTTGGGGGTAAGACCTGGTCCTGGAGATTCGTGCAGTATTAATCACTTATTT 459 
ISM16upsAG6 GAATCTGTTGGGGGGGTAAGAACTGGTCCTGCAAATTCATGCGACCTTGAACACAAATAC 459 
ISM11upsAH5 GCACATAATTTAA---CAAGACGTGGTCCTGCAAATTCATGCGATCTTGAACACAGATTC 456 
ISM2upsAB12 GAATCTGTTGGGGGGGTAAGATATGGTCCTGCAAATTCATGCGATCTTGAACACAGATTC 459 
ISM16upsAE10GCAGCTCGTTTGAGGGTAACATATGTTCCTGAAGATTCGTGTAAGCTTAGTCACAAATTC 459 
ISM3upsAC6  GCAGCTGGTTGGGGGGTAATACCTGGTCCTGCAAATTCATGCGATCTTGAACACAGATTC 459 
ISM49upsAF8 TTTGTTGG--AATTCGCAAT-TATCCTTATACTGATCCATGTTATCTTGATCATAGATTT 465 
IAM17upsAA3 GAATCTGGTGGTGATTTAAGGTCTGCTTATTCAGATGCTTGTTCACTTACATACAAATTT 459 
IAM17upsAD3 CCAGTAAATAAGCA---TAATTACTATTATTCATATCCATGTAATTTAGATCATAAGGAA 462 
ISM49upsAG3 CCAGTAAATAAGCA---TAATTACTATTATTCATATCCATGTAATTTAGATCATAAGGAA 462 
ISM11upsAG9 -----AAATAA--A---AAGTTACATGCCTAGAAATCCATGTTATCTTGATTATGCTTTT 465 
ISM3upsAB11 GTATAGAACTGTCC--CTGGA------------AATCCATGTAATCTTGATTATATATTT 447 
ISM3upsAD6  GCAGCGAAATATGT--TTGGATA-GCTCCTAGTAATCCATGTTATCTTGATTATATATTT 459 
ISM2upsAD10 GCAACGAAATATGT--TTGGACA-CCTCCTAGTAATCCTTGCTATTTTGATTTTAAGTTT 462 
ISM16upsAE3 ACTTTATCCTAACT--ATAGA------------AGTCCCTGTGATCTTAATTTTTGGTTT 444 
ISM2upsAD3  GTATAGAACTGTCC--CTGAA------------AGTCCATGTGATCTTAATTTTTGGTTT 447 
IAM17upsAB7 ATGGATAGGTGTGT--CTAAATATGGTTCTACAGATCCATGTTATCTGGATCATATGAGG 459 
                                               * * **     *              
ISM51upsAG3 CATACTAAT-ATAAACAATGGTACTAATCATGGAAGAAATCCTTGCGATCTTAGAAATCA 518 
ISM49upsAF3 CATACTAAT-ATAAACAATGGTACTAATCATGGAGGAAATCCTTGCGATCTTAGAAATCA 518 
ISM16upsAG6 TATACTAAT-ATAGATATTGGATATCTACCTGCGAGGAATCCTTGTCATGGAAGAAAAGA 518 
ISM11upsAH5 TATACTAAT-ATAAATAATGGATATCTACCTGCGAGGAATCCTTGCCATAATAGAAATCA 515 
ISM2upsAB12 TATACTAAT-ATAAATAATGGATATCTACCTGCGAGGAATCCTTGTCATGGAAGAAAAGA 518 
ISM16upsAE10CATACTAAT-ATAACAAAT------CAACATGAAAGGAATCCTTGTCATGGAAGAAAAGA 512 
ISM3upsAC6  TATACTAAT-ATAAATAATGGATATCTACCTGCGAGGAATCCTTGCCATAATAGAAATCA 518 
ISM49upsAF8 TATACAAAT-ATAAAAGTTAATTCTATAGAAGGAAGAAACCCTTGTAATGGTAGAGAAAA 524 
IAM17upsAA3 CATACTAAT-ATAACAACTGATGGGGGGGATGGAAGGCATCCTTGTCATGGTAGGGAAAA 518 
IAM17upsAD3 CATACTAAT-TTACGGTATGATGATGTGAATTTGAGACATCCTTGCCATGGTAGAGAACA 521 
ISM49upsAG3 CATACTAAT-TTACGGTATGATGATGTGAATTTGAGACATCCTTGCCATGGTAGAGAACA 521 
ISM11upsAG9 CATTCTAATACTCCTGGAAATCGAAGAGAATTT-AGACATCCTTGTGCTGGTAGAAACAA 524 
ISM3upsAB11 CATACTAAT-GTATGGCATCGTAACGCAGAAGATAGAAATCCTTGTCTTTTTAGTCGTGC 506 
ISM3upsAD6  CATACTAAT-GTATGGAATGAGCGTGCACATGATAGAGATCCTTGTCTTTTTAGTCGTGC 518 
ISM2upsAD10 CATACTAAT-GCTCCAAATGATCGTTCAAAGGATAGACATCCTTGTTATTTGAGAGATAT 521 
ISM16upsAE3 CATACGAAT-GTTTGGAAGCGAACACCACGTGAAAGAGATCCTTGTTATCGTAGGCAACC 503 
ISM2upsAD3  CATACTAAT-GTATGGCATGGTAAAGCAGAAGATAGAAATCCTTGTCTCTTTAGTGATAA 506 
IAM17upsAB7 AATACAAAT-TTATTGAATAATAGAGTAAATGAGAGAAATCCTTGCCATGGCGGAAATCA 518 
             ** * ***                          *  * *****        *       
  105 
ISM51upsAG3 AAATCGTTTTGGTGAAAATGCCGAAGCGTATTGTAATAGTGATAAAATAAGAGGTAATGA 578 
ISM49upsAF3 AAATCGTTTTTCTGAAAATGCCGAAGCGTATTGTAATAGTGATAAAATAAGAGATTAT-A 577 
ISM16upsAG6 AAATCGTTTTTCTGAAAATGCCGAAGCGTATTGTAATAGTGATAAAATAAGAGATTATAG 578 
ISM11upsAH5 AAATCGTTTTGACGAAAATGCCGAAGCGTATTGTAACAATGATAAAATAAGAGATAATGG 575 
ISM2upsAB12 AAATCGTTTTGACGAAAATGCCGAAGCGTATTGTAATAGTGATAAAATAAGGGTTATTGG 578 
ISM16upsAE10AAATCGTTTTGACGAAAATGCCGAAGCGTATTGTAATAGTGATAAAATAAGAGGTAATGA 572 
ISM3upsAC6  AAATCGTTTTGACGAAAATGCCGAAGCGTATTGTAATAGTGATAAAATAAGAGGTAATGA 578 
ISM49upsAF8 AAAACGTTTTGGTGAAAATGCCGAAGCGTATTGTAATAGTGATAAAATAAGAGGTAATGA 584 
IAM17upsAA3 CAATCGTTTTTCTGAAAGTCAAGAATATGGATGTAGTAATGTATACATAAAAGGAAATGA 578 
IAM17upsAD3 AAACCGATTTGATGAAGATGAAGAATCTGAATGTGGAA---ATAAAATACGTAATTATAA 578 
ISM49upsAG3 AAACCGATTTGATGAAGATGAAGAATCTGAATGTGGAA---ATAAAATACGTAATTATAA 578 
ISM11upsAG9 AACTCGTTTTTCAAACGAAAGTGAAGCAGAATGTGGTAGTGATAAAATAAGGGTTATTGG 584 
ISM3upsAB11 AAAACGTTTTTCAAATGAAGGTGAAGCAGAATGTAATGGTGGTATAATAACTGGTAATAA 566 
ISM3upsAD6  AAAACGTTTTTCAAATGAAGGTGAAGCAGAATGTAATGGTGGTATAATAACTGGTAATAA 578 
ISM2upsAD10 AAATCGTTTTTCAGATAGAGGAGATGCAATATGTACTAATAATAAAATCAATTGTAATAA 581 
ISM16upsAE3 AAAAAATAATCCGAATTTGGAAGGAGCAGTATGTACAAATAGTAAAATAAAAGGTAATGA 563 
ISM2upsAD3  AAATCGTTTTTCAAATGGTGGTGGAGCAGAATGTGATAATAATAAAATAACTGGTAATGA 566 
IAM17upsAB7 AAGACGTTTTGATGAAGATCAAGTATGTGAATGTGGTAAAAGTAGAATAAAAGGTAATGA 578 
             *       *    *       *        ***            **         *   
ISM51upsAG3 AAATAACAGAAATGATGGTACAGCATGTGTACCATTTAGAAGGCAAAATTTATGTGATAA 638 
ISM49upsAF3 GGATA--AAAAGTGCTGGTACAGCATGTGCACCATTCCGAAGACAAAATTTGTGTGATAA 635 
ISM16upsAG6 GATAA---AAAGTGCTGGTGGAGCATGTGTACCATTTAGAAGGCAAAATTTATGTGATAA 635 
ISM11upsAH5 GGAAA---GAAGTGCTGGTGGAGCATGTGCACCATTCCGAAGGCAAAATATGTGTGATAA 632 
ISM2upsAB12 AAATA---ACAGGAAGGATGGAGCATGTGCACCATTCCGAAGGCAAAATTTGTGTGATAA 635 
ISM16upsAE10AAATAACAGAAATGATGGTACAGCATGTGCACCATTCAGAAGACAAAATTTGTGTGATAA 632 
ISM3upsAC6  AAATA---ACAGTAATGCTGGAGCATGTGCGCCATTCCGAAGACAAAATTTGTGTGATAA 635 
ISM49upsAF8 AAATA---ACAGTAATGCTGGAGCATGTGCACCATTTCGGAGGCAAAATTTGTGTGATAA 641 
IAM17upsAA3 AAATA---ACAGTAATGGTACAGCATGCGTACCACCAAGAAGAAGACATATATGTGATCA 635 
IAM17upsAD3 AAGAG---AAAATGATGCTATAGCCTGTGCGCCACCTAGAAGACGACATATGTGTGATAA 635 
ISM49upsAG3 AAGAG---AAAATGATGCTATAGCCTGTGCGCCACCTAGAAGACGACATATGTGTGATAA 635 
ISM11upsAG9 AAATA---ACAGAAATGATGGAGCATGTGCACCATATAGGAGAAGACATATATGTGACTT 641 
ISM3upsAB11 AGG-----TGAATG----TGGGGCATGTGCACCGTATAGGAGAAGACATATATGTGACTA 617 
ISM3upsAD6  AGG-----TGAATG----TGGGGCATGTGCACCGTATAGGAGAAGACATATATGTGACTA 629 
ISM2upsAD10 TGA-----TGGTTG----CGGAGCCTGTGCTCCATATAGAAGAATACAGTTATGCGATTA 632 
ISM16upsAE3 AAACAAAATAATTGACATTGGAGCGTGTGCCCCATATAGAAGACGAAATATCTGCGATTA 623 
ISM2upsAD3  AGG-----TAAAAT----TGGAGCATGTGCTCCATATAGAAGGAGAGAATTGTGTGATTA 617 
IAM17upsAB7 AAAT---AAAAATGATGGTGGATCCTGTGCCCCTCCAAGAAGAAAACATATATGTGATAA 635 
                                   * ** *  **     * **   * *  * ** **    
ISM51upsAG3 AAATTTAGAATATTTAGATAACAAAAACACGAACACTACTGATGATTTATTGGGAAATGT 698 
ISM49upsAF3 AAATTTAGAATATTTGATTAATGAAAACACAAATACTACTCACGATTTATTGGGAAATGT 695 
ISM16upsAG6 AAATTTAGAATATTTGATTAATGAAAACACGAAAACTACTCATGATTTATTGGGAAATGT 695 
ISM11upsAH5 AAATTTAGAATATTTGATTAATGAAAACACGTAAACTACCCATGATTTATTAGGAAATGT 692 
ISM2upsAB12 AAATTTAGAATATTTGATTAATGAAAACACAGAAAATACGCATGATTTATTGGGAAATGT 695 
ISM16upsAE10AAATTTAGAATATTTGATTAATGAAAACACAAATACTACGCATGATTTATTGGGAAATGT 692 
ISM3upsAC6  AAATTTAGAATATTTGATCAATAAAAACACAGAAAATACTCATGACTTATTGGGAAATGT 695 
ISM49upsAF8 AAACCTGGAAGCTATAAATGCAACTAATACAAAAAATACTCATGATTTATTGGGAAATGT 701 
IAM17upsAA3 AAATTTAGAATTTTTAGATAATCCTCACACTGATGATACTGATGATTTGTTGGGAAATGT 695 
IAM17upsAD3 AAACTTGGAAGCTCTAAATGATATAAATACCCAAAATATTCATGATTTGTTAGGAAATGT 695 
ISM49upsAG3 AAACTTGGAAGCTCTAAATGATATAAATACCCAAAATATTCATGATTTATTGGGAAACGT 695 
ISM11upsAG9 AAATTTGGAATACATAGATGTACATAATACAAAAAATTCTAACGACTTGTTAGGAAATAT 701 
ISM3upsAB11 TAATTTGCACCATATAAACGAAAATAATATAAGGAATACTCATGATTTATTGGGGAATTT 677 
ISM3upsAD6  TAATTTGCACCATATAAACGAAAATAATATAAGGAATACTCATGATTTATTGGGGAATTT 689 
ISM2upsAD10 TAATTTAGAGCATATAAATGATAGTAATATTAATAGTACTGATGATTTATTGGGGAATCT 692 
ISM16upsAE3 CAATTTAGAACATCTAAATGAAAGAAATGTTTTAAATACTCATGATTTATTGGGAAATGT 683 
ISM2upsAD3  TAATTTGGAACATATAGATGTAAATAATGTGAAAAGTATTCATGATTTATTGGGGAATTT 677 
IAM17upsAB7 AAACTTGGAAGCACTAAATGAAAGTAATACCAAAAATACTCATGATTTATTGGGAAATGT 695 
             **  *  *     *           *         *    * ** ** ** ** **  * 
  106 
ISM51upsAG3 GTTAGTTACAGCAAAATATGAAGGTGAATCTATTGTTAAAAATCATCCACATA------A 752 
ISM49upsAF3 ACTAGTTACAGCAAAATATGAAGGTGAATCTATTGTTAGGAATCATCCAAATA------G 749 
ISM16upsAG6 GTTAGTTACAGCAAAATATGAAGGTGAATCTATTGTTAGGAATCATCCAAATA------A 749 
ISM11upsAH5 ACTAGTTACAGCAAAATACGAAGGTGAATCTATTGTTAAAAATCATCCAAACA------A 746 
ISM2upsAB12 GTTAGTTACAGCAAAATATGAAGGTGAATCTATTGTTAAAAATCATCCACATA------A 749 
ISM16upsAE10GTTAGTTACAGCAAAATATGAAGGTGAATCTATTGTTGCGAAGCATCCACATA------A 746 
ISM3upsAC6  GTTAGTTACAGCAAAATATGAAGGCGAATCTATTGTTGCGAAGCATCCACATA------A 749 
ISM49upsAF8 GTTAGTTACAGCAAAATATGAAGGTGATATTATTGTTAGTAATCATCCAAATA------C 755 
IAM17upsAA3 GTTAGTTACAGCAAAATATGAAGGTCAATCTATTGTTGAAAAGCATCCAAATA------A 749 
IAM17upsAD3 GTTAGTTACAGCAAAATACGAAGGTGAATCAATTGTTAATAATCATCCACATA------A 749 
ISM49upsAG3 ACTAGTTACAGCAAAATACGAAGGTGAATCAATTGTTAATAATCATCCACATA------A 749 
ISM11upsAG9 CTTGGTCACAGCAAAATATGAAGGTGAATCTATTGTTGAAAAGCATCCAAATA------A 755 
ISM3upsAB11 GTTAGTTATGGCAAGGAGTGAAGGTGAATCTATTGTGAAAAGTCATGAATATACAGGTTA 737 
ISM3upsAD6  GTTAGTTATGGCAAGGAGTGAAGGTGAATCTATTGTGAAAAGTCATGAATATACAGGTTA 749 
ISM2upsAD10 ATTAGTTATGGCAAAAAGTGAGGGTGATTCGATTGTGAAAAGTCATGAAAATACAGGTAA 752 
ISM16upsAE3 GTTAGTTATGGCAAAACGTGAAGGAGAATCTATTGTGAATAGTCAAGCAAATA------A 737 
ISM2upsAD3  GTTAGTTATGGCAAGGAGTGAAGGTGAATCTATTGTGAATAGTCATAAAAATAC------ 731 
IAM17upsAB7 ATTAGTTACAGCAAAATATGAAGGCGAATCTATTGTGAATAGTCATAAACATA------G 749 
              * ** *  ****     ** **  *    *****    *  **   * * *        
ISM51upsAG3 AGGAACTT-CAGAC-----GTATGTACTGCACTTGCACGCAGTTTTGCAGATATAGGTGA 806 
ISM49upsAF3 AGGATCTT-CAGAA-----GTATGTATTGCCCTTGCACGAAGTTTTGCCGATATAGGTGA 803 
ISM16upsAG6 AGATACTT-CAGAA-----GTATGTACTGCACTCTCACGAAGTTTTGCAGATATTGGAGA 803 
ISM11upsAH5 AAAAACTT-CAGAC-----GTTTGTACTGCCCTTGCAAGAAGTTTTGCAGATATAGGTGA 800 
ISM2upsAB12 AGGAACTT-CAGAC-----GTATGTACTGCACTTGCACGCAGTTTTGCCGATATAGGTGA 803 
ISM16upsAE10AGACAATT-CACAA-----GTATGTACTTCTCTTGCACGAAGTTTTGCTGATATAGGTGA 800 
ISM3upsAC6  AGACAATT-CACAA-----GTATGTATTGCCCTTGCAAGAAGTTTTGCAGATATAGGTGA 803 
ISM49upsAF8 AAAAACGT-CAGAC-----GTATGTACTGCCCTTGCACGAAGTTTTGCAGATATAGGAGA 809 
IAM17upsAA3 AGAAACAT-CAGAC-----GTTTGTACTGCCCTTGCACGAAGTTTTGCAGATATAGGAGA 803 
IAM17upsAD3 AGGAACTT-CAGAC-----GTTTGTACTGCTCTTGCACGAAGTTTTGCAGATATAGGTGA 803 
ISM49upsAG3 AGGAACTT-CAGAC-----GTTTGTACTGCTCTTGCACGAAGTCTTGCAGATATAGGTGA 803 
ISM11upsAG9 AGAAACAT-CAGAC-----GTTTGTACTGCACTTGCAAGAAGTTTTGCAGATATAGGAGA 809 
ISM3upsAB11 TGGTATATACAAATCAGGTATATGTACTTCTCTTGCTCGCAGTTTTGCAGATATAGGTGA 797 
ISM3upsAD6  TGGTATATACAAATCAGGTATATGTACTTCTCTTGCTCGCAGTTTTGCAGATATAGGTGA 809 
ISM2upsAD10 TGGTATTTATAAATCGGGGGTATGTACTTCTCTTGCTCGCAGTTTTGCAGATATAGGTGA 812 
ISM16upsAE3 TGGAACGT-TAAAT-----GTATGTACTGCACTTGCACGAAGTTTTGCAGATATAGGTGA 791 
ISM2upsAD3  TGGCATG-ATAAAC-----GTATGTGCTTCTCTTGCACGAAGTTTTGCTGATATAGGCGA 785 
IAM17upsAB7 TGGAATGT-TAAAC-----GTATGTATTGCCCTTGCACGAAGTTTTGCAGATATAGGTGA 803 
                      * *       * ***  * * **  *  * *** **** ***** ** ** 
ISM51upsAG3 TATTGTAAGAGGAAAAGATATGTTT---AAA---CGTAATGAAGAAGACGCAGTGCAGAA 860 
ISM49upsAF3 TATTGTAAGAGGAAGGGATATGTTT---AAA---CGTAATGACAAAGATGCAGTGCAGAA 857 
ISM16upsAG6 TATTGTAAGAGGAAAAGATATGTTT---AAA---CGTAATGAAGAAGACGCAGTGCAGAA 857 
ISM11upsAH5 TATTGTAAGAGGAAGAGATATGTTT---AAA---TCTAATGAGGATGTCG------AAAA 848 
ISM2upsAB12 TATTGTAAGAGGAAGAGATATGTTT---AAA---CCTAATGACAAAGATGCAGTGCGGCA 857 
ISM16upsAE10TATTGTAAGAGGGAGAGATATGTTT---AAA---CCAAATGAAGAAGACGCAGTGCAGAA 854 
ISM3upsAC6  TATTGTAAGAGGAAGGGATATGTTT---AAA---CGTAATAACCATGACAATGTAGAAAA 857 
ISM49upsAF8 TATTGTAAGAGGAAGAGATATGTTT---AAA---TCTAAT------GAGAATGTAGAAAA 857 
IAM17upsAA3 TATTGTAAGAGGAAGAGATATGTTT---AAA---TCTAAT------GACAAAGTAGAAAA 851 
IAM17upsAD3 TATTATAAGAGGAATAGATATGTTT---AAA---CCAAATGTCCATGACAAAGTAGAAAA 857 
ISM49upsAG3 TATTATAAGAGGAATAGATATGTTT---AAA---CCAAATGTCCATGACAAAGTAGAAAA 857 
ISM11upsAG9 TATTATCAGAGGAAAAGATCTGTTTCTTGGT---AATAATGATAATGATAAAGTAAAAAA 866 
ISM3upsAB11 TATTATTAGAGGAAAAGATCTTTTTCTGGGG---CATAAAGAACAAAAAAAAAAATTACA 854 
ISM3upsAD6  TATTATTAGAGGAAAAGATCTTTTTCTGGGG---CATAAAGAACAAAAAAAAAAATTACA 866 
ISM2upsAD10 TATAATCAGAGGAAAAGATCTTTTTCTGGGG---CATAATCATAAAAAAAAACCATTACT 869 
ISM16upsAE3 TATTGTAAGAGGAACAGATCTTTTCCTTGGTGGTCCTAGTCAAGAGAAAAAAAAATTAGA 851 
ISM2upsAD3  TATTGTAAGAGGAAAAGATTTGTATCTCGGT---GATAAAGGAGAAAAAAAAAAATTAGA 842 
IAM17upsAB7 TATTGTAAGAGGAAAAGATCTTTTCCTTGGTGGACCTAAGCAAGAGAAAAAAGAATTAGA 863 
            ***  * ***** *  *** * *              *                       
  107 
ISM51upsAG3 AGG---------------TCTAAGGGCAGTTTTCAAGAAAATACATAGTAG-------TT 898 
ISM49upsAF3 AGG---------------TCTAAGGGCAGTGTTTAAGAAAATAAATGACAA-------CT 895 
ISM16upsAG6 AGG---------------TCTGAGGGCGGTTTTTAAGAAAATAAATGACAA-------CT 895 
ISM11upsAH5 AGG---------------ACTAAAAGTAGTTTTCCAGAAAATATATGATGA-------CT 886 
ISM2upsAB12 TGG---------------TTTAAAGGTAGTTTTTAAGAAAATATATGATAAATTGTCACC 902 
ISM16upsAE10AGG---------------TCTAAGAGAAGTTTTCAAGAAAATAAAAGACGA-------CT 892 
ISM3upsAC6  CGG---------------TCTAAGAGAAGTTTTTAGGAAAATATATAATGG-------CT 895 
ISM49upsAF8 GGG---------------ACTAAAAGCAGTTTTTAAGAAAATAAATAATGG-------AT 895 
IAM17upsAA3 AGG---------------ACTACAAGTAGTTTTCGGGAAAATAAAAGACGA-------CT 889 
IAM17upsAD3 GGG---------------TCTCCGAGAGGTTTTCAAGAAAATACATGACTTG------AA 896 
ISM49upsAG3 GGG---------------TCTCCGAGAGGTTTTCAAGAAAATACATGATGGA------AT 896 
ISM11upsAG9 AGAGAAACTACAAAATAATTTAAAAAGTATTTTTGCCAAAATATATAAGGAA------TT 920 
ISM3upsAB11 GGAAAA------------TTTAGAAAAAATTTTTAACAAATTTAAGACAATAT----ATG 898 
ISM3upsAD6  GGAAAA------------TTTAGAAAAAATTTTTAACAAATTTAAGACAATAT----ATG 910 
ISM2upsAD10 GGATAA------------TTTAGAAAAGATTTTTAAAAAATTTAGGGAAAAAT----ATA 913 
ISM16upsAE3 AGAAAA------------TCTGAAAAAAATATTTGAAAACATTAAGAATAAAA----ATA 895 
ISM2upsAD3  GAAGAA------------TTTGAAAGATATTTTCAAGCAAATACATGAAAAAT----TGA 886 
IAM17upsAB7 AGAAAA------------TCTAAAAAAGATATTTCATAATATTCAGAAAAGCG----ATA 907 
                                *        * **     *  *                   
ISM51upsAG3 TGAATAAAAGCAAAATTAATGATTATGA------TGGTGATGGTCCAGAGTATTATAAAT 952 
ISM49upsAF3 TAAATGAAAAAAGAATCACACATTATAA------TGATGGATCTGGAAATTATTATAAAT 949 
ISM16upsAG6 TAAAGGAAAAAGAAATTA---GTGATTA------TGATAATGATCCAAATTATTATAAAT 946 
ISM11upsAH5 TAAAGAAAAAAGAAATTA---GTGATTA------TGATAATGATCCAAATTATTATAAAT 937 
ISM2upsAB12 TAAAGTACAAGAACATTACA-AAGATGT------TGATGGATCTGGAAATTATTATAAAT 955 
ISM16upsAE10TGAACAAAAACGGAATTAATGATTATAA------TGATGAAAATGGAAATTATTATAAAT 946 
ISM3upsAC6  TGAAGGACAAGGGAATTCATCATTATAAAGATGATGATATTTCTGGAAATTACTCCAAAT 955 
ISM49upsAF8 TGAAGGACAAGGGAATTCGTTATTATTA---TGACAATGGATCTGGAAATTATTATAAAT 952 
IAM17upsAA3 TGAAGAAACAAGGAATTATTCATTATGA------TCATGATGGTCCACACTATTACAAAT 943 
IAM17upsAD3 TAAAAGCAAAATTAA----TGATTATGATGGT---GATGGTCC---AGAGTATTACAAAT 946 
ISM49upsAG3 GGAAGGTGAGGTAAA----AAATTATTACGATCCTGATGGATCTGGAAATTATTATAAAT 952 
ISM11upsAG9 GAAATTGGAAAATAACTC-TGACTACAAAGATGATGATGGATCTGGAAATTATTATAAAT 979 
ISM3upsAB11 CAGGTCTTG-------AGGACGTTGCAAT-----TGATGATA------------------ 928 
ISM3upsAD6  CAGGTCTTG-------AGGACGTTGCAAT-----TGATGATA------------------ 940 
ISM2upsAD10 AAGACCTTA-------ATAACCTTCCAAT-----TGATGATA------------------ 943 
ISM16upsAE3 CAAAACTTA-------GTACACTAACACT-----TGAAAAAG------------------ 925 
ISM2upsAD3  CGGATCCAAGAGCAAAAGACCACTACAAAG---ATGAAAAAGACGGAAATTTTTTTCAAT 943 
IAM17upsAB7 GTAGTCTTC-------AACGCCTTTCAAT-----AGAAAAAG------------------ 937 
 
ISM51upsAG3 TAAGAGAAGCATGGTGGACAGCGAACAGAGACCAAGTATGGAGAGCTATAACATGTTATA 1012 
ISM49upsAF3 TAAGGGAAGAGTGGTGGACTATAAATAGAGATCAAGTATGGAGAGCTATAACATGTTATA 1009 
ISM16upsAG6 TAAGAGAAGATTGGTGGAATGTGAATAGAGAACAAGTATGGAGAGCTATAACATGTTATA 1006 
ISM11upsAH5 TAAGGGAAGATTGGTGGACAGCGAACAGAGACCAAGTATGGAGAGCTATAACATGTTATA 997 
ISM2upsAB12 TAAGAGAAGATTGGTGGGCACTTAACAGAGATCAAGTATGGAGAGCTATAACATGTTATA 1015 
ISM16upsAE10TAAGGGAAGATTGGTGGAAAGCTAACCGAGACCAAGTATGGAAAGCCATAACGTGTGAAG 1006 
ISM3upsAC6  TAAGGGAAGCTTGGTGGATAGCTAACAGAGATCAAGTCTGGAAAGCTATAACATGTGAAG 1015 
ISM49upsAF8 TAAGAGAAGCATGGTGGAATGTGAATAGAAATAAAGTATGGGAAGCCATAACATGTAAAG 1012 
IAM17upsAA3 TAAGAGAAGATTGGTGGACGGCTAACCGCGATCAAGTATGGAAAGCCATAACATGCAAAG 1003 
IAM17upsAD3 TAAGAGAAGCATGGTGGACAGCGAACAGAGATCAAGTATGGAAAGCCATAACCTGTGGCG 1006 
ISM49upsAG3 TAAGAGAAGCATGGTGGAATGTGAATAGAAATAAAGTATGGGAAGCCATAACCTGTGGCG 1012 
ISM11upsAG9 TAAGAGAAGCTTGGTGGACATCGAACAGGGATCAAGTATGGAAAGCCATAACATGCAAAG 1039 
ISM3upsAB11 TTAGAGAATACTGGTGGGCGCTTAATAGAGAAGACGTATGGAAAGCCATAACATGCAAAG 988 
ISM3upsAD6  TTAGAGAATACTGGTGGGCGCTTAATAGAGAAGACGTATGGAAAGCCATAACATGCAAAG 1000 
ISM2upsAD10 TAAGAGAATATTGGTGGGCACTTAATAGAAACGATGTATGGGAAGCATTGACATGCTCTG 1003 
ISM16upsAE3 TTAGGGAATACTGGTGGGCACTTAATAGAAATGATGTATGGAAAGCATTAACATGTTCTG 985 
ISM2upsAD3  TAAGGGAAGATTGGTGGACGGCTAACCGCGATCAAGTATGGAAAGCCATAACATGCAATG 1003 
IAM17upsAB7 TTAGGGAATACTGGTGGGCAATTCATAGAAGAGAGGTATGGGATGCATTAACATGCAAGG 997 
            * ** ***   ******       *  *     * ** ***   **  * ** **      
  108 
ISM51upsAG3 TTCCGTATTATGTTAATTATTTTAAAAAAAAGTCAGGCGATACTATCGTTTTTACCAATG 1072 
ISM49upsAF3 TTCCGTATTATGTTAATTATTTTAAAAATATATCGGAGAAATCTAGGAATTTTACCGATG 1069 
ISM16upsAG6 TTCCGTATTATGTTAATTATTTTAAAAAAACGTCAGACAATACTATCGTTTTTACCAATG 1066 
ISM11upsAH5 TTCCGTATTATGTTAATTATTTTAAAAAAAAGTCAGACAATACTATCGTTTTTACCAATG 1057 
ISM2upsAB12 TTCCGTATTATGTTAATTATTTTAAAAAAACGTCAGACGATACTATCGTTTTTACCAATG 1075 
ISM16upsAE10CTCCACAAAAAGTTGATTATTTTAGAAAAGGTTCAAATGGAGAAAGTATTTTTTCAAATA 1066 
ISM3upsAC6  CTCCACAAAAAGTTGATTATTTTAGAAAAGGTTCAAATGGAGAAAGTATTTTTTCAAATA 1075 
ISM49upsAF8 CTCCACAAAAAGCTAATTATTTTAGAAAAGGTTTAGATGGTAGTGATGTTTTTACAAGTC 1072 
IAM17upsAA3 CTCCACAAAAGGTTGATTATTTTAGAAAAGGTTTAGATGGAAAAATAATTTTTTCAGATT 1063 
IAM17upsAD3 CACTACCTAAATCTGCATATGTCTTGCAATCAGAAAATAATACACAATTACCTTCATATC 1066 
ISM49upsAG3 CACTACCTAAATCTGCATATTTCATGCAATCAGAAGATAATAAACAATTATTTTCATATC 1072 
ISM11upsAG9 CACCAGACAAAGCTAATTATTTCATATATAAATCGGACAAATTTCGTAAGTTTTCTAGTG 1099 
ISM3upsAB11 CACCAACAGGTGCTGATTACTTCGTTTATAAATCAGGTAGTTTACTTAACTTTTCTAGT- 1047 
ISM3upsAD6  CACCAACAGGTGCTGATTATTTCGTTTATAAATCAGGTAGTTTACTTAACTTTTCTAGT- 1059 
ISM2upsAD10 CTCCAGGAGATGCTAAATATGTGAAATATTTTCCAAGTAATACAACGATTGTTTCATTT- 1062 
ISM16upsAE3 CACCATATGAAGCTCAATATTTCATAAAATCAAGCGATAAAGAACACTCATTTTCAAGT- 1044 
ISM2upsAD3  CACCATATAAAGCTTGGTATTTTATGCATTCAGAAGATAATAAACAATTATTTTCAGAT- 1062 
IAM17upsAB7 CACCTACTGGTGCTGATTATTTCGTATATAAACCAGATAGGTTACGTAACTTTTCAAGTC 1057 
              *          *   **  *     *                        * *   *  
ISM51upsAG3 ACGGAAAATGTGGCCATTATGAAGGTGCTCCTCC---TACCAATTTAGATTACGTCCCTC 1129 
ISM49upsAF3 ACGGAAAATGTGGCCATTATGAAGGTGCTCCTCC---TACCAATTTAGATTATGTTCCTC 1126 
ISM16upsAG6 ACGGAAAATGTGGCCATTATGAAGGTGCTCCTCC---TACCAATTTAGATTATGTTCCTC 1123 
ISM11upsAH5 ACGGAAAATGTGGCCATTATGAAGGTGCTCCTCC---TACCAATTTAGATTACGTCCCTC 1114 
ISM2upsAB12 ACGGAAAATGTGGCCATTATGAAAATAATATTCT---TACAAATTTGGATTACGTCCCTC 1132 
ISM16upsAE10GTGGAAAATGTGGTGGTAAGGAAGCACCCGTTCC---TACCTATTTAGATTACGTCCCTC 1123 
ISM3upsAC6  GTGGAAAATGTGGTGGTAAGGAAGCACCCGTTCC---TACCAATTTAGATTACGTCCCTC 1132 
ISM49upsAF8 AAGGATATTGTGGTCGTAAGGAACTAACCGTTCC---TACCTATTTAGATTACGTCCCTC 1129 
IAM17upsAA3 ATGGACCATGTGGACGTTATGAAACAATCGTTCC---TACCTATTTAGATTATGTCCCTC 1120 
IAM17upsAD3 TTAAATGCGGCCATAATAATAAGGATGATCCTCC---TACCAATTTAGATTATGTTCCTC 1123 
ISM49upsAG3 CTAAATGCGGTCATAATAATAAGGATGATCCTCT---TACCAATTTAGATTATGTTCCTC 1129 
ISM11upsAG9 ATAGGTGTGGACATAATGA---AGGTGATCCTCC---TACCAATTTAGATTATGTCCCTC 1153 
ISM3upsAB11 --GATAGGTGTGGTCATAATAATAACGATGGTCCACTTACCAATTTAGATTACGTTCCTC 1105 
ISM3upsAD6  --GATAGGTGTGGTCATAATAATAACGATGGTCCACTTACCAATTTAGATTACGTTCCTC 1117 
ISM2upsAD10 --GATCAGTGTGGACATAATGATATGGATGTTCC---TACCAATTTAGATTACGTACCTC 1117 
ISM16upsAE3 --GAATATTGTGGTCATTATAAAAACGGTGATCCACTTACCAATTTAGATTACGTGCCTC 1102 
ISM2upsAD3  --TATAAATGCGGCCATTATGAA---GGTTCTCCTCTTACCAATTTGGATTATGTCCCTC 1117 
IAM17upsAB7 ACGGAAAGTGCGGCCACAAGGAAGGAACTGTTCC---TACGAATCTAGATTACGTCCCTC 1114 
                     *        *            **    ***  ** * ***** ** **** 
ISM51upsAG3 AATTTTTACGTTGGTTCGAGGAATGGGCCGAAGATTTA 1167 
ISM49upsAF3 AATTTTTACGTTGGTTCGAGGAATGGGCCGAAGATTTA 1164 
ISM16upsAG6 AATTTTTGCGTTGGTTCGAGGAATGGGCCGAAGACTTA 1161 
ISM11upsAH5 AATTTTTACGTTGGTTCGAGGAATGGGCCGAAGACTTA 1152 
ISM2upsAB12 AATTTTTACGTTGGTTCGAGGAATGGGCCGAAGATTTA 1170 
ISM16upsAE10AATTTTTGCGCTGGTTCGAGGAATGGGCCGAAGATTTA 1161 
ISM3upsAC6  AATTTTTACGTTGGTTCGAGGAATGGGCCGAAGACTTA 1170 
ISM49upsAF8 AATATTTACGTTGGTTCGAGGAATGGGCCGAAGACTTA 1167 
IAM17upsAA3 AATTTTTAAGATGGTTCGAGGAATGGGCCGAAGACTTA 1158 
IAM17upsAD3 AATATTTACGTTGGTTCGAGGAATGGGCCGAAGATTTA 1161 
ISM49upsAG3 AATATTTACGTTGGTTCGAGGAATGGGCAGAAGACTTA 1167 
ISM11upsAG9 AATTTTTACGTTGGTTCGAGGAATGGGCCGAAGATTTA 1191 
ISM3upsAB11 AATTTTTGCGTTGGTTCGAGGAATGGGCCGAAGATTTA 1143 
ISM3upsAD6  AATTTTTGCGTTGGTTCGAGGAATGGGCCGAAGATTTA 1155 
ISM2upsAD10 AATTTTTAAGATGGTTCGAGGAATGGGCCGAAGATTTA 1155 
ISM16upsAE3 AATTTTTAAGATGGTTCGAGGAATGGGCCGAAGACTTA 1140 
ISM2upsAD3  AATTTTTACGTTGGTTCGAGGAATGGGCCGAAGATTTA 1155 
IAM17upsAB7 AATTTTTAAGATGGTTCGAGGAATGGGCCGAAGATTTA 1152 
              *** ***  * ***************** ***** *** 
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ISM4917DBLF3 ATGTAATTGTTGTTTTTTTTTTTGTTAGAATATTTAAATTTATTATAAACCTATTAATAT 60 
ISM4917DBLE3 ATGTAATTGTTGTTTTTTTTTTTGTTAGAATATTTAAATTTATTATAAAACTA--AATAT 58 
IAM1817DBLF5 ATGTAATTGTTGTTTTTTTTTTTGTTAGAATATTTAAATTTATTATAAACCTAT--TTGA 58 
IAM1817DBLE12ATGTAATTGTTGTTTTTTTTTTTGTTAGAATATTTAAATTTATTATAAACCTATTAATAT 60 
IAM1817DBLG11ATGTAATTGTTGTTTTTTTTTTTGTTAGAATATTTAAATTTATTATAAACCTATTAATAT 60 
ISM4917DBLH12ATGTAATTGTTGTTTTTTTTTTTGTTAGAATATTTAAATTTATTATAAAAGTATTAATAT 60 
             *************************************************  **    *   
ISM4917DBLF3 ATATTTTTTTTAAAA-ATATATATATA----------AAACTAATTATTATTATTATATA 109 
ISM4917DBLE3 ATAATTTTTTTT-----TTCTTTTTTA----------AAAATATATAT-------ATAAA 96 
IAM1817DBLF5 ATATTTGATTAGA-----AAATATATA----------AAACTAATAATTAT---TATATA 100 
IAM1817DBLE12AAATTTTTTTTAAAA-ATATATATATA----------AAACTAATAATTATTATTATATA 109 
IAM1817DBLG11ATATTTTTTTTTAAAAATATATATATA----------AAACTAATAATTATTATTATATA 110 
ISM4917DBLH12ATATTTTTTTAAAAATATATATATATATATATATATAAAACTAATAATTATTATTATATA 120 
             * * **  **           * * **          *** **   **       *** * 
ISM4917DBLF3 CT----TATTACATATTATTTATTAATATATAT-ATATTATATATATATTATAATATTAC 164 
ISM4917DBLE3 AC----TA--AAATAATAATTACATACATATAC-ATATTA------------AATATTAT 137 
IAM1817DBLF5 CA----TATTAAATATTATTTATTAATATATAC-ATATATATATAATATTATAATATTAC 155 
IAM1817DBLE12CA----TATTAAATATTATGTATTAATATATATTATATATA----ATATTATAATATTAC 161 
IAM1817DBLG11CA----TATTAAATATTATTTATTAATATATATAATATATA-----TATTATAATATTAC 161 
ISM4917DBLH12CAAACATATGAAATATTATTTATTAATATATAT--TATATA-----TATTATAATATTAC 173 
                   **  * *** **  **   * *****   ***              *******  
ISM4917DBLF3 TACTATTATAATTACTATATATATATATAAATATAAT--------ACTTATATATATATA 216 
ISM4917DBLE3 T--TATTA----------ATATATATATAAATATA-------------TATATATATATA 172 
IAM1817DBLF5 AACTATTATAATTACTATATATAAATATATATATAA------------TACTTATATATA 203 
IAM1817DBLE12AACTATTATAATTAATATATATATATAAATATATATACAATACTTATATATATATATATA 221 
IAM1817DBLG11TACTATTATAATTAATATATATATATAAACATATATATA------ATACTTATATATATA 215 
ISM4917DBLH12TACTATTATAATTCCTATATATATATAAATATATATATA------ATACTTATATATATA 227 
                *****          ***** *** * *****                 ******** 
ISM4917DBLF3 TATTCCAACACAATACTATTATTATTATTCTACCCTATCACTATGCTCCCATAACATA-C 275 
ISM4917DBLE3 CATCCAAA---------------------------TATTACAATACTCCCATAACATA-C 204 
IAM1817DBLF5 TATTCCAAC--AAAAACAATATTATTATTCTACCATATCACTATACTCCCATAACATAAC 261 
IAM1817DBLE12TATTCCAACACAATACTATTATTATTATTCTACCATATCACTATACTCCCATAACATA-C 280 
IAM1817DBLG11T--TTCAACA-AATA-TAATATCATTATTCTACCATATCACTATACTCCCATAACATA-C 270 
ISM4917DBLH12TATTCCAACACAATACTATTATTATTATTCTACCATATTACAATACTCCCATAACATA-C 286 
                   **                           *** ** ** ************* * 
ISM4917DBLF3 ATA-CATATATACATACATACCCCCACGTACGTACCAAAACACCACCAAACCATGTATGC 334 
ISM4917DBLE3 ATA-CATA--------CATACCCCCACGTACGTACCAAAACACCACCAAACCATGTATGC 255 
IAM1817DBLF5 ATAACATACATACATACATACCCCCACGTACGTACCAAAACACCACCAAACCATGTATGC 321 
IAM1817DBLE12ATA-CATA--------TATACCCCCACGTACGTACCAAAACACCACCAAACCATGTATGC 331 
IAM1817DBLG11GCA--ATA-------------CGCCAC-----CACCACCGCCCACACGAACCATGTATGC 310 
ISM4917DBLH12GCA--ATA-------------CGCCAC-----CACCACCGCCCACACGAACCAAGCAAAC 326 
               *  ***             * ****      ****   * *   * ***** * *  * 
ISM4917DBLF3 CACGATATAAACCACGTA----TG-CTTGACATAATGTAGT------------CCCGAAA 377 
ISM4917DBLE3 CACGATATAAACCACGTAC-CACG-TATGACATAATGTAGT------------GGTGG-- 299 
IAM1817DBLF5 CACGATATAAACCACGTATGTATG-TATGACATAATGTAGT------------GGTGGAG 368 
IAM1817DBLE12CACGATATAAACCACGTATGTATG-TATGACATAATGTAGTCACGAACAAAATGGTGAGG 390 
IAM1817DBLG11CACGATATAAACCACGTATGTATG-CATGACATCATGTTGT------------CGCAAC- 356 
ISM4917DBLH12C----CACAAAT---ATATGTATGACATGACATAATGTAGT------------CATGAA- 366 
             *     * ***     **     *   ****** **** **                    
ISM4917DBLF3 CAAAAGAATCACAAAAATGGCGTCGCCCATGAGGC-----CAAGTAGTAGGGGTGGTGGT 432 
ISM4917DBLE3 ---------TGTTAAAATGGCGGC-----TG---------CAGGTGGGGGTGGTAAGGAT 336 
IAM1817DBLF5 T-------TAACAAAAATGGCGCC----------------CAAGAAGCCA-ACTGCGGAG 404 
IAM1817DBLE12CCAGGAGCTGGTGGTGGTGGGAGTGGTCGTGGTGGGGGTGCTGCTGGTAGTAGTAAAGAG 450 
IAM1817DBLG11--------CATGGAGAGTGGTAAGGG--------------CGGT-------GGCGGTGGT 387 
ISM4917DBLH12--------TAACCAAAATGGTGAAGC--------------AAGTTAAAACTGGTGGCGTT 404 
                              ***                                     *   
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ISM4917DBLF3 ACGCAGGAGGATCCTATT------GATAAAACAAGTGCCAAACATTTATTGGATAGCATA 486 
ISM4917DBLE3 AAGTATGATGATGCCAAG------GAT---------GCAAAGGACCTTTTGGATAAAATT 381 
IAM1817DBLF5 GACTATAATAAAGTCAAC------AAT---------GCGAAGGAGCTTTTTGATATGATT 449 
IAM1817DBLE12AAGGAGGATGAACCTGACTATACTAATGTCAAGGATGCTAAGGAACTTTTGGATAAAATT 510 
IAM1817DBLG11ACTAAGAAGGG---T---------------------GCGAAAGAAGTATTGGATGAATTT 423 
ISM4917DBLH12ATTGAGGATGCAACT---------------------GCTAAACATATATTTGATGGGATT 443 
                 *  *                            ** **  *  * ** ***    *  
ISM4917DBLF3 GGGAAAATAGTGCATAA-------AAAAGCGCA---TCGTGACGCTCAAAAATATTATAC 536 
ISM4917DBLE3 GGAGAAGATATATACAA-------AATAGCAAA---TAAGGCTGCTCTAAAGTACGAAAA 431 
IAM1817DBLF5 GGAGAAACTGTACAGAA-------AAAAGTGCA---TGGTGCTACTAAAAAATATTATAC 499 
IAM1817DBLE12GGGCAACAAGTGTACAAT----GAAAAAGTGAAAAATGGTGAAGCTCAAACATATGATAG 566 
IAM1817DBLG11GGGCAACAAGTGTACAAAGAAGTGAAAAATG-A---TGCTGATGCTGAAAAATATAAAGA 479 
ISM4917DBLH12GG--AAGGACTATACAA-----CAACAAGTGCA---TAGTGCTTCTAAAATATATACTAG 493 
             **  **    *  * **       *  *    *   *   *   **  **  **       
ISM4917DBLF3 TCATTTACATGGAAGTTTGAAGGACGCAAAATTTGAGAAACTTCCAAACGGTCAACAAAC 596 
ISM4917DBLE3 TGAATTGCATGGACGTTTGTCAGAAGCAAGATTTCAGGAAGATCCAAAGAAACAACAAAC 491 
IAM1817DBLF5 TGAGTTACATGGAGATTTGTCACAAGCAACATTTGAGGGGA----AAAAAATTAGTGGAT 555 
IAM1817DBLE12TTACTTGAAAGGAGATTTGAACAAAGCAAATGGTTATAGTT-----CGGAAACAGCTGGC 621 
IAM1817DBLG11GGCGTTGAAAGGAAATTTGCAGGAAGCAAAA---------GGTATGGGGGAAAGAGCTGA 530 
ISM4917DBLH12TGAATTGCATGGAGATTTAACAAAAGCAAAATTTCGACATGGTATATCGTGGGAAGAAGC 553 
                 **  * ***  ***     * ****                                
ISM4917DBLF3 ACCACCAAATCCATGCGATCTTGATTATCAATGGCA---TACTAATGCTACTAACGTTAG 653 
ISM4917DBLE3 CCCAGGAAATCCATGCAAACTTAATCATGAATATCA---TACTAATGCTACTAACGGTAA 548 
IAM1817DBLF5 C-----ACCTCCATGTAATCTTGATTATACTAAACA---TACTAATGTTACCATTGGTGG 607 
IAM1817DBLE12ACCATTAA-TCCATGCACACTTGTAGAGGAATATCG---TAGTAAGGCTAATGGTGATGG 677 
IAM1817DBLG11CACCGATGATCCATGCGATTTTGATTATACTAAGGAACTCATTGGTGCTGCTGGCGGTGA 590 
ISM4917DBLH12AAACAAAAATGTATGTGGTCTAAAACATTCATATGA---TACTAATGTTAGGTGGGGTGA 610 
                      *  ***     *     *             * *   * *      * *   
ISM4917DBLF3 AAGT------TATCCATGTAGA------GTTGGAAAAGA------AGAACGTTTTTCTCA 695 
ISM4917DBLE3 AAGT------TATCCATGTAGA------ACTGGAAAAGA------AGAACGTTTTTCTCA 590 
IAM1817DBLF5 GGGTAGGGAGTATCCTTGTAGA------AATGGAACAAA------AGAGCGTTTTCCCGA 655 
IAM1817DBLE12TGAAAGG---TATCCGTGCACAGAGTTAAGTGGAAAAGAT---GTAGAACGTTTTTCGGA 731 
IAM1817DBLG11ACGG------CATCCGTGCAAAAATTTAAAAGAAAATACAAATGAAAAACGTTTTTCCAA 644 
ISM4917DBLH12AAGT------TATCCTTG-------TGCAAAGAGATCA-----GAAAAACGTTTTTCTGA 652 
                        **** **             *  *          * * ****** *  * 
ISM4917DBLF3 AGTACATGGCGGTGAATGTGATGATAAGAAAATAGAAGGTAATGGTCGTAATAATGGT-G 754 
ISM4917DBLE3 AGTACATGGCGCTGAATGTGATAATAAAAAAATAAAAGATAATGAT---AGTAATGGT-G 646 
IAM1817DBLF5 TACAGAAGGAGCACAATGTGATAAGAAAAAAATAAAAGATAGTAAAAACAGTAGCGAAAG 715 
IAM1817DBLE12TACACTTGGTGGCCAATGCACTGATCAACAAATAGAAGGTAATGATCGTAAGAATGGT-G 790 
IAM1817DBLG11TACACTTGGTGGTCAGTGTACTAAGGAAAAAATAAGTGGTAGTACA---AATACATGT-G 700 
ISM4917DBLH12TGAAGGTGGCGGTGAATGTGATGATAGAAAAATAAAAGATAGTAAA---AACAATGGT-G 708 
                *   ** *   * **   * *     *****   * ** *      *  *      * 
ISM4917DBLF3 GAGCCTGCGCTCCCTTCAGAAGATTACATTTATGCGTTAGAAATTTGGAAAATATCAATA 814 
ISM4917DBLE3 GAGCATGTGCTCCATATAGACGATTACATTTATGCGTTAGAAATTTAGAAAATATAAGTG 706 
IAM1817DBLF5 GAGCATGTGCTCCTTTTAGACGATTACATCTATGCGACAAAAATCTGGAAAATATCAGTG 775 
IAM1817DBLE12GCGCCTGTGCTCCATATAGACGATTATATCTATGTGATTATAATTTGGAAAAAATACCAA 850 
IAM1817DBLG11GTGCTTGCGCTCCATACCGACGTCTACATCTATGTCATCATAATTTGGAAACTATA---G 757 
ISM4917DBLH12GAGCCTGTGCTCCATATAGACGGTTACATTTATGTGATTATAATTTGGAAAAAATAACAG 768 
             * ** ** ***** *   ** *  ** ** ****       *** * ****  **      
ISM4917DBLF3 TTAATAATAAATACATTAATAAAGATACATTGTTGGCGGATGTATGTCTTGCAGCCAAAT 874 
ISM4917DBLE3 CATTGCATAAG---ATTAATAAAGATACATTATTGGCGGATGTATGTCTTGCAGCCCTAC 763 
IAM1817DBLF5 ATTTTAACAAT---ATTAATAATGATACATTATTGGTAGATGTGTGCCAGGCAGCCAAAC 832 
IAM1817DBLE12CGTCGAAGACG------TCTACTGACACGTTGTTGGCAGAAGTGTGTATGGCAGCCAAAT 904 
IAM1817DBLG11ACACAAAGTCG---ACGACG---CATGATTTATTGGCAGAGGTGTGTTATGCAGCAATAC 811 
ISM4917DBLH12ATACACATACA---ACTACTACTCATAATTTATTGGTAGATGTGTGTCTTGCAGCAAAAT 825 
                   *                 *    ** ****  ** ** **    *****   *  
ISM4917DBLF3 ATGAAGGGGACTTAATAAAAACACATTATACACCATATCAA-CACAAA-----TATCGTG 928 
ISM4917DBLE3 ATGAAGGACAATCAATAACACAAGATTATCCAAAATATCAAGCACAATATGCTTCTTCTG 823 
IAM1817DBLF5 ATGAAGGACAATCAATAATACAAGATTATCCAAAATATCAAGCAACATATGCTTCTTCTG 892 
IAM1817DBLE12ATGAAGGGGGCTTAATAAAAACACATTATACACGATATCAACAAATAT------ATGGTA 958 
IAM1817DBLG11ATGAGGGAGAGTCACTACGAGGTCAACATGGAGAACATAAAGGAAC------------TA 859 
ISM4917DBLH12ATGAAGGACAATCAATATCAGTTCAACATGGAAAATATCATACAGA------------TA 873 
             **** **    * * **  *    *  **  *  * ** *   *              *  
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ISM4917DBLF3 ATTCTCCTTCTCAAATATGTACTATGTTAGCACGAAGTTTTGCAGATATAGGTGACATCG 988 
ISM4917DBLE3 CTTCTCGTTCTCAAATATGTACTATGTTAGCACGCAGTTTTGCTGATATTGGAGACATTA 883 
IAM1817DBLF5 GTTCTTCTTCTCAAATGTGTACTATGTTAGCACGAAGTTTTGCAGATATAGGAGACATTA 952 
IAM1817DBLE12ATTCTCCTTCCCAATTATGTACGGTGTTGGCACGAAGTTTTGCAGATATAGGTGATATTA 1018 
IAM1817DBLG11ATAATGAATCTCAATTATGTACTGTATTGGCACGCAGTTTTGCAGATATAGGTGATATCG 919 
ISM4917DBLH12GTTCTGGTTCTACAATATGTACGGTATTGGCGCGAAGTTTTGCAGATATTGGAGACATTA 933 
              *  *   **   * * *****  * ** ** ** ******** ***** ** ** **   
ISM4917DBLF3 TACGCGGCAAAGATCTATATAGTGGTAAT----AAGAAA---------------AA---- 1025 
ISM4917DBLE3 TCAGAGGAAAAGATCTGTATCGTGGTAAT----AATGGA---------------AA---- 920 
IAM1817DBLF5 TACGAGGAAGAGATCTTTATATACGTAAT----AAGAAA---------------AA---- 989 
IAM1817DBLE12TACGAGGAAAAGATCTGTATCTCGGTAATCCGCAAGAAAGT--------GCACAAA---- 1066 
IAM1817DBLG11TACGTGGCAAAGATCTTTTCCTCGGTAATGATGAAGAAAAA--------AAACAAA---- 967 
ISM4917DBLH12TTCGAGGAAAAGATCTATATCTTGGAAAAAAAAAAAAAAAAGCAAAATGAAACAAAAACA 993 
             *  * ** * ****** *      * **     **   *               **     
ISM4917DBLF3 ----------GGAAAA-ATTAGAACAGAATTTACAAAAAATTTTCAAAGAAATATATGAC 1074 
ISM4917DBLE3 ----------GGATAA-ATTACAAGAAAATTTAAAAAAAATTTTCGAGAAAATATATGAC 969 
IAM1817DBLF5 ----------AGATAA-ATTAGAAGATAATTTACAAAAAATTTTCAAGATGATTCAGGGA 1038 
IAM1817DBLE12----------GAATAATATTAGAAAAGAATTTAAAAAAATATTTCCAACAAATACATAAT 1116 
IAM1817DBLG11----------GAAAAAAATTACAACAACATTTGAAAGAAATTTTCGGGAAAATACATAAG 1017 
ISM4917DBLH12GAAACAGAAAGAGAAAAATTAGAACAGAAATTGAAAGAAGTTTTCGCGAAAATACATAGT 1053 
                           ** **** ** *  * **  ** **  ****      **  *     
ISM4917DBLF3 AA------A---TTGGAT------AATAGCA------TAAAATCAAACTATAATGATGC- 1112 
ISM4917DBLE3 AA------A---TTGGATGGGAAGAAAGGCG------CAAAAGACTACTACAAAGATGAA 1014 
IAM1817DBLF5 AA------A---A-----------------A------TCAATCTAAACTAAGTCAACTT- 1065 
IAM1817DBLE12GACGTGACG---TCTAGCGGGAGGAATGGTG------TAAAAGACCGCTACAAAGATAC- 1166 
IAM1817DBLG11GAAGTGACG---ACAAATGGGAAGAATGTGAAGACGCTACAAGCTCGCTACGAAGGTGAT 1074 
ISM4917DBLH12GAAGTGACGTCGACGAGCGGCAATAATAAGGAGGTGCTAAAAGCACGCTACGATGGTGAC 1113 
              *                                      *      ***           
ISM4917DBLF3 -----TCCATATTATTATCAATTACGTGAAGATTGGTGGAATAATAATAGAATAATGGTA 1167 
ISM4917DBLE3 AATGGTGGAAATTATTATCAATTACGAGAAGATTGGTGGAACGCTAATAGACAAGAAGTA 1074 
IAM1817DBLF5 --------ACACTAG-ATCAGGTAAGAGAATACTGGTGGGATGCAAATCGGCACACCGTG 1116 
IAM1817DBLE12--TGACAAAAATTTTTTTCAATTACGAGAAGATTGGTGGTATGCTAATAGAGAAACAGTA 1224 
IAM1817DBLG11AAAAAAAATTATTTTTTTCAATTAAGAGAAGATTGGTGGACAGCGAATCGAGAAACAGTA 1134 
ISM4917DBLH12GGTGATAATTATTAT---CAATTAAGGGAAGATTGGTGGGATGCTAATAGACTTGATGTA 1170 
                       * *     **  ** * *** * ******      *** *       **  
ISM4917DBLF3 TGGTATGCTATGACGTGTGGTGAACCAGAAAAGGCTGAATATTTTAGAACAGCATGTTCT 1227 
ISM4917DBLE3 TGGTACGCGATAACATGCGGCG---CTGGGGGTTATTCATATTTTCGACAAACATGTGGT 1131 
IAM1817DBLF5 TGGAAAGCTATCACATGCAACG---CTGGAAGTTATAAATATTCTCGACCAACATGT--- 1170 
IAM1817DBLE12TGGAAAGCCATCACATGCAACG---CTCAGGGTTTTGACTATTTTCGACAAACATGTGGT 1281 
IAM1817DBLG11TGGAAAGCATTAACATGCAACGCTGGGAATG---CTAAATATTTTCGACCAACATGTGGT 1191 
ISM4917DBLH12TGGAAAGCTATCACGTGCGGTGCACCACATGGTGCTCAATATTTTCGACAAACATGTAAT 1230 
             *** * **  * ** **    *             *   **** * **  * *****    
ISM4917DBLF3 ---GGTGG---AACAACTCCAACT------AATAAGAAATGCCGATGTGA---------- 1265 
ISM4917DBLE3 ---GGAGG---AAAAACTGCGACT------GAAGGTAAATGCCGATGTCC---------- 1169 
IAM1817DBLF5 ---AGTGA---ACAACCTTTGAGT------CAGGATAAGTGCCAATGTAT---------- 1208 
IAM1817DBLE12GATGATGA---AAAAACTGCAACTCGGGTTAAAGACAAATGCCGGTGTGA---------- 1328 
IAM1817DBLG11GGTGGTGATGAAAAAACTGGAATTCTGACTCGTAGTCAATGCCGGTGTGACGACAAGCCA 1251 
ISM4917DBLH12GATGATGG------GACTTCTTCTCGTGCTATTCACCAATGCCGTTGTCAGAAGAAAGAC 1284 
                   *         **     *             * ****  ***             
ISM4917DBLF3 --------CAACGTAAGTATT------GTCCCCACCTATTTCGACTATGTGCCGCAGTTT 1311 
ISM4917DBLE3 --------TAGTT---ATAAG------GTCCCTACATATTTTGACTATGTGCCACAATAT 1212 
IAM1817DBLF5 --------CAATG---GCGGT------GTTCCCACTAATTTTGACTACGTGCCACAGTAT 1251 
IAM1817DBLE12--------CGGCG---ACCAG------GTCCCCACATATTTTGACTACGTCCCTCAATTT 1371 
IAM1817DBLG11AAGGCTGGCGACGGAGATGTAAATATTGTCCCCACATATTTTGACTATGTGCCACAGTAT 1311 
ISM4917DBLH12GGCACACACGACAGCGACCAG------GTCCCCACATATTTTGACTATGTGCCACAGTAT 1338 
                                        ** ** **  **** ***** ** ** ** * * 
ISM4917DBLF3 CTTCGCTGGTTCGAGGAATGGGCCGAAGACTTA 1344 
ISM4917DBLE3 TTGAGATGGTTCGAGGAATGGGCCGAAGACTTA 1245 
IAM1817DBLF5 CTTCGCTGGTTCGAGGAATGGGCCGAAGATTTA 1284 
IAM1817DBLE12TTAAGATGGTTCGAGGAATGGGCCGAAGACTTA 1404 
IAM1817DBLG11CTTCGCTGGTTCGAGGAATGGGCCGAAGATTTA 1344 
ISM4917DBLH12CTTCGCTGGTTCGAGGAATGGGCAGAAGATTTA 1371 
              *  * ***************** ***** *** 
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2.5 upsC multiple sequence alignment of predominant sequences from 2 
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ISM335B1A2  CACATATAGTACGACTAAGAAACAAAATAATATCATAACAAACATAGTGACTACCGTTAC 60 
ISM335B1B6  CACATATAATACGACTAAGAAACAAAATAATATCATAACAAACATAGTGACTACCGTTAC 60 
ISM335B1B7  CACATATAGTACGACTAAGAAACAAAATAATATCATAACAAACATAGTGACTACCGTTAC 60 
ISM25B1A11  CACATATAGTACGACTAAGAAACAAAATAACATCACAACAAACATAGTGACTACCATTAC 60 
ISM25B1C9   CACATATAGTACGACTAAGAAACAAAATAACATCACAACAAACATAGTGACTACCGTTAC 60 
ISM25B1C4   CACATATAGTACGACTAAGAAACAAAATAACATCATAACAAACATAGTGACTACCATTAA 60 
            ******** ********************* **** ******************* ***  
ISM335B1A2  AT-GATATTACCACATAATTCATACCATTATATAATATTACTACATGGTAATGATAACCA 119 
ISM335B1B6  AT-GATATTACCACATAATTCATACCATTATATAATATTACTACATGGTAATGATAACCA 119 
ISM335B1B7  AT-GATATTACCACATAATTCATACCATTATATAATATTACTACATGGTAATGATAACCA 119 
ISM25B1A11  ATAGATATTACCACATAATATAAAGCATTAAATAATATTATTGCATGTTAGTGATAACTA 120 
ISM25B1C9   AT-GATATTACCACATAATTCATACCACTATATAATATTACTACATGATAGTGATAACCA 119 
ISM25B1C4   ATAGGTATTACCACACAATTCATACCACTATATAATATTACTACATGATAGTGGTAACTA 120 
            ** * ********** ***  * * ** ** ********* * **** ** ** **** * 
ISM335B1A2  CTATATCATATACACCACTATATAGTAATAGTAGCGGAGATATTATGTGCACAAATATAT 179 
ISM335B1B6  CTATATCATATACACCACTATATAGTAATAGTAGCGGAGATATTATGTGCACAAATATAT 179 
ISM335B1B7  CTATATCATATACACCACTATATAGTAATAGTAGCGGAGATATTATGTGCACAAATATAT 179 
ISM25B1A11  CTATATCATATACACCACTATATAGTAATAGTAGCGGTGGTAATATGTACACGTATATAT 180 
ISM25B1C9   TTATATCATATACACCACTATATAGTAATAGTAGCGAAGATATTATGTGCACAAATATAT 179 
ISM25B1C4   CTATATCATATACACCATTATATAGTAATAGTAGCGGCGGTATCATGCACACGTATATAT 180 
             **************** ******************  * **  ***  ***  ****** 
ISM335B1A2  TATAATAGTGGTAGCCACAACCACGACATCATGGAAATATAGATTTTCATTCATATCTTC 239 
ISM335B1B6  TATAATAGTGGTAGCCACAACCACGACATCATGGAAATATAGATTTTCATTCATATCTTC 239 
ISM335B1B7  TATAATAGTGGTAGCCACAACCACGACATCATGGAAATATAGATTTTCATTCATATCTTC 239 
ISM25B1A11  TGTAATAGTGGTAGCGACAATCACGATATCATGGTAATGTAGATTTTTATTCATATCTTC 240 
ISM25B1C9   TATAATAGTGGTAGCAACAACCACGGTATCATGGTAATGTAGATTTTCATTCATATCTTC 239 
ISM25B1C4   TGTAACAGTGGTAGCTACAATCACTGCATCATGGTAATATAGATTTTCGTTTATATCTTC 240 
            * *** ********* **** ***   ******* *** ********  ** ******** 
ISM335B1A2  CTTATCGTTAGTTTTCCATACACTATTAATATGTATTTATGTTATAATGGTAGACTATGT 299 
ISM335B1B6  CTTATCGTTAGTTTTCCATACACTATTAATATGTATTTATGTTATAATGGTAGACTATGT 299 
ISM335B1B7  CTTATCGTTAGTTTTCCATACACTATTAATATGTATTTATGTTATAATGGTAGACTATGT 299 
ISM25B1A11  CTTATCGTTTGTTGTCCATACACTTTTAATATGTATTTATGTTATAATGGTAAACTATGT 300 
ISM25B1C9   CTTATCGTTAGTTTTCCATACCCTATTAATATGTATTTATGTTATAATGGTAGAATATGT 299 
ISM25B1C4   TTTATTGTTTGTTGTCCATACACTATTAATATGTATTTATGTTATAATGGTAAACTATGT 300 
             **** *** *** ******* ** *************************** * ***** 
ISM335B1A2  TAACAATGTATGAATGACTATCGTAAATTAATAATAGATACATGAAAAC------TGTGT 353 
ISM335B1B6  TAACAATGTATGAATGACTATCGTAAATTAATAATAGATACATGAAAAC------TGTGT 353 
ISM335B1B7  TAACAATGTATGAATGACTATCGTAAATTAATAATAGATACATGAAAAC------TGTGT 353 
ISM25B1A11  TAACAATGTATGAATGATCATCGTAGATTAATAATAAATTCATGAAAACAATGTGTATGT 360 
ISM25B1C9   TAACAATGTATGAATGACCATCGTAAATTAATAATAGATGCATGAAAACAATGTGTTTTT 359 
ISM25B1C4   TAACAATGTATGAATGATCATCGTAGATTAATAATAGATGCATGGAAACCGTGTATATGT 360 
            *****************  ****** ********** ** **** ****      * * * 
ISM335B1A2  ATATGTATGTGTGC--------ATTTACAACATAATGTAGTCGGGAAGAAGAATACAAAA 405 
ISM335B1B6  ATATGTATGTGTGC--------ATTTGCAACATAATGTAGTCGGGAAGAAGAATACAAAA 405 
ISM335B1B7  ATATGTATGTGTGC--------ATTTACAACATAATGTAGTCGGAAAGAAGAATACAAAA 405 
ISM25B1A11  ATATGTATGTGTGT--------ATTTACGACATAATGTAGTCGTG--GAAGCATACAAAA 410 
ISM25B1C9   ATATGTATGTGTGCGTA----CATTTATGACATCATGTAGTCACGAACGATAA-ACAAAA 414 
ISM25B1C4   ATATGTATATATATATGTGTGCATTTATGACATAATGTAGTCGGGAAGAAGAATACAAAA 420 
            ******** * *          ****   **** ********       *  * ****** 
ISM335B1A2  ATGGGGCCGC-CAGGTAGTACTGGTATGCAGGAGGATCGTATTGATGAACGAAGTGCCAA 464 
ISM335B1B6  ATGGGGCCGC-CAGGTAGTACTGGTATGCAGGAGGATCGTATTGATGAACGAAGTGCCAA 464 
ISM335B1B7  ATGGGGCCGC-CAGGTAGTACTGGTATGCAGGAGGATCGTATTGATGAACGAAGTGCCAA 464 
ISM25B1A11  ATGG---CGC-GAGGTCGTGGTGGTG---GGGATGGTATTGAGCATGATAAAGATGCCAA 463 
ISM25B1C9   ATGG---CGC-CAAGCAGTGCCGGTACGCAGGAGGATCCTATTGATGAACGAAGTGCCAA 470 
ISM25B1C4   ATGGGGCCCCAGAAGCCGAGTC-------AGGAAGAGTATAATAAAGTCAACAATGCGAA 473 
            ****   * *  * *  *            *** *    *    * *       *** ** 
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ISM335B1A2  ACATTTATTGGATAGCATAGGGAAAAAAGTGCAT---GACAAAGTGGAAAAGGATGATGC 521 
ISM335B1B6  ACATTTATTGGATAGCATAGGGAAAAAAGTGCAT---GACAAAGTGGAAAAGGATGATGC 521 
ISM335B1B7  ACATTTATTGGATAGCATAGGGAAAAAAGTGCAT---GACAAAGTGGAAAAGGATGATGC 521 
ISM25B1A11  ACATTTATTGGATAGCATAGGGGAAAAAGTGTACAGAGAAAAAGTACAAAGTGATGATGC 523 
ISM25B1C9   ACATTTATTGGATAGCATAGGGAAAAGAGTGCAC---AAAGAAGTGAAAAAGGAAGCTGA 527 
ISM25B1C4   GGATCTTTTCGATTTAATTGGAAAATATATAGAA---AAAAAAGTGC---GTGATGCTGC 527 
              ** * ** ***   ** **  **    *  *     *  ****       ** * **  
ISM335B1A2  TAAAAATTATATTGATGATTTGAAAGGAGATTTGGCAAGCGGAACAAGTTCTCA----TT 577 
ISM335B1B6  TAAAAATTATATTGATGATTTGAAAGGAGATTTGGCAAGCGGAACAAGTTCTCA----TT 577 
ISM335B1B7  TAAAAATTATATTGATGATTTGAAAGGAGATTTGGCAGGCGGAACAAGTTCTCA----TT 577 
ISM25B1A11  TAAAAATTATATTGGTGAATTGAAAGGAGATTTGAACAAAGCAACAAATCGTAG----TT 579 
ISM25B1C9   ACAACGTAGTAGGAGTGATTTGAAAGGAAGTTTGTCATTTGCAACATTTTCTGT----TG 583 
ISM25B1C4   TCTAGAACGTAAGGGAAATTTGAAAGGAAATTTAAAAAGCGCAAAATATAGAGAAGGCTA 587 
               *     **      * *********  ***       * ** *  *         *  
ISM335B1A2  CGGAATTAGTTA-GCAC-CGATAAAACATGCAAACTTGTAGATGATTATTATAATGAGCG 635 
ISM335B1B6  CGGAATTAGTTA-GCAC-CGATAAAACATGCAAACTTGTAGATGATTATTATAATGAGCG 635 
ISM335B1B7  CGGAATTAGTTA-GCAC-CGATAAAACATGCAAACTTGTAGATGATTATTATAATGAGCG 635 
ISM25B1A11  CGGAATTAAGTATGCAG-CCTTGATCCGTGCATGTTTG---------ATTATACTGCACG 629 
ISM25B1C9   TGGAATCAG-CATACAC-CACAGATCCGTGCCAACTTATAAAAGATAAAGGTCATAAACT 641 
ISM25B1C4   TATCATCGAGCATGCAAACACAAATATATGTCATTTAATACATACACATGATACAAATGT 647 
                **     *  **  *    *    **     *           *   *         
ISM335B1A2  TGTTAATGGTGGTGGTGAACGGCATCCGTGCGTAAATGGAACA---GTAGAATATGTAAA 692 
ISM335B1B6  TGTTAATGGTGGTGGTGAACGGCATCCGTGCGTAAATGGAACA---GTAGAATATGTAAA 692 
ISM335B1B7  TGTTAATGGTGGTGGTGAACGGCATCCGTGCGTAAATGGAACA---GTAGAATATGTAAA 692 
ISM25B1A11  TCTTGGTACTAACAGTAACAGGTATCCGTGCGCTAATAGATCA---CCAG---------T 677 
ISM25B1C9   TCTTGGTGCTCGCGGTGA------TCCGTGCAAAAAAGACACAAACGGAAACAATGTAGA 695 
ISM25B1C4   TACTGAGGGGCATGGAAAAGAGTATCCTTGTGCAAATAGATCA----GATA--------T 695 
            *  *          *  *      *** **    **     **     *            
ISM335B1A2  CCGTTTTTCGGATACACTTGGTGGCCAATGCACTGATCATAGAATAAAAGGTAATGAACG 752 
ISM335B1B6  CCGTTTTTCGGATACACTTGGTGGCCAATGCACTGATCATAGAATAAAAGGTAATGAACG 752 
ISM335B1B7  CCGTTTTTCGGATACACTTGGTGGCCAATGCACTGATCATAGAATAAAAGGTAATGAACG 752 
ISM25B1A11  TCGTTTTTCCGATGAAAGCCGAAGCCAATGTACACAAAATAGAATAAAAGATAGTAC--- 734 
ISM25B1C9   CCGTTTTTCGGATAAACAACAAGCAGAATATGATAACAAAAAAATAAAATGTAGTA---- 751 
ISM25B1C4   TCGTTTTTCTGATAAACAAGGAGCAGAATGTGATGAGAAAAAAATAAGAGATAATGAA-- 753 
             ******** ***  *          ***      *  * * ***** *  ** *      
ISM335B1A2  TAATAAAACTGGTGGAGCATGTGCTCCACTCAGACGATTACATTTATGTGACAAAAATAT 812 
ISM335B1B6  TAATAAAACTGGTGGAGCATGTGCTCCACTCAGACGATTACATTTATGTGACAAAAATAT 812 
ISM335B1B7  TAATAAAACTGGTGGAGCATGTGCTCCACTCAGACGATTACATTTATGTGACAAAAATAT 812 
ISM25B1A11  TAGCGGTACTGTAGGAGCATGTGCGCCTTTTAGACGATTATCTGTATGTGATTATAATTT 794 
ISM25B1C9   -----ATAGTGAAGGAGCTTGCGCGCCGTTCAGACGATTACATTTATGCAACAAAAATAT 806 
ISM25B1C4   -GACGACAGGGTAGGAGCATGTGCTCCATATAGACGATTACATCTATGCGACCAACATTT 812 
                   *  *  ***** ** ** **    *********  * ****  *  *  ** * 
ISM335B1A2  GGAAAAAATGGACGCAAATAATTATGATAGTGGTAAAGCTACGCATACGTTGCTCTCCGA 872 
ISM335B1B6  GGAAAAAATGGACGCAAATAATTATGATAGTGGTAAAGCTACGCATACGTTGCTCTCCGA 872 
ISM335B1B7  GGAAAAAATGGACGCAAATAATTATGATAGTGGTAAAGCTACGCATACGTTGCTCTCCGA 872 
ISM25B1A11  AGAAAAAATAAGCACTAAAAAA---------AACAAAGCTAGACATAAGTTGTTGTTAGA 845 
ISM25B1C9   GGTAAAAATGGACACAAATAATGATGATAGTAGTAAAGCTAAACATAATTTATTGTTAGA 866 
ISM25B1C4   ATCGCACATGAAAGCTGAAAAA---------ATTAATACTAAAGATAATTTGTTGTTAGA 863 
                 * **     *  * **             **  ***   ***  **  * *  ** 
ISM335B1A2  GGTGTGTCTTGCAGCAAAATATGAAGGAGAATCAATAAAAGATGATCATGCGCAATATCA 932 
ISM335B1B6  GGTGTGTCTTGCAGCAAAATATGAAGGAGAATCAATAAAAGATGATCATGCGCAATATCA 932 
ISM335B1B7  GGTGTGTCTTGCAGCAAAATATGAAGGAGAATCAATAAAAGATGATCATGCGCAATATCA 932 
ISM25B1A11  GGTGTGTATGGCAGCAAAATACGAGGCAGAGTCACTACAAGGTTATTATGGTATATATGA 905 
ISM25B1C9   CGTGTGTATGGCAGCAAATTACGAGGCAGAGTCATTAATAACTTATCATGATCAACATCA 926 
ISM25B1C4   AGTGTGTCTTGCAGCACAATATGAAGGACAATCAATAAGAGTTGATCATGATAAATATAA 923 
             ****** * ****** * ** ** * * * *** **  *  * ** ***    * ** * 
ISM335B1A2  AGCAAAATATAATGATTTCCGTACCAATATATGTACTGAGTTAGCACGAAGTTTTGCAGA 992 
ISM335B1B6  AGCAAAATATAATGATTTCCGTACCAATATATGTACTGAGTTAGCACGAAGTTTTGCAGA 992 
ISM335B1B7  AGCAAAATATAATGATTTCCGTACCAATATATGTACTGAGTTAGCACGAAGTTTTGCAGA 992 
ISM25B1A11  TGCAAAATATCACGATACTGGTTTTACAATATGTACTGCATTAGCACGAAGTTTTGCAGA 965 
ISM25B1C9   AATGAC------TAATGTGGGTTCTCAATTATGTACCGAGTTGGCACGAAGTTTTGCCGA 980 
ISM25B1C4   ATTAGACAATGATAATTCTGGTTCTAAATTGTGTACTGAGTTAGCACGAAGTTTTGCTGA 983 
                          **    **       * ***** *  ** ************** ** 
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ISM335B1A2  TATAGGAGATATTGTAAGAGGAAGAGATCTGTATCTGGGTTATGATCAAAAA-------- 1044 
ISM335B1B6  TATAGGAGATATTGTAAGAGGAAGAGATCTGTATCTGGGTTATGATCAAAAA-------- 1044 
ISM335B1B7  TATAGGAGATATTGTAAGAGGAAGAGATCTGTATCTGGGTTATGATCAAAAA-------- 1044 
ISM25B1A11  TATAGGAGATATTGTAAGAGGAAGAGATCTGTATCTTGGT---AATCCAGAA-------- 1014 
ISM25B1C9   TATAGGTGACATTATACGAGGAAAAGATCTATATCTTGGCAATAAAAAAAAAAAGCTAAA 1040 
ISM25B1C4   TATAGGAGACATTATACGAGGAAAAGATCTGTATCTCGGT---AATCCGCAA-------- 1032 
            ****** ** *** ** ****** ****** ***** **     *     **         
ISM335B1A2  --GAAAAAGACCG--AAGAGAAAATTTAGAAAAGAATTTGAAAGAAATTTTCAAGAAAAT 1100 
ISM335B1B6  --GAAAAAGACCG--AAGAGAAAATTTAGAAAAGAATTTGAAAGAAATTTTCAAGAAAAT 1100 
ISM335B1B7  --GAAAAAGACCG--AAGAGAAAATTTAGAAAAGAATTTGAAAGAAATTTTCAAGAAAAT 1100 
ISM25B1A11  --GAAATAAAACA--AAGACAACAATTAGATGAGAATTTAAAAACGATTTTTAAGAATAT 1070 
ISM25B1C9   TGGAAAAGAAACAGAAAGGGATCAATTAGAAAGTAAGTTGAAAGAAATTTTCGGGGATAT 1100 
ISM25B1C4   --GAAAGTGCACA--AAGAAAACAATTAGAAAAGAATTTGAAAGAAATTTTCAAGGAAAT 1088 
              ****     *   ***  *  * *****    ** ** ***   *****   * * ** 
ISM335B1A2  ACATGGAGAATTG---AAGGATCCAAA------------AAAATCTCATTATAATGATCC 1145 
ISM335B1B6  ACATGGAGAATTG---AAGGATCCAAA------------AAAATCTCATTATAATGATCC 1145 
ISM335B1B7  ACATGGAGAATTG---AAGGATCCAAA------------AAAATCTCATTATAATGATCC 1145 
ISM25B1A11  ATATGAGAAATTATTAGAGGATAACAAGACGAATGGTGTAAAAGACCGCTACGAAGATAA 1130 
ISM25B1C9   ATATAAGGACGTGACGAGAGGGAAGAAGGAGGAG---ATAGAAAGGCGCTACGGAAG--- 1154 
ISM25B1C4   ACATAGTGGATTGACGACGACGAACGG---------CGCACAAGCTCGCTACGGAGG--- 1136 
            * **       *                           * **   *  **          
ISM335B1A2  TGATGGAAATTTTTATCAATTAAGAGAAGATTGGTGGACTGCGAATCGGCACACCGTGTG 1205 
ISM335B1B6  TGATGGAAATTTTTATCAATTAAGAGAAGATTGGTGGACTGCGAATCGGCACACCGTGTG 1205 
ISM335B1B7  TGATGGAAATTTTTATCAATTAAGAGAAGATTGGTGGACTGCGAATCGGCACACCGTGTG 1205 
ISM25B1A11  TGACGGAAATTATTATAAATTAAGGGAAGATTGGTGGACTGCGAATAGGCACACCGTGTG 1190 
ISM25B1C9   TGATGGAAATTATTATAAATTAAGAGAAGATTGGTGGACGGCGAATCGAGAAACAGTATG 1214 
ISM25B1C4   TGATGAAAATTATTTTCAATTACGAGAAGATTGGTGGAACGCTAATAGACAAGAAGTATG 1196 
            *** * ***** ** * ***** * *************  ** *** *  *    ** ** 
ISM335B1A2  GGAAGCAATTACATGTAGCAAGAAGCTAGCAAATACTCATTATTTTCGACAAACGTGCAA 1265 
ISM335B1B6  GGAAGCAATTACATGTAGCAAGAAGCTAGCAAATACTCATTATTTTCGACAAACGTGCAA 1265 
ISM335B1B7  GGAAGCAATTACATGTAGCAAGAAGCTAGCAAATACTCATTATTTTCGACAAACGTGCAA 1265 
ISM25B1A11  GAAAGCACTAACATGTGACAACAGGCTAGGGGGTTATTCATATTTTCGACAAACGTGCAA 1250 
ISM25B1C9   GAAAGCTATCACATGTAA-GGCGGAC--GCAAGTAGTGCATACTTTCGAGCAACGTGCGA 1271 
ISM25B1C4   GAAAGCAATTACATGTGATGCTGGG------AATGCTCAATATGTTGGACTTACATGTTC 1250 
            * ****  * ******                 *  *   **  ** **   ** **    
ISM335B1A2  TGGAGGAGAACAAACTAAAGGTTA-CTGCCGAT-GTGACGACAAGCCAAAGGCTGGCAAC 1323 
ISM335B1B6  TGGAGGAGAACAAACTAAAGGTTA-CTGCCGAT-GTGACGACAAGCCAAAGGCTGGCAAC 1323 
ISM335B1B7  TGGAGGAGAACAAACTAAAGGTTA-CTGCCGAT-GTGACGACAAGCCAAAGGCTGGCAAC 1323 
ISM25B1A11  TGGAAAAGAACCAACTAAAGGTTA-CTGCCGGT-GTAACGGCGACC---AGCCAGGTAAG 1305 
ISM25B1C9   TAGTGCTGATAAAA--AAGGTCCATCTGTAGCTAGAAACCAATGCCGGTGTGACGGCGTA 1329 
ISM25B1C4   TGAGG--GAAGAAG------------TGCGACTCATGAAAAATGCACATGCGCTAGTGGA 1296 
            *      **   *             **    *    *                 *     
ISM335B1A2  GGCGACGTAAATATTGTCC---CCACA---TATTTTGACTACGTCCCTCAGTTTCTTCGC 1377 
ISM335B1B6  GGCGACGTAAATATTGTCC---CCACA---TATTTTGACTACGTCCCTCAGTTTCTTCGC 1377 
ISM335B1B7  GGCGACGTAAATATTGTCC---CCACA---TATTTTGACTACGTCCCTCAGTTTCTTCGC 1377 
ISM25B1A11  GACAATCCAAATACCGATC---CCCCAACCTATTTTGACTACGTGCCGCAGTATCTTCGC 1362 
ISM25B1C9   AAGAGCGCAAATGCCGACCAGGTCCCCACATATTTTGATTATGTGCCGCAGTATCTTCGC 1389 
ISM25B1C4   GA------------TGTTC---CTACA---TATTTTGACTACGTGCCACAGTTTCTTCGC 1338 
                           *  *      *    ******** ** ** ** **** ******* 
ISM335B1A2  TGGTTCGAGGAATGGGCCGAAGACTTA 1404 
ISM335B1B6  TGGTTCGAGGAATGGGCCGAAGACTTA 1404 
ISM335B1B7  TGGTTCGAGGAATGGGCCGAAGACTTA 1404 
ISM25B1A11  TGGTTCGAGGAATGGGCCGAAGACTTA 1389 
ISM25B1C9   TGGTTCGAGGAATGGGCCGAAGACTTA 1416 
ISM25B1C4   TGGTTCGAGGAATGGGCCGAAGATTTA 1365 
            *********************** *** 
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Curriculum vitae 
 
Biography 
Name: Joseph Paschal MUGASA 
Date of Birth: 13th February 1972 
Place of birth:  Morogoro, Tanzania 
Nationality: Tanzanian 
Languages:  English and Swahili 
 
ADDRESS: 
Ifakara Health Research and Development Centre (IHRDC)  
P.O. Box 53 Ifakara, Tanzania.  
Tel +255 23 2625164 
Fax +255 23 2625312 
Mobile + 255 784 412940 
E-mail: jpmugasa@ihrdc.or.tz , Joseph.Mugasa@unibas.ch 
 
EMPLOYMENT 
2003-present Research Scientist, Ifakara Health Research and Development 
Centre (IHRDC) 
1999-2003 Research Assistant, Sokoine University of Agriculture, 
Department of Veterinary Microbiology and Parasitology 
 
ACADEMIC QUALIFICATIONS 
Sept. 2005-April 2008: PhD in Microbiology - University of Basel, Switzerland and 
IHRDC, Tanzania. Thesis:  “Expression of Plasmodium falciparum var genes in 
naturally infected children from Tanzania”. Supervisor: Prof. Hans-Peter Beck 
Sept. 2000-Dec. 2002: Master of Science in molecular epidemiology of human 
diseases and genetics. Katholieke Universiteit Leuven, Belgium. Thesis:  
“Molecular characterization of PapG, the functional adhesins in Avian 
Pathogenic E. coli (APEC)”. Supervisor: Prof. Bruno Goddeeris 
Sept. 1994-Sept 1998: Bachelor of Animal Science, Sokoine University of 
Agriculture (SUA), Tanzania 
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PROFESSIONAL DUTIES, WORKSHOPS AND MEETINGS 
 
Jan. 2003-present. Involved in studying differential gene expression of PfEMP1 in 
field isolates from children with severe malaria in Tanzania and molecular 
genotyping of anti-malarial drug resistance markers. 
March 17- 28, 2007. World Health Organization special program for research and 
training in tropical diseases (WHO/TDR) and the national Centre for Genetic 
Engineering and Biotechology in Thailand (BIOTEC) -organized International 
training workshop entitled: Functional Genomics of Malaria Parasites Practical 
Course, Bangkok, Thailand. 
March 13-14, 2007. Computational Biology Congress, Basel, Switzerland 
Feb. 26-March 2, 2007.  Advanced training course on bioinformatics, entitled:  
Working with Pathogen Genomes, Welcome Trust Genome Campus, Hinxton, 
Cambridge, UK 
Nov. 31 – Dec. 8, 2004.  Third Wellcome Trust/EMBO Workshop entitled: 
HIV/AIDS and TB: the Way Ahead, Cape Town, South Africa. 
Nov. 1-5, 2004.  African Malaria Network Trust (AMANET) Workshop entitled: 
Molecular Biology and Immunology in Malaria Vaccine Development, Witwatersrand 
University, Johannesburg, South Africa. 
Sept. 15-17, 2003.  Medical Genetics Training Course for Developing Countries, 
International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, 
Italy   
May 18 - June 6, 2003. East African Training Workshop: Yeast Techniques in Malaria 
Research and Research in Protozoan Pathogens and Research Ethics, Tanga, Tanzania. 
Funded by Seattle Biomedical Research Institute (SBRI) and National Institute for 
Medical Research (NIMR)   
Sept 17. – Dec 17 2003: Attended training in Molecular Biological Methods in Malaria 
Research, Department of Parasitology and Infection Biology, Swiss Tropical 
Institute (STI).  
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Laboratory Experiences 
 Molecular Biology: 
General molecular biology technologies, cloning and sequencing, quantitative 
real-time PCR, Magnetic beads isolation of specific mRNA, Transfection 
techniques, Reverse Transcription PCR, RFLP analysis 
 Microbiology: 
Basic techniques in microbiology, i.e Microbial isolations and culture 
 Bioinformatics  
Application of various programs for sequencing analysis and database search 
online ie DNAMAN, DANstar, Bioedit, MUSCLE, Mega, Arlequin, Phylip, NCBI, 
PlasmoDB,geneDB, Artemis and Artemis Comparison Tool (ACT), VectorBase 
 Biostatics 
Basic Knowledge in statistical software (Stata, SPSS and Epi Info) 
 
Awards 
September 1999: Among winners of VLIR scholarships for Masters studying in 
Belgians universities 
 
PUBLICATIONS  
Mugasa JP, Qi W, Rusch S, Rottman M and Beck HP. Genetic Diversity of 
Expressed Plasmodium falciparum var genes from Tanzanian Children with 
Severe Malaria. Submitted to BMC 
Rottmann M., Lavstsen T., Mugasa J.P., Kaestli M., Jensen A.T., Muller D, 
Theander T., Beck, H.P. 2006. Differential expression of var gene groups is 
associated with morbidity caused by Plasmodium falciparum infection in 
Tanzanian children. Infection and Immunity. 74(7): 3904-11. 
Vandemaele F.J., Mugasa J.P., Vandekerchove D., Goddeeris B.M. 2003. 
Predominance of the papGII allele with high sequence homology to that of 
human isolates among avian pathogenic Escherichia coli (APEC). Veterinary 
Microbiology 97(3-4): 245-57. 
 
During my studies I attended lectures and courses of the following lecturers 
 
N. Weiss, G. Pluschke, T. Smith, P.Vounatsu, HP Beck, I. Felger, R. Brun, Pieters, J, 
Cornelis, G Schwede T and Tanner M. 
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